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Abstract 
 
A peptide nucleic acid (PNA) encoded 1296 member peptide library was synthesised 
and incubated with a variety of cell types. Library members entering cells were 
extracted, hybridised onto DNA microarrays and the peptide identity was determined 
via deconvolution. Global consensus analysis highlighted the tetrapepide, Glu-Llp-
Glu-Glu (Llp is 6-hexamine-N-aminoacetic acid), a surprise in view of the basic 
residues typically observed in cell penetrating peptides. When evaluated, Glu-Llp-
Glu-Glu revealed cellular uptake comparable to a known basic peptide (tetraLlp). In 
depth delineation via clustering analysis allowed assessment of differential cellular 
uptake, with the identified peptides showing clear cellular specificity. This was 
verified by peptide synthesis and cellular uptake analysis by flow-cytometry, and in 
all cases an endocytic uptake mechanism was confirmed. This approach establishes a 
strategy for the identification of short peptides as tools for selective delivery into 
specific cell types. 
 
The incubation of a 10,000 member PNA-encoded peptide library with D54 and 
HEK293T transfected with CCR6 cells followed by microarray analysis allowed 
detailed information on the interaction between peptide-ligands and cell surface 
receptors to be extracted. This allowed the identification of new ligands for integrins 
and G-protein coupled receptors and offers a novel approach to ligand discovery 
allowing the comparative analysis of different cell types for the identification of 
differences in surface-receptor ligands and/or receptor expression between various 
cell types. In addition, this work included the development of a novel method for the 
indirect amplification of a PNA library by amplification of a complementary DNA 
library hybridised to the PNA. 
 
The generation of 10,000 defined pieces of DNA would have a myriad of 
applications, not least in the area of defined or directed sequencing and synthetic 
biology, but also in applications associated with encoding and tagging. By this 
approach DNA microarrays were used to allow the linear amplification of 
immobilised DNA sequences on an array followed by PCR amplification. Arrays of 
increasing sophistication (1; 10; 3875; 10,000 defined oligonucleotides) were used to 
validate the process, with sequences verified by selective hybridisation to a 
complementary DNA microarray with DNA sequencing demonstrating error rates of 
ca  0.2%. This technique offers an economical and efficient way of producing 
hundreds to thousands of specific DNA primers, while the DNA-arrays can be used 
as “factories” allowing specific DNA oligonucleotide pools to be generated with or 
without masking. This study also demonstrated a significant variance observed 
between the sequence frequencies found via Solexa sequencing compared to 
microarray analysis.   
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Abbreviations 
Amino acids 
Three-letter code (one-letter code) 
Ala (A) alanine 
Arg (R) arginine 
Asn (N) asparagine 
Asp (D) aspartic acid 
Gln (Q) glutamine 
Glu (E) glutamic acid 
Gly (G) glycine 
Ile (I)  isoleucine 
Leu (L) leucine 
Lys (K) lysine 
Met (M) methionine 
Phe (F) phenylalanine 
Pro (P)  proline 
Ser (S)  serine 
Tyr (Y) tyrosine 
Val (V) valine  
 
General 
AA  amino acid 
Ac  acetyl 
A  adenine 
Aloc  allyloxycarbonyl 
Ar  aryl (NMR) 
Azoc  azidomethyloxycarbonyl 
Bhoc  benzhydryloxycarbonyl 
Boc  tert-butoxycarbonyl 
br  broad (NMR) 
C  cytosine 
DAPI  4',6-diamidino-2-phenylindole 
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CCR6  C-C chemokine receptor type 6 
Cbz  carbobenzyloxy 
CM  complete medium 
CPP  cell penetrating peptide 
d  doublet (NMR) 
DCC  dicyclohexylcarbodiimide 
DCM  dichloromethane 
DCU  dicyclohexylurea 
dd  doublet of doublets (NMR) 
Dde   N-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl] 
DIC  diisopropylcarbodiimide 
DIPEA N,N-diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMEM Dubelco’s Modified Eagle Medium 
DMF   N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
ds  double-stranded 
ECM  extracellular matrix 
EDTA  ethylenediaminetetraacetatic acid 
EMEM Eagle’s Minimum Essential Medium 
ESAC  encoded self-assembling chemical 
FACS  fluorescence activated cell sorting 
FAM  5(6)-carboxyfluorescein 
FBS  foetal bovine serum 
FISH  fluorescence in situ hybridisation 
FITC   fluorescein isothiocyanate 
Fmoc   9-fluorenylmethoxycarbonyl 
FRET  fluorescence resonance energy transfer 
G  guanine 
GDP  guanosine diphosphate  
GMEM Glascow Minimum Essential Medium 
Nina Svensen                                                                                            Abbreviations 
  xii
   
GPCR  G protein coupled receptor 
GTP guanosine triphosphate 




HOBt  1-hydroxy-1H-benzotriazole 
HPLC  high performance liquid chromatography 
IMEM  Improved Modified Eagle Medium 
IR  infrared 
J  scalar coupling constant (Hz) 
Llp  lysine-like peptoid 
LRMS  low resolution mass spectroscopy 
m  multiplet (NMR) or medium (IR) 
MALDI-TOF matrix-assisted laser desorption/ionisation time-of-flight 
Me  methyl 
Mmt  monomethoxytrityl 
mRNA  messenger ribonucleic acid 
MS   mass spectrometry 
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NEAA  non-essential amino acids 
NEM  N-ethylmorpholine 
NMP  N-methyl-2-pyrrolidone 
NMR  nuclear magnetic resonance 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEGA  polyethylene glycol dimethyl acrylamide 
PerCP  peridinin chlorophyll protein complex 
PNA   peptide nucleic acid 
PS polystyrene 
PyBOP  benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
q  quartet (NMR) 
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quint.  quintuplet (NMR) 
Rho  rhodamine 
RNA  ribonucleic acid 
RP  reverse phase 
 
RPMI  Roswell Park’s Memorial Institute 
rRNA  ribosomal ribonucleic acid 
s  singlet (NMR) or strong (IR) 
SDS   sodium dodecyl sulfate 
SNP  single-nucleotide polymorphism 
SPPS  solid phase peptide synthesis 
ss  single-stranded  
SSC  saline sodium citrate 
T  thymine 
t  triplet (NMR) 
TAMRA tetramethyl-6-carboxyrhodamine 
TAT  trans-acting activator of transcription 
TBE  tris borate ethylenediaminetetraacetatic acid 
td  triplet of doublets (NMR) 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TIS   triisopropylsilane 
TLC  thin layer chromatography 
Tm  melting temperature 
TRITC  tetramethyl rhodamine isothiocyanate 
UV  ultraviolet 
w  weak (IR) 
  chemical shift (NMR) 
Nina Svensen                                                                                                   Chapter 1 
  14






















Chapter 1 Basic concepts 
Nina Svensen                                                                                                   Chapter 1 
  15
   
1.1 Peptide nucleic acids 
The extensive use of deoxyribonucleic acids (DNAs) or ribonucleic acids (RNAs) in 
molecular biology has highlighted a number of shortcomings of these natural bases, 
such as rapid enzymatic degradation and poor mismatch discrimination. This has led 
to the development of numerous DNA (and RNA) analogues. One very attractive 
synthetic DNA mimic, the so-called peptide nucleic acids (PNAs), were reported by 
Nielsen in 1991.1,2 PNAs have an uncharged, achiral and acyclic polyamide 
backbone composed of N-(2-aminoethyl)glycine units with a side chains comprising 
one of the four nucleobases, adenine (A), cytosine (C), guanine (G), or thymine (T), 
linked through a methylene carbonyl spacer (Scheme 1.1). By convention, PNAs are 
depicted like peptides, with the N-terminus on the left and the C-terminus on the 
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Scheme 1.1: General structure of DNA/PNA duplexes. 
 
1.1.1 PNA synthesis 
To prepare full length PNA, PNA monomers (Scheme 1.2) are typically coupled in 
the same manner as amino acids are in solid-phase peptide synthesis3,4,5 (SPPS),  
here the carboxylic acid of the monomer is activated, followed by coupling to the 
free amino-group of the previous monomer in the growing chain.6  
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PNA is stable to weak bases as well as strong acids and a range of protecting groups 
has been used for PNA synthesis.21 In the two most conventional strategies, the 
backbone-amino group is protected with either an Fmoc7 or a Boc8 group, and the 
nucleobase exocyclic amines are Bhoc- or Cbz-protected respectively. The 
Fmoc/Bhoc- and Boc/Cbz-protected PNA monomers are commercially available. 
Various other protecting groups for the backbone amino group have been reported, 
e.g. Mmt, 4-N3-Cbz, and Aloc as well as protecting groups for the nucleobase 
exocyclic amines, e.g. Cbz, Bhoc, bis-Boc, and Mmt.9,10,11,12 However, during PNA 
synthesis with the Boc/Cbz-protected PNA monomers repeated trifluoroacetic acid 
(TFA) mediated Boc-deprotections are required, as well as harsh acidic cleavage 
conditions (hydrofluoric acid or trifluoromethanesulfonic acid) for Cbz-deprotection. 













Scheme 1.2: Dde/Mmt-protected PNA monomer. 
 
1.1.2 Orthogonal peptide-PNA conjugate synthesis 
Neither the Fmoc/Mmt, Fmoc/Bhoc, nor Fmoc/bis-Boc-protected PNA monomers 
would allow orthogonal synthesis of peptide-PNA conjugates with Fmoc/tBu-
protected amino acids. This has lead to the development of a number of alternative 
protection strategies that allow orthogonal synthesis of peptide-PNA conjugates.9,14 
A very attractive alternative emerged with the synthesis of Dde/Mmt-protected PNA 
monomers as well as alternative Dde-deprotection conditions that are fully 
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orthogonal to the Fmoc group (Scheme 1.2).14,15 Traditionally, Dde-deprotection is 
carried out by transenamination with hydrazine but these conditions also remove the 
Fmoc-group16. However, a mixture of hydroxylamine hydrochloride and imidazole 
removes the Dde-group but has no reactivity towards the Fmoc-group.15 
Furthermore, the Dde-group is stable to piperidine mediated Fmoc-deprotection as 
well as TFA. Other Fmoc-orthogonal protecting groups for the backbone-amino 
group, such as Aloc, Azoc, and 4-N3Cbz have also been employed.
9 However, Aloc 
deprotection necessitates the repeated use of a palladium catalysts at neutral 
conditions, and afforded PNA-peptide conjugates in low yields and purities.14 The 
Azoc and the 4-N3Cbz protecting groups require neutral conditions using phosphines 
and phosphines followed by TFA respectively.9 In addition, slightly basic or even 
neutral deprotection conditions may result in undesirable side reactions (section 
1.1.2.1) and result in low yields and purities.17 
 
1.1.2.1 Potential side reactions and complications in PNA synthesis 
The increased nucleophilicity of the primary amines in PNA (compared to the 
primary amines in amino acids) can cause attack of the amine on either the 
nucleobase acetyl moiety18,19,20 (acyl migration) or on the interunit amide 
moieties13,20 (N-terminal detachment, Scheme 1.3). Dde protection of the monomers 
helps limit these potential side reactions, as Dde can be removed at slightly acidic 
pH, where the primary amine is protonated and non-nucleophillic.  
 
Due to its bulk, the PNA oligomer may aggregate if synthesised on high-loading 
resins, which would result in incomplete coupling and deprotection.6 Thus, synthesis 
of long PNAs (> 5 residues) restrains the choice of resin to those of low loading 
(0.05-0.1mmol/g).6 
 
Nina Svensen                                                                                                   Chapter 1 
  18




























Scheme 1.3: Potential side reactions in PNA synthesis: acyl migration (a) and N-
terminal detachment (b). 
 
1.1.3 Properties of PNA 
PNA hybridises to DNA, PNA, and RNA following standard Watson-Crick base 
paring2. Duplexes can form in both anti-parallel and parallel orientations but the anti-
parallel orientation (N-terminus of PNA facing the 3’-end of DNA) is strongly 
preferred21. The backbone of PNA does not contain any anionic phosphate groups or 
other negatively charged groups meaning there is an absence of electrostatic 
repulsion during and after hybridisation with DNA, which means that the interaction 
between PNA/DNA is stronger than that between DNA/DNA strands and 
hybridisation can occur under low salt conditions.6 The strong PNA/DNA interaction 
confers higher thermal stability on PNA/DNA duplexes than the corresponding 
DNA/DNA duplexes leading to significantly higher melting temperatures (Tm) as 
well as increased mismatch discrimination, with an average decrease of 15 °C in Tm 
for a single-base mismatch in a 15-mer PNA/DNA duplex, in comparison to a 
decrease of 11 °C in the Tm of the corresponding DNA/DNA duplex
2. 
 
PNAs can also form PNA/DNA/DNA triplexes as well as other types of 
structures.22,23 For example, PNA/DNA/DNA triplexes formed through Hoogsteen 
base-pairing, are observed between cytosine-rich PNAs and guanine/cytosine-rich 
DNA duplexes (Scheme 1.4).24  
 
Under low salt concentrations double-stranded (ds) PNAs containing a high 
pyrimidine/purine ratio or homopyrimidine dsPNAs (composed of only thymine and 
cytosine bases) bind to purine-rich DNA duplexes by strand displacement to form a 
highly stable PNA/PNA/DNA triplex (Scheme 1.4).1,25  In this conformation, one 
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PNA binds to the single DNA strand following Watson-Crick base-pairing rules (by 
preference in the anti-parallel mode), while the other PNA binds to the PNA/DNA 
duplex through Hoogsteen base-pairing (preferably in the parallel mode) displacing 
the other single-stranded (ss) DNA, which forms a P-loop structure (Scheme 1.4).25 
Cytosine mediated triplex invasion is pH-dependent as protonated cytosines are 
required for Hoogsteen base-pairing (Scheme 1.2d). The ability of PNAs to bind to 
dsDNA by strand displacement has been successfully used as a powerful tool in 































Scheme 1.4: Schematic representations of (A) PNA/DNA duplexes, (B) PNA-
(DNA)2 triplexes and (C) triplex invasion complexes. (D) Hoogsten and Watson-
Crick base pairing. 
 
Furthermore, PNA is stable over a wide pH range6 and is resistant to enzyme 
degradation because it is poorly recognised by either nucleases or proteases6. This 
resistance to enzymatic degradation extends the possible lifetime of PNAs in vivo28. 
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However, PNA is not recognised by DNA polymerases and cannot function as a 
template or primer in the polymerase chain reaction (PCR).6,21 These characteristics 
make PNA the molecule of choice for cell assays and DNA microarray screening29. 
 
1.1.4 Applications of PNA 
The unique characteristics of PNA have given PNA great potential as a tag, in 
diagnostics, functional genomics, and molecular biology.21,30  
 
1.1.4.1 PNAs as a tag 
Fluorescence resonance energy transfer31,32,33 (FRET) in connection with nucleic acid 
tagging has been improved by the utilisation of PNA. In one example a PNA 
encoded peptide library is labelled with a FRET-pair and the conjugate library 
subjected to protease.33 If the peptide is recognised by the protease it will be 
degraded, while the PNA remains intact, leading to cleavage of the quencher from 
the conjugate and fluorescence from the donor. The PNA may then be hybridised to a 
complementary microarray revealing the sequence of the peptide. 
 
Another PNA-tagging method uses PNA based molecular beacons, which are self-
complementary PNAs labelled with both a fluorophore and a quencher.34 In the 
absence of a complementary DNA the PNA strand self-hybridises placing the donor 
and the acceptor in close proximity such that fluorescence is quenched. When 
hybridised to a complementary DNA or RNA strand, the fluorophore and quencher 
distance is increased leading to loss of the quench (Scheme 1.5a). This technique has 
lead to the development of forced intercalation-PNA molecular beacons, which 
enhance fluorescence rather than quench it while exhibiting increased mismatch 
discrimination, even at low temperatures. These PNAs have an open conformation 
and are coupled to an intercalator dye, e.g. thiazole orange (donor) and a near 
infrared dye, e.g. NIR667 (acceptor).35 The PNA is designed such that upon 
hybridisation with a fully complementary nucleic acid sequence the intercalator dye 
becomes fluorescent and its fluorescence is subsequently quenched by the near-
infrared dye, which emits at a different wavelength (Scheme 1.5b). 
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Scheme 1.5: Detection of complementary target nucleic acids using (A) PNA 
molecular beacons and (B) forced intercalation-PNA molecular beacons.35 
 
1.1.4.2 PNA in diagnostics 
PNAs unique hybridisation properties have led to the development of diagnostic 
assays, such as PNA-fluorescent in situ hybridisation (FISH), whereby fluorescently 
labelled PNA probes are employed to image nucleic acid targets inside cells and 
tissue.36 For example, the accurate telomere lengths of chromosomes have been 
determined using PNA-FISH, and PNA-FISH has applications in cancer and ageing 
studies.37  
 
The detection of single base-pair mutations or single-nucleotide polymorphisms 
(SNPs) using PNA-directed PCR clamping hold great promise in diagnosis and 
research of human genetic disease.38,39 In the PCR clamping technique, one primer 
site (and hence PCR) is blocked by a fully complementary PNA. Thus a single base-
pair mismatch presented by a genetic disease in the target DNA sequence destabilises 
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Scheme 1.6: The PNA-directed PCR clamping method.38 
 
1.1.4.3 Applications of PNA in functional genomics 
Southern blotting, which reveals the size and sequence information of DNA, has 
been improved by the utilisation of PNA.40 Hereby, biotinylated PNA is hybridised 
to denatured DNA at low salt concentrations disfavouring formation of DNA/DNA 
duplexes, followed by size separation of ssDNA by gel electrophoresis. The 
PNA/DNA duplexes may then be detected on a nylon membrane using 
chemiluminescence-based methods. 
 
1.1.4.4 PNA in molecular biology 
PNA has been shown to have applications in antigene and antisense interference by 
strand invasion of dsDNA41, or by binding to messenger RNA42 (mRNA) 
respectively. This has lead to advances in therapeutic areas such as cancers43, and 
bacterial44 and viral45,46 infections. The advantage of employing PNA rather than the 
natural nucleic acids in antigene and antisense technology is that PNA is not 
degraded in the cytosol by nucleases in the same way as the natural nucleic acids47.   
 
As an antigene, PNA can inhibit transcription by strand-invasion of chromosomal-
DNA forming triple-helixes, which sterically hinders and blocks transcription.48 For 
example, PNA targeting the transcription-initiation sites for the human progesterone 
receptors A and B, have been reported to inhibit formation of the transcription 
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complex.49 Chromosomal-DNA replication has also been inhibited by PNAs by 
formation of triple helixes50, and plasmid-DNA replication can be inhibited in the 
same manner in vivo.51  
 
PNAs have also been reported in antisense interference by hybridising to 
complementary mRNA to form triple helixes, which sterically hinder and block 
translation of the target genes.42 In addition, antisense PNAs have been shown to 
inhibit microRNAs.52  
 
The main complication of the application of PNA in antigene and antisense research 
is the poor cellular penetration of PNA due to its high molecular weight and its lack 
of ability to function as a carrier system or interact with cell-surface receptors.53 
Moreover, traditional transfection agents developed for ionic nucleic acids (e.g. 
polymers and cationic lipids) are often incapable of delivering the uncharged PNA. 
Cellular delivery of PNA by other methods, such as conjugation to steroids54 or cell-
penetrating peptides55,56 (e.g. arginine-rich peptides, Penetratin), alteration of the 
structure of PNA to increase its cell-permeability57,58, co-transfection with DNA59, 
and electroporation60 has been reported. For example, the Tat48-57 decapeptide or a 
hepta-arginine peptide delivered conjugated PNA with a fluorescein-label into cells 
with high efficiency.55 Similarly, incorporation of D-arginine residues into the PNA 
backbone instead of glycine side chains produced a cell-permeable PNA analogue, 
guanidine-PNA (GPNA), which inhibited protein translation (Scheme 1.7).57 PNA 
has also been conjugated to a triphenylphosphonium carbamate, which functions as a 
prodrug such that it improves the cell permeability of the construct but is degraded in 












Scheme 1.7: Structure of a GPNA-monomer.56 
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PNA has also been employed in advances in nucleic acid purification, whereby 
duplex formation between hexahistidine-PNA conjugate and complementary DNA in 
combination with nickel affinity chromatography has been reported as a nucleic acid 
purification strategy.61  
 
Genetic typing often relies on PCR amplification of variable numbers of tandem 
repeats. However, in this technique, small allelic products of heterozygous 
individuals are preferentially amplified compared to large alleles, which can lead to 
erroneous genotyping patterns.62 PNA hybridised to the DNA template during PCR 
has been demonstrated to render the template unavailable for inter-strand and intra-
strand interactions but not inhibit the primer extension as the polymerase displaces 





Scheme 1.8: Genotyping PCR using PNA for reliable amplification of different size 
alleles.62 
 
PNA has also been applied to enhance the specificity of restriction enzyme 
digestions of genomic DNA.26 A short bis-PNA (Scheme 1.9) is hybridised to a 
specific site of complementary DNA, where after DNA not protected by PNA is 
methylated. Following PNA dehybridisation, the PNA complementary DNA is 
digested by a methylase-sensitive restriction enzyme, allowing the PNA to function 
as a sequence-directing genome cutter. Bis-PNA mediated dsDNA strand invasion 
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has been exploited in development of a method for constructing DNA nickases.27 
Hereby, bis-PNA is hybridised to complementary DNA by strand-invasion exposing 
a ssDNA loop, which is hybridised with a complementary oligonucleotide. The 
resulting dsDNA is digested by a restriction enzyme, the dsDNA is degraded, and the 
bis-PNA is removed allowing the DNA duplex to rehybridise (albeit with a nick, 
Scheme 1.9).  
 
 
Scheme 1.9: Construction of site-directed DNA nickases using PNA mediated strand 
invasion. 
 
PNA-FISH is also employed in commercial diagnosis systems for bacterial infections 
(AdvanDx, Inc.Woburn, MA, USA),63 where a fluorescently labelled complementary 
PNA probe is in-situ hybridised to species-specific ribosomal RNA (rRNA) of the 
target bacteria. This allows direct identification of harmful bacteria in whole blood 
and other body secretes using fluorescent microscopy.  
 
1.2 Solid-phase peptide synthesis 
Numerous advances have been made in the formation of amide bonds; and one of the 
most prominent was the development of SPPS by Merrifield 1963 (Scheme 1.10).5 In 
Nina Svensen                                                                                                   Chapter 1 
  26
   
addition to the synthesis of common peptides, SPPS allows for synthesis of peptide 
derivatives including the coupling of unnatural amino acids and peptides with 
backbone modifications. Here solid-supported synthesis will be discussed with a 





























Scheme 1.10: SPPS of peptides. R is a side chain of any amino acid. P is a protecting 
group. AA is any amino acid. 
 
In SPPS an insoluble gel based resin is coupled to a linker, on which the peptide 
chain is elongated by repeated cycles of coupling and deprotection and the peptide is 
cleaved off the solid support at the end of the synthesis. The strength of the SPPS 
strategy is the ease of purification (simply washing the supported peptide) and an 
opportunity for achieving high yields over numerous steps. However, homogenous 
products can only be achieved with high conversion in each step (>99%). A potential 
downside to SPPS is the requirement to use high concentrations and excess reagents 
(often between 2-10 equiv.) to force reactions to completion.  
 
1.2.1.1 Parallel SPPS methods 
Geysen et al. (1984) developed SPPS into a parallel synthesis method using the so-
called multipin method for antibody epitope mapping.64 Synthesis of hundreds of 
individual peptides supported on polyacrylic acid-grafted polyethylene pins, which 
were arrayed in a 96 well-plate, was achieved. Coupling, washing, and neutralisation 
steps were carried out by immersing the pins into specific solutions. The use of a 
range of grafts (such as polyacrylamide and polystyrene) and linkers were reported. 
The main downside to this effective technique was the small amounts of material 
obtained compared to standard solid supports. 
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The so-called “tea-bag” method, developed by Houghten (1985), is another parallel 
approach to SPPS, where functionalised resin beads are sealed into small 
polypropylene mesh packets (like tea-bags).65 Individual peptide synthesis is then 
carried out by immersing the “tea-bags” into separate specific amino acid coupling 
solutions producing yields and purities comparable to traditional SPPS techniques. 
Based on the “tea-bag” approach other molecular resin-based systems have been 
designed. For example, using Irori resin carriers compound libraries were 
synthesised in polypropylene “mesh” microreactors using optical66 or 
radiofrequency67 encoding. 
 
Parallel synthesis of peptides on cellulose membranes, termed SPOT synthesis, was 
reported by Frank (1992).68 Using this technique activated Fmoc-protected amino 
acids were coupled at specific locations on amino functionalised membranes by 
manual or automatic dispension. Thereafter, unreacted amino groups could be 
capped by acetylation and the peptides released from the support by employing a 
cleavable linker on the derivatised membrane. This technique is cost effective and 
uses only small amounts of reagents, which gives the method many applications in 
high-throughput screening and in molecular biology, such as antibody or enzyme 
substrate screening. 
 
A great expansion of parallel SPPS was achieved with the emergence of the split and 
mix method first reported by Furka et al. (1988) with the synthesis of equimolar 
peptide library mixtures.69,70 By this method, the solid-support is divided in separate 
fractions and one or more reactions are carried out on each separate fraction. This is 
followed by mixing of all the reaction products in one pool, then division and another 
set of separate reactions are carried out and the process is repeated as many times as 
desired. Different building blocks can be employed in each step, leading to a great 
variety and number of products (Scheme 1.11). The maximum number of products 
that can be achieved by split and mix synthesis is: the number of building blocks in 
each step raised to the power of the number of steps (reaction cycles). Thus, a 
pentapeptide library with the 20 natural amino acids as building blocks would 
generate 3,200,000 (205) different compounds with just 100 coupling reactions. If 
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there is no competition between the introduced reactants, each library member will 
be synthesised in approximately equimolar quantities in the final mixture. However, 
split and mix reactions often produce product mixtures, which necessitates 
deconvolution or encoding strategies to identify individual products. The technology 











Scheme 1.11: Schematic representation of split and mix synthesis. 
 
1.2.2 Encoding strategies 
Numerous chemical and non-chemical encoding strategies for combinatorial libraries 
have been developed and the description of all of these lies beyond the scope of this 
thesis. As such the discussion of encoding strategies will be limited to DNA- and 
PNA-encoding.  
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1.2.2.1 DNA-encoding 
There are many examples of the application of DNA libraries being used as an 
encoding tag for peptides or small molecules72-80, enabling the high-throughput 
screening of peptide interactions with biological targets or screening of drug 
candidates. The concept of DNA-encoding was first demonstrated by Brenner 
(1992), who reported split-and-mix synthesis of a combinatorial DNA-encoded 
peptide library by alternating amino acid and nucleic acid couplings72. This library 
was employed in ligand/protein affinity studies and the DNA-encoding allowed 
PCR-amplification followed by DNA-sequencing in order to identify the active 
peptides. 73,74,75,76,77,78,79,80 
 
Affymax and Nielsen simultaneously reported the bead supported synthesis of DNA-
encoded libraries composed of up to 823,543 heptapeptides73,74. This synthesis 
approach has been employed in other libraries76.  
 
DNA encoded self-assembling chemical (ESAC) libraries have been reported as an 
efficient tool to identify molecules that bind target proteins.77 This technique allows 
hybridisation of specific small molecule-linked DNA oligonucleotides from different 
sub-libraries to generate DNA-duplexes synergistically encoding two compounds 
leading to large libraries with diverse chemical groups that can be screened against 
biological targets.  
 
Other examples of DNA-encoded libraries involving enzymatic DNA ligation have 
been patented by Nuevolution78 and Praecis79. Recently, synthesis of million to 
billion member small molecule libraries encoded by double stranded DNA were 
reported by combination of enzymatic and chemical synthesis in a split-and-pool 
format, allowing screening against two kinase targets.80 
 
DNA barcoding is a taxonomic method for rapid species identification based on 
DNA sequences81,82,83, whereby a short genetic marker (a barcode, 400-800 bp) in an 
organism's DNA is used to identify the respective organism as belonging to a 
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particular species, such that the information of one or a few gene regions can be used 
to identify all species of life.  
 
1.2.2.2 PNA-encoding84,85,86,87,88 
The greater chemical stability of PNA, its resistance to biological degradation and 
strong binding affinity for DNA (section 1.1.3) renders PNA a superior encoding 
alternative to DNA.33,84-88 PNA-encoding has been employed in small molecule 
libraries, where each molecule is linked to a unique PNA tag, which allows 
identification of the small molecules by hybridisation of the PNA-tag on a predefined 
microarray location.85 Furthermore, it has been shown that PNA does not alter or 
otherwise interfere with the interaction between the small molecules and a protease.  
 
PNA-encoded peptide-libraries have been employed to identify optimal substrates 
and inhibitors for proteases. In one example, following incubation with cathepsin the 
enzyme bound PNAs were purified by size exclusion followed by DNA microarray 
hybridisation to decode the small molecule structures.86,88 The approach was further 
developed to study cysteine protease activity on complex mixtures of proteins from 
crude cell lysates and led to the identification of human caspase inhibitors.86  
  








Scheme 1.12: Schematic representation of DNA microarray hybridisation of a PNA-
encoded small molecule library. 
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PNA-encoded split-and-mix peptide libraries have been employed to study the 
substrate specificity of proteases as well as tyrosine kinases.33,87 This approach 
included the synthesis of a FRET-based 10,000-member PNA-encoded peptide 
library labelled with 5(6)-carboxyfluorescein (FAM) and tetramethyl-6-
carboxyrhodamine (TAMRA, Scheme 1.13).33 Upon enzymatic cleavage of the 
peptide (Β-Ala-Ser-AA4-AA3-AA2-AA1-Ala, Scheme 1.13), the quencher (TAMRA) 
was removed from its close proximity to the donor (FAM, Scheme 1.13) allowing 
FAM fluorescence to be visualised. After enzymatic incubation the PNA tags were 
hybridised onto a complementary DNA microarray, which allowed not only the 
identification of peptides recognised by the protease but also quantification of the 


















PNA tag (encoding the peptide)  
 
Scheme 1.13: Structure of the FRET-labelled PNA-encoded peptide library. 
 
1.2.3 The combinatorial chemistry approach adopted in this 
project 
This project presents: 1) Screening of a combinatorial library of potential delivery 
agents and extraction of those with enhanced cellular uptake. 2) Screening of a 
combinatorial library of potential peptide ligands for cell surface receptors 
controlling cell signalling pathways and thereby moderating cell behaviour from the 
outside of the cell.  
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The libraries herein were synthesised by split-and-mix combinatorial chemistry with 
PNA tags along with each amino acid or peptoid monomer coupling. Thus each 
peptide was covalently linked to a unique PNA tag much like a barcode, from which 
the peptide identity could be derived by hybridising the PNA-tags to a 
complementary DNA microarray (section 1.3). This one-spot-one-compound 
approach circumvents laborious structure determination after library screening by 
allowing the PNA tag to be read like a barcode. In addition, this approach allows the 
target biological assays to be carried out before or after hybridisation of the library to 
the microarray. 
 
1.3 DNA microarrays 
DNA microarrays are comprised of DNA oligonucleotides chemically attached to a 
solid surface, usually a glass slide, in a predefined location. DNA microarrays were 
first developed to assay global gene expression.89-92 Microarray technology 
established a method for the simultaneous study of the relative expression of 
thousands of genes in a single experiment. 89,90,91,92 
 
The advantage of microarrays allows opportunities for the high throughput screening 
of tens of thousand of library members at once. This permits easy identification of 
“hits” as well as multiplexed analysis of positive and negative responses. 
Importantly, the multiple assays that one microarray experiment comprises are 
carried out under the same reaction conditions, often with internal controls. This 
allows the discovery of unique patterns in addition to mere identification of positive 
responds. However, this multidimensional analysis produces a vast amount of data, 
which poses a number of statistical problems, including evaluation of the standard 
deviations, as well as the normalisation and standardisation of the data.  
 
Other advantages of microarray technology are the use of microliter reaction 
volumes and nano- and picomolescale amount of samples required. Microarray 
technology has been applied in the high-throughput screening of a variety of 
biomolecules, such as DNA90, peptides93, proteins94, live cells95, tissue96, 
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carbohydrates97, polymers98, and small molecules99. Microarrays have been 
established as a vital tool in many research areas including proteomics, genetic 
screening, diagnostics, and drug discovery. 100 
 
DNA microarrays are classically applied in gene expression profiling, where the 
presence and relative amount of a gene in a control and a sample of interest is 
identified.101 This method allows rapid identification of specific genes expressed at 
high levels in a disease state.  
 
DNA microarrays are also employed in genome-wide genotyping as well as detection 
of mutations or SNPs, identifying susceptibility to development of a specific 
disease.102  
 
Microarray technology has led to the development of the so-called “comparative 
genomic hybridisation” technique, where two sets of genomes are compared in a 
single experiment to determine if expression of specific genes has been up or down 
regulated establishing a powerful diagnostic tool.103  
 
1.3.1 DNA microarray fabrication104,105,106,107 
DNA microarrays can be custom synthesised to contain high numbers (up to 
176,000; Agilent) of relatively long (up to 200 bp) DNA oligonucleotides.92 DNA 
microarrays are typically prepared by in-situ DNA synthesis either by: 
photolithography, where photolithography-masks (real or virtual) are applied to 
direct oligonucleotide synthesis104-107; by inkjet printing mediated synthesis108,109;  by 
semiconductor directed synthesis, where an array of individually controlled 
microelectrodes embedded in a fluidic chamber selectively generate chemical 
reagents by means of an electrochemical reaction110; or by laser facilitated synthesis 
using oligonucleotides with photolabile protecting groups111.  
 
The spotting of pre-synthesised DNA onto a surface, such as a bead (e.g. Illumina) or 
a glass surface is more expensive and laborious than in-situ DNA array synthesis. 
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However, this approach does allow DNA sequences to be purified and characterised 
prior to printing, thereby eliminating base deleted oligonulceotides which arise 
during in situ synthesis.  
 
1.3.2 Surfaces and immobilisation 
The surface material and chemistry should be optimised for immobilisation of DNA 
probes, but resist unspecific association of target molecules. Moreover, the surface 
may also influence the density of probe molecules, the reaction efficiency of 
biological assays and the data quality, as the background must be compatible with 
the detection method. Most microarrays are comprised of modified glass slides as 
these are flat, planar, resistant to high temperatures, easy to handle and are 
transparent affording low light absorption.112 Classical, commercially available 
surface modifications are amine, aldehyde, epoxide, and activated ester. These 
modifications can be achieved by reacting a glass surface with the desired functional 
group displayed on the end of propyltrimethoxysilane.100 
 
Biomolecules may be immobilised on microarrays via covalent bonds or via 
adsorption, which are non-covalent interactions between the biomolecules and the 
slide surface. For example, the attachment of amino-modified DNA to a succinimidyl 
ester surface forms a covalent amide bond. An example of absorption is DNA 
immobilisation on an amine surface through electrostatic interactions between the 
amine groups and the phosphate groups of DNA. However, this technique results in a 
probe orientation parallel to the surface rather than an upright orientation, which 
affords higher hybridisation efficiency.112 
      
1.4 Cell surface receptors 
Cell surface receptors are glycoproteins embedded in the cell membrane of all 
mammalian cells and they have specific ligand-binding moieties exposed to the 
extracellular matrix (ECM)113. Following binding of a ligand to a cell surface 
receptor, a biological signal is propagated across the membrane to the intracellular 
matrix mediating cellular responses such as differentiation, proliferation, and 
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migration etc113. There are hundreds of known cell surface receptors and discussion 
of all of these lies beyond the scope of this thesis. Focus will be on two of the largest 
and most diverse families of cell surface receptor: integrins and G-protein coupled 
receptors (GPCRs).114,115,116  
 
1.4.1 Integrins 
Integrins are a large family of heterodimeric transmembrane receptors that govern 
ECM and cell-cell adhesion.114 In mammals 18 α and 8 β-integrin genes encode 
proteins that combine and form 24 αβ receptors117. The extracellular domains of 
these receptors interact with a range of ECM proteins and cell surface proteins (e.g. 
fibronectin, collagen, laminin, and vitronectin; Table 1.1) while the cytoplasmic 
domain is linked to the actin-cytoskeleton.118,119  
 
Table 1.1: Integrins found in mammalian cells.120 
Name Synonyms Distribution Ligands 
11   many collagens, laminins 
21   many collagens, laminins 
41 VLA-4 hematopoietic cells fibronectin, VCAM-1 
51 fibronectin receptor widespread fibronectin and proteinases 
61 laminin receptor widespread matrix macromolecules laminins 
L2 LFA-1 T-lymphocytes ICAM-1, ICAM-2 
M2 Mac-1, CR3 neutrophils and monocytes serum proteins, ICAM-1 
IIb3   platelets fibrinigen, fibronectin 
V3 vitronectin receptor 
activated endothelial cells, 
melanoma, glioblastoma 
vitronectin,[7] fibronectin, fibrinogen, 
osteopontin, Cyr61 
V5   
widespread, esp. fibroblasts, 
epithelial cells vitronectin and adenovirus 
V6    
proliferating epithelia, esp. 
lung and liver fibronectin; TGF1+3 
64   epithelial cells laminin 
 
Most integrins are Ca2+ or Mg2+ dependent, i.e. only when an extracellular Ca2+ or 
Mg2+ ion is bound to the receptor, will it adopt the correct conformation for ligand 
binding. Common peptidic features found in many ligands including vitronectin, 
laminin, and fibronection for a range of integrins are Arg-Gly-Asp (RGD) and to a 
lesser extent Leu-Asp-Val (LDV), which have long been exploited in designing 
probes and therapeutics for modulating specific cellular function.117  
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Integrins are activated by conformational changes induced either by ligands binding 
to their extracellular moiety or by conformational changes of their cytoplasmic 
domain121. This latter form of signalling, termed “inside-out-signalling”, ensures 
rapid and flexible responses as it enables the cell to change the receptor conformation 
from within the cell thereby allowing binding or release of ligands (Scheme 1.14).  
 
 
Scheme 1.14: Schematic representation of the conformational changes during 
integrin activation and signalling. (A) The low affinity leg-bent structure. (B) Inside-
out activation disrupts the βTD/βA complex, allowing stable αA/βA complex 
formation and thereby stabilising αA in the open, high affinity state. (C, D) Binding 
of ligand (L, red) to αA stabilises the occupancy of βA, which opens up the 
βA/hybrid hinge and forces genuextension* and leg separation resulting in outside-in 
signalling.122 
 
Through the cell surface moiety, integrins attach the cell to the ECM through 
multiple receptors with low binding affinity: a type of binding, which ensures that 
the cell does not become irreversibly attached to the ECM and retains highly 
controlled and fast responses as well as the ability to migrate. Thus, integrins 
comprise a main mode of responce to the ECM and play an important role in many 
                                                 
* Comes from the Integrin’s ability to bend and stretch like a knee (Genu). 
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cellular processes including adhesion, definition of cellular shape, cell mobility, 
endocytosis, and signal transduction both from the ECM to the cell and from the 
cytoplasm through the receptor to the ECM.114-117114,115,116,117  
 
The cell signalling pathways that integrins govern, amongst others, control cell 
growth, cell division, apoptosis, proliferation, migration, differentiation as well as 
viral binding and entry into the cell.117,123 These processes, if not tightly regulated, 
can lead to down-regulation of vital genes, which is the cause of a variety of diseases 
including cancer and thrombosis. 
 
1.4.2 Syndecans 
Syndecans act as co-receptors especially for integrins and GPCRs, whereby they 
modulate the ligand-dependent activation of primary cell surface signalling 
receptors.124 Syndecans are thus involved in the same cellular functions as primary 
receptors they cooperate with, such as in signal transduction, cell proliferation, 
migration, and ECM and cell-cell adhesion. They consist of a single hydrophobic 
transmembrane domain, a short C-terminal cytoplasmic domain that interacts with 
the actin-cytoskeleton, and an extracellular domain comprising a protein core 
covalently attached to chodroitin sulphate chains and 3-5 heparin sulphate 
chains125,126. These chains interact with various ligands such as fibronectin, fibroblast 
growth factors, antithrombin-1, transforming growth factor-beta, and vascular 
endothelial growth factor. In addition, the core proteins themselves can act as 
integrin ligands.126 Mammals express four syndecans, three of which (syndecan 1-3) 
have restricted tissue distribution and syndecan-4 is expressed ubiquitously in all cell 
types.124  
 
1.4.2.1 Integrin and syndecan synergy  
The syndecan co-receptor function is maintained by core proteins, which target the 
large heparin sulphate chains to the appropriate plasma membrane compartment, 
which makes them ideal receptors for dilute ligands distant from the membrane.127 
However, much of the mechanism of the synergistic action of syndecans and 
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integrins remains to be elucidated.127 Links between integrin and syndecan-4 indicate 
a pathway via active PKC, which activates integrin promotion of migration of cells 
on ECM substrates (e.g. fibronectin, collagen and laminin)128,129.  
 
There is also evidence that this is a highly specific system whereby the integrin and 
syndecan synergy vary depending on the integrin that is involved; e.g. 51 integrin-
mediated spreading of myoblasts on fibronectin is PKC-dependent, whereas 71 
integrin-mediated spreading on laminin is PKC-independent127. 
 
 
Scheme 1.15: Integrin and syndecan-4 synergy involving protein kinase signalling 
and regulates endocytosis. From left: Syndecan-4 binds protein kinase Cα (PKC) 
and phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), which is prevented by 
phosphorylation of syndecan-4 by PKC130. PKC activity and binding of talin is 
necessary for integrin activation129. From right: Endocytosis and recycling of 
syndecan-4 is dependent on ARF6 regulated association of the cytoplasmic domain 
of syndecan and one of the PDZ domains of syntenin (scaffolding protein)131. 51-
integrin and syndecan-4 binding of fibronectin activates the Tyr kinase, focal 
adhesion kinase (FAK) and the Src kinases, which also contribute to FAK activation. 
By enabling dynamin binding to the cytoplasmic domain of syndecan-4, FAK 
regulates focal-adhesion disassembly132, which activates integrin endocytosis. Thin 
arrows = indirect signalling links. Thick arrows = translocation. Fibronectin 
represents the ECM.127 
 
1.4.3 G-protein coupled receptors 
GPCRs are transmembrane receptors associated with a G-protein and consist of 
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different subunits dependent of specific protein function133. GPCRs have an 
extracellular N-terminus and an intracellular C-terminus combinded by 7 
transmembrane domains (helices) that form a barrel cavity, which constitute the 
binding site for smaller ligands. GPCRs also have 3 extracellular loops, where larger 
ligands bind as well as 3 intracellular loops that are associated with a G-protein. 
Ligands interaction with protease-activated GPCRs differ from other GPCRs in that 
these are activated by cleavage of part of the extracellular domain 
 
Ligand interaction with the GPCRs causes conformational change in the receptor, 
causing the receptor to act as a guanine nucleotide exchange factor. This allows the 
GPCR to activate an associated G-protein by catalysing exchange of its bound 
guanosine diphosphate (GDP) for guanosine triphosphate (GTP). Hereby, the G-
protein's  subunit dissociates along with the GTP, which will further affect 
intracellular signaling proteins or target functional proteins directly depending on the 
 subunit type (Scheme 1.16).133 A single GPCR can activate many molecules of G-
protein because it is released unaltered after the interaction.  
 
GPCRs bind an array of ligands from small peptides to large proteins reflecting their 
wide range of functions. In fact, there are approximately 750 GPCR genes in the 
human genome comprising 3% of the entire genome. Although, many GPCRs are 
orphan† the GPCR used in this study, the C-C chemokine receptor type 6 (CCR6)134, 
has a well-known natural ligand (CCL20 also know as MIP-3α).135,136 GPCRs are 
also in synergy with the co-receptor, the syndecans.124,125 
 
Through signalling pathways GPCRs govern some of the most vital cellular 
processes including: binding of neurotransmitters regulating the nervous system; 
controlling blood pressure; heart rate; digestive processes; binding of chemokines 
regulating inflammatory responses; binding of opsins (visual sense), odorants and 
pheromones (sense of smell); as well as regulating cell density sensing.115 These 
essential biological functions make GPCRs amongst the most heavily investigated 
drug targets in the pharmaceutical industry115,137.  
                                                 
† Orphan receptors are receptors for which no ligand has been identified. 
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Scheme 1.16: Schematic representation of the GPCR signal transduction cascade. 
Upon ligand binding the receptor (pink) is activated, which causes activation a 
coupled G-protein by catalysing the exchange of GDP for GTP. Hereby, Gα-GTP is 
released and can bind to an effector protein E, causing it to switch states to an 
activated form, E*.138 
 
Thus, research into selective peptide-ligands for GPCRs, as well as syndecans and 
integrins, could lead to: advances in understanding of cell surface receptors and 
provide a means for directing their actions; the identification of new ligands; and 
possibly improve the design of drug targets for these receptors. 
 
1.4.3.1 Chemokine receptor CCR6 
There are 19 chemokine receptors that bind chemokines, which are small secreted 
proteins that regulate leukocyte trafficking, a process that is essential for lymphoid 
organogenesis and inflammatory responses, and host defence. Chemokine receptors 
contain two cysteines in the N-terminal domain, which do not form disulfide bridges 
(except CCR6 which only contain one cysteine).136 All chemokine receptors also 
contain cysteines in all three extracellular loops, which form disulfide bridges and 
are essential for receptor function.136  
 
The natural CCR6 ligand, CCL20 is expressed in lymphoid, liver, and lung tissue as 
well as on activated monocytes.134,135 The CCR6 receptor is expressed on lung 
memory T and B cells and immature dendritic cells in the lymphoid tissue and CCR6 
plays a role in inflammatory responses in the skin and gut.134,135 Besides, CCL20 the 
CCR6 receptor also binds defensins, which are small cysteine rich cationic peptides 
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expressed in immune cells, where they assist in killing phogocytosed bacterias by 
binding to the bacteria membrane leading to pore formation.136   
 
1.5 Endocytosis in mammalian cells 
Endocytosis is the process by which cells take up material from the ECM by 
engulfing it with their membrane.139,140,141 This technique is used by almost all 
eukaryotic cells to transport large polar molecules, which cannot pass the 
hydrophobic plasma membrane. Endocytosis happens by one of three processes: 
phagocytosis, pinocytosis and receptor mediated endocytosis (Scheme 1.17).  
 
By phagocytosis the cell membrane folds around an object, such as microorganisms, 
cell debris and apoptotic cells and ingests this in a phagosome (i.e. a large vacuole 
made up by the plasma membrane; Scheme 1.17).142  
 
During pinocytosis part of the cell membrane invaginates in a non-specific manner 
and forms a pocket, which buds off into the cell forming a vesicle filled with solutes 
and other small molecules dissolved in the ECM.143  
 
During receptor-mediated endocytosis ligands bind to transmembrane receptors, 
which accumulate locally and this part of the cytoplasmic membrane is then 
associated with either caveolin or clathrin. Caveolin or clathrin-coating mediates 
formation of a small pit, which encloses the ligand-receptor complexes and the 
surrounding ECM followed by budding off the pit into the cytoplasm (Scheme 
1.17).140,144 Hereafter, clathrin is removed forming the early endosome. This form of 
transport provides a specific and concentrating mechanism for uptake of ligands 
without taking in correspondingly large amounts of the extra cellular fluid. Thus, the 
process of receptor mediated endocytosis both up and down regulates transmembrane 
signal transduction.  
 
Common for all types of endocytosis is that the early endosomal vesicles or 
phagosomes fuse and release their cargo into the late endosome. In the case of 
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receptor-mediated endocytosis many ligands dissociate from their receptor here and 
the receptor is recycled to the cell surface (Scheme 1.17).139 Enzymes from the trans-
Golgi network are deposited into the late endosome followed by delivery of the late 
endosomal material into the lysosome, where the material is hydrolysed and released 




Scheme 1.17: Schematic representation of different forms of endocytosis.  
 
1.6 Cell penetrating peptides 
Cell penetrating peptides (CPPs) are typically highly cationic peptides146, with a high 
abundance of amino acids such as Arginine or Lysine, or alternating 
charged/hydrophobic amino acids residues.146 Perhaps the most highlighted CPP is 
the so-called TAT peptide, named after the trans-acting activator of transcription 
(TAT) which demonstrates a remarkable ability to penetrate cells via binding to the 
TAT-receptor during human immunodeficiency virus infection.147,148 The so-called 
TAT peptide (GRKKKRQRRR) has subsequently been shown to promote cellular 
delivery or uptake of conjugated proteins, phage, liposomes, small molecules and 
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nanoparticles,146,149-155 with the peptide able to traverse almost all tissues via receptor 
mediated-endocytosis, including the brain. 149,150,151,152,153,154,155  
156,157,158,159,160,161,162,163,164 
The uptake mechanism of CPPs (and any conjugated cargo) into mammalian cells 
has been the subject of some controversy and both energy-dependent and 
independent pathways have been reported.150,155-164 Through the energy-dependent 
pathway CPPs traverse the cell membrane by endocytosis,163,164 although, the exact 
mechanism of endosomal uptake is poorly defined with no single uptake pathway 
identified, indeed several endocytosis pathway may be operating depending on the 
class of structure and cell type.163,164 It has also been suggested that CPPs enter cells 
by interaction with cell surface polysaccharides such as heparin sulphate, however, 
this too is the subject of some debate.165,166  
 
CPPs are readily synthesised and typically have low immunogenicity156,167 and offer 
numerous opportunities for the delivery of a variety of cargos.155,156 Furthermore, 
CPPs have been shown to selectively deliver therapeutic cargos by exploiting peptide 
affinity for tissue-specific markers, which comprise the so-called vascular ‘‘zip 
code’’ system. 168,169 Thus a chimeric peptide comprising of a tumor homing peptide 
combined with a cell-penetrating peptide has been reported to yield a peptide with 
tumor homing specificity that could efficiently deliver cargo molecules inside 
cells.170 Other CPPs such as RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) have also 
entered clinical trials and represent the first generation tumor homing peptides that 
do not home to the corresponding normal organ but seem to recognize molecules that 
are upregulated during tumor progression.171,172,173 This peptide-based targeted 
delivery increases the efficacy and decreases the side effects caused by the overall 
toxicity of the corresponding therapeutic compound.174  
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Chapter 2 Microwave-assisted 
orthogonal synthesis of PNA-peptide 
conjugates
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2.1 Introduction to PNA-peptide conjugate synthesis 
The orthogonal, solid phase synthesis of peptide-PNA conjugates using a Dde/Fmoc 
strategy with Dde/Mmt protected PNA monomers 2.1–2.4 (Scheme 2.1) and 
Fmoc/tBu protected amino acids has been reported previously6,14,15, 29. However, this 
approach is time consuming and non-automated, limiting wider applications of PNA-
peptide conjugates in chemistry and biology. As described in section 1.1, PNA has 
unique characteristics making it a very interesting and in vivo applicable DNA 
mimic. Thus, improved and faster synthesis of PNA could lead to more extensive 





















































2.3 2.4  
 
Scheme 2.1: The four Dde/Mmt-protected PNA building monomers employed in this 
project: (2.1) cytosine, (2.2) adenine, (2.3) guanine, and (2.4) thymine. 
 
To speed-up and automise PNA synthesis, microwave heat acceleration of both PNA 
monomer coupling and Dde deprotection was developed. To ensure that this method 
was applicable to orthogonal PNA-peptide conjugate synthesis, the previously 
reported orthogonality between Dde- and Fmoc-protection groups needed to be 
kept.6,14,15 This strategy was developed with the synthesis of two specific receptor-
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based, cellular binding, PNA–encoded peptide ligands, Arg-Gly-Asp-12-mer-PNA 
and Arg-Gly-Glu-12-mer-PNA. 
  
2.2 Choice of resins 
In previously reported procedures, polyethylene glycol dimethyl acrylamide (PEGA) 
resin was the resin of choice because of its high swelling-properties and low loading, 
which enables complete coupling of the bulky PNA chain. However, its large 
swelling ratio increases the amount of monomer required in each reaction as a larger 
reaction volume is required to suspend the resin. Although, microwave-aided 
synthesis is less laborious and time consuming than general reaction conditions, the 
microwave heating should be used with care with PEGA resin, as this resin is fragile 
and excessive stirring fragments the resin. During synthesis of PNA sequences (up to 
20 PNA/amino acids), this problem can be circumvented by reducing the stir rate to a 
maximum 300 rpm.  
 
2.3 Synthesis of PNA-peptide conjugates 
Resin 2.5 (Scheme 2.2) and the PNA monomers 2.1–2.4 were synthesised according 
to previously reported procedures,14 with the sole exception that the coupling of the 
functionalised nucleobases to the backbone was carried out with solid-supported 
dicyclohexylcarbodiimide (PS-DCC) rather than conventional DCC.175,176  
 
PNA-peptide synthesis was carried out in an automated CEM peptide synthesiser. 
PNA monomer coupling (Scheme 2.2) was carried out using pre-activated monomers 
(0.22 M Dde-monomer, 5.5 equiv.) in DMF, mixed with 0.20 M benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 5 equiv.) also in DMF 
and with N-ethylmorpholine (NEM; 11 equiv.) for 1 min followed by microwave 
irradiation for 20 min at 60 oC. After PNA monomer coupling the filtrate was 
collected and unreacted monomers were recovered. Dde-deprotection was carried out 
under acidic Dde-deprotection conditions (20% NH2OH·HCl/imidazole 1:0.75 in 
NMP/DMF 5:1). Here the key advantage of the NH2OH·HCl deprotection conditions 
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is highlighted, namely limiting the N-terminal detachment side reaction, which 
makes PNA synthesis problematic.  
 
Fmoc-deprotection and amino acid couplings were carried out according to standard 
literature procedures3,14 (Scheme 2.2). Following amino acid addition, the peptide 
was capped with acetic anhydride/pyridine (1:1) for 20 min, before the PNA was 
capped with 5(6)-carboxyfluorescein as described above for PNA monomer 








































































































Scheme 2.2: Orthogonal coupling of Dde/Mmt protected PNA monomers and 
Fmoc/tBu-protected amino acids. (i) 5.5 equiv. Dde-monomer, 5 equiv. PyBOP, and 
10 equiv. NEM in DMF, microwave irradiation, 20 min, 60 oC; (ii) 20% 
NH2OH·HCl/imidazole 1:0.75 in NMP/DMF 5:1, 1 h, room temperature or 
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microwave irradiation, 10 min, 60 oC; (iii) 5 equiv. amino acid, 5 equiv. 
HTBU/HOBt,  10 equiv. DIPEA in DMF, microwave irradiation, 20 min, 60 oC; (iv) 
20% piperidine in DMF, 2 x 10 min, room temperature; (v) acetic anhydride/pyridine 
(1:1), 20 min, (vi) 5.5 equiv. 5(6)-carboxyfluorescein (FAM), 5 equiv. PyBOP, and 
10 equiv. NEM in DMF, 20 min, 60 oC. Resin = PEGA (0.04 mmol/g). Rink = Rink 
amide linker. X = A or T. Z = Asp or Glu.  
 
The peptide–PNA conjugates were cleaved from the solid support with 5% 
triisopropylsilane (TIS) in TFA and purified by reverse phase high performance 
liquid chromatography (RP-HPLC) and analysed by matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF): Arg-Gly-Glu-Ahx-Lys(FAM)-
TATC-TGTT-TCTA-NH2: 12.42 min (95.2% purity), MALDI-TOF m/z (%) 
4206.33 [M+H]+ (100). Arg-Gly-Asp-Ahx-Lys(FAM)-TATC-TGTT-TCAT-NH2: 
12.37 min (95.2% purity), MALDI-TOF: m/z (%) 4193.04 [M+H]+ (100). 
 
Using these acidic Dde-deprotection conditions, the peptide-PNA constructs Arg-
Gly-Asp-Ahx-Lys(FAM)-TATC-TGTT-TCAT-NH2 and Arg-Gly-Glu-Ahx-
Lys(FAM)-TATC-TGTT-TCTA-NH2 (Scheme 2.2, Figure 2.1) were synthesised 
with all PNA and amino acid coupling, and deprotection cycles carried out in an 
automated microwave peptide synthesiser (CEM). These conjugates would be 
synthetically difficult to obtain via previous methods, as their sequences contain 
multiple poly-thymine residues6. However, this improved microwave-assisted 
synthesis yielded the conjugates Arg-Gly-Asp-Ahx-Lys(FAM)-TATC-TGTT-
TCAT-NH2
 and Arg-Gly-Glu-Ahx-Lys(FAM)-TATC-TGTT-TCTA-NH2 with 
respective overall isolated yields of 14% and 16% (over 36 steps) and purities of 
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Figure 2.1: (a) RP-HPLC of Arg-Gly-Glu-12-mer-PNA synthesised under acidic 
Dde-deprotection conditions (20% NH2OH·HCl/imidazole 1:0.75 in NMP/DMF 5:1). 
Eluting with A for 5 min; 100% A to 100% B over 20 min; 100% B for 5 min. (b) 
RP-HPLC of PNA-TGTT TCAT synthesised under basic Dde- deprotection 
conditions (20% NH2OH·H2O/imidazole 1:0.75 in NMP/DMF 5:1).  Column: 
Phenomenex Luna, C18, 15 cm x 1.00 cm, 5 cm.; λ = 220 nm; solvent A: H2O with 
0.1% TFA; solvent B: CH3CN with 0.1% TFA, eluting with 95% A to 95% B over 3  
in; 100% B for 1 min.  
     
a 
b 
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2.4 Conclusion 
Mild thermal effects achieved via microwave heating accelerated PNA synthesis 
allowed the automated synthesis of peptide-PNA conjugates while improving 
synthetic efficiency. This approach achieved PNA synthesis in a manner orthogonal 
to Fmoc chemistry, and in a way that prevented unwanted PNA side reactions, which 
shows Dde-chemistry is the method of choice for PNA-peptide conjucate synthesis. 
Hereby two PNA-encoded peptides, Arg-Gly-Asp-Ahx-Lys(FAM)-TATC-TGTT-
TCAT-NH2 and Arg-Gly-Glu-Ahx-Lys(FAM)-TATC-TGTT-TCTA-NH2 were 
synthesised by this method with overall isolated yields of 14% and 16% respectively 
(40 steps). Moreover, this strategy allowed synthesis of traditional synthetically 
difficult PNA-sequences containing multiple poly-Thymine residues. 
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Chapter 3 Targeting specific cellular 
delivery 
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3.1 Introduction to cell penetrating peptides 
Selective delivery of cargos into specific cell types has the capacity to ensure optimal 
distribution of therapeutic entities into diseased cells while limiting possible adverse, 
off-target effects.174 One possible route whereby this might be achieved is via 
receptor mediated endocytosis, which provides opportunities for targeted delivery 
where specific receptors are (over) expressed with so-called cell penetrating peptides 
(CPPs) that have been shown to facilitate cell penetration and delivery of a variety of 
covalently linked cargos.149-153, 174 
 
As described in section 1.6, CPPs are readily synthesised and typically have low 
immunogenicity156 and offer numerous opportunities for the delivery of a variety of 
cargos.155,156 Hereby, this peptide-based targeted delivery increases the efficacy and 
decreases the side effects caused by the overall toxicity of the corresponding 
therapeutic compound.174 The aim of this part of the project was to develop a strategy 
for the high-throughput screening of a PNA-encoded peptide/peptoid hybrid library 
to allow the identification of versatile, and human cell selective cell penetrating 




Figure 3.1: The strategy to allow the identification of cell selective penetrating 
peptides. An encoded 1296 member peptide library was incubated with cells.  Any 
extra-cellular peptides or peptides binding to the surface of the cells were released 
with trypsin and washed away. Cells were lysed, intracellular PNA extracted and 
hybridised onto a complementary 44,000 DNA microarray. 
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3.2 Encoded Library Synthesis 
A 1296 member fluorescein-labelled PNA encoded17,72 tetrapeptide-library 
(Library1) was designed and synthesised using split and mix methods69,70 (Scheme 
3.1). Six amino acids were used: Pro (turn), Glu (acidic), Leu (hydrophobic), Lys 
(basic), Tyr (aromatic), and a Lysine-like peptoid monomer (Llp, basic; Scheme 3.1) 
to represent the overall classes of the natural amino acids as well as a moiety, which 
is known to enhance cellular delivery and resist enzymatic degradation.177 Each 
amino acid was encoded by a PNA-quartet (Table 3.1) with each quartet designed to 
have maximum 50% similarity with other tags and maximum 50% purine content 
with the PNA tags designed to have uniform Tm and not include palindrome 
sequences or poly-thymine moieties (maximum 3 consecutive thymines; see table 1 


































































(a). repeat iii-iv x 3
(b). repeat i-ii x 3





























Scheme 3.1: Synthesis of a PNA encoded 1296 member peptide library: (i) 20% 
piperidine in DMF, 2 x 10 min;  (ii) amino acid [Fmoc-Pro-OH, Fmoc-Leu-OH, 
Fmoc-Glu(OtBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Llp(Boc)-
OH, 5 equiv]. HTBU/HOBt (5 equiv.). DIPEA (10 equiv.) in DMF, 20 min, 60 oC;  
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(iii) 20% NH2OH·HCl/imidazole 1:0.75 in NMP/DMF 5:1, 1 h or 10 min, 60 oC; (iv) 
Dde/Mmt-protected PNA monomer (5.5 equiv.), PyBOP (5 equiv.), and N-
ethylmaleimide (NEM, 10 equiv.) in DMF, 20 min, 60 oC; (v) acetic 
anhydride/pyridine (1:1), 20 min, (vi) 5(6)-carboxyfluorescein (FAM, 5.5 equiv.), 
PyBOP (5 equiv.), and NEM (10 equiv.) in DMF, 20 min, 60 oC. Resin = PEGA 
(0.04 mmol/ml). Rink = Rink amide linker.178 
 
Table 3.1:  PNA-encoding of the 6 amino acids.   
 
 
3.3 Library screening and hybridisation 
HeLa (human cervix epitheloid carcinoma), HEK293T (transformed human embryo 
kidney cells), SH-SY5Y (human neuroblastoma), K562 (human erythroleukemic 
cells), and ARN8 (human amelanotic melanoma cells) as well as mouse embryonic 
stem cells, E14 and human primary lymphocytes, human primary monocytes, and 
human primary neutrophils were incubated with the Library (100 µM) to ensure 
efficient exposure of each library member to the cells (this corresponds to 77 nM of 
each member) as well as yielding sufficient material following cell lysis for 
microarray analysis. Following incubation, washing and treatment with trypsin, the 
cells were lysed, the library members were extracted and purified by filter 
centrifugation (between 3,000 and 10,000 Da) and hybridised onto custom designed 
microarrays with 4 subarrays of 44,000 features each with 33 replicates of each 
oligonucleotide complementary to each member of the library as well as 1232 non-
coding negative controls (Agilent). Microarray scanning with data analysis 
(BlueFuse, BlueGenome) was used to extract the intensity of the FAM label, thereby 
determining the relative amount of PNA hybridised to each spot and the identify the 
peptide (Figure 3.2 and appendix II).  
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Figure 3.2: Sections of FITC-filtered fluorescence image of 44,000 feature DNA 
microarrays with 33 replicates of each oligonucleotide complementary to each 
member of the Library-1 library as well as 1232 non-coding negative controls 
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hybridised with the Library-1 library or PNA extracted from cells in 110 µL 1 x 
GenHyb (Genetix) buffer overnight from 50 oC to 32 oC.  
 
3.3.1 Microarray data and normalisation 
Raw microarray data was obtained from Bluefuse, which allows grid alignment and 
signal estimation, in a Microsoft Excel format. In Microsoft Excel the top ~5% and 
the bottom ~5% of each of the 33 replicate-sets were removed as outliers (erroneous 
values caused by dust, scrapes etc179,180). The mean fluorescence intensity was 
calculated over each of the remaining 29 replicates and over the non-complementary 
DNA features (negative controls).  
 
The 1296 mean intensities were corrected for the microarray background by 
subtracting the mean intensity of the non-complementary negative control features. 
Hereafter, the data was normalised for the control hybridisation by calculation the 
ratio between the background corrected mean intensities of the data sets obtained 
from hybridisation of PNA extracted from cells and the data set obtained from the 
hybridisation of the untreated 1296-peptide/PNA library (appendix II).  
 
Initially a generic consensus uptake sequence for all cell types was sought by 
analysis of scatter plots of the normalized mean intensities versus the variable 
monomers for positions AA1 to AA4 (Figure 3.3a). This revealed a generic global 
consensus sequence for all the cell types of Glu-Llp-Glu-Glu; a surprise in view of 
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Figure 3.3: DNA microarray analysis of a peptide-PNA library identifies a generic 
consensus sequence of highly cell-penetrating peptide. (a) Scatter plots of the 
background-corrected and normalised mean intensities of the FAM-labelled PNA 
derived from microarray hybridisation of PNA extracted from cells onto a 
complementary DNA microarray, plotted versus the monomers for positions AA1 to 
AA4. (b) Heat-map showing consensus sequences of the best cell-penetrating 
peptides extracted from the scatter plots.  
 
3.3.2  Quantitative delivery of the consensus sequence 
To verify and quantitatively compare the cellular delivery abilities of the consensus 
sequence, Glu-Llp-Glu-Glu, this peptide and the positive control, tetra-Llp were 
synthesised with a fluorescent tag at the N-terminus: FAM-Ahx-AA4-AA3-AA2-AA1-
NH2 (X-AA4-AA3-AA2-AA1-NH2).
15,17 and incubated with the cells and analysed by 
flow cytometry. 
 
The identified consensus sequence, X-Glu-Llp-Glu-Glu-NH2 had uptake levels 
similar to or greater than X-Llp-Llp-Llp-Llp-NH2 in K562, SH-SY5Y, HEK293T, 
HeLa, and ARN8 cells indicating that this novel highly anionic delivery agent could 
in some cases result in better delivery than the known, highly basic, peptide-based 
delivery agent (Figure 3.4). 
b 
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Figure 3.4: Flow cytometry analysis of the fluorescein-labelled X-Glu-Llp-Glu-Glu-
NH2 (written as Glu-Llp-Glu-Glu) and X-Llp-Llp-Llp-Llp-NH2 (written as tetraLlp) 
using a FACS Calibur cytometer with FITC and PE/PI filters (10,000 populations, 
n=3). Any extracellular peptide was released by treatment with trypsin (which also 
served to detached the cells) while trypan blue was used to quench any extracellular 
fluorescence181, ensuring that any observed increase in fluorescence was from just 
the intracellular peptide. (a) FITC filtered flow cytometry histograms gated for live, 
single cells following incubation with “hit”-tetramer as well as propidium iodide 
(selectively stains the nuclei of necrotic and apoptotic cells)182 to exclude dead cells 
(data not shown).  (b) Mean FITC filtered fluorescence of histograms versus the 
“hit”-tetramers. Error bars indicate ± s.d. 
 
3.3.3 Clustering analysis‡ 
To allow comparison of the data sets from different arrays, the 9 data sets were 
normalised so that the data sets had the same mean intensity arbitrarily set to 100 and 
the 1296 mean intensities in each data set were multiplied with respective 
normalisation factors (appendix II).  
 
The data set for each cell type were normalised allowing comparison of the data sets 
derived from different arrays (appendix II) and the data for the 9 cell types were 
clustered using Enthought Python and a Euclidean distance method (Figure 3.5a-b). 
                                                 
‡ The clustering analysis was performed in collaboration with Dr. Michael Dewar and Dr. J. Douglas 
Armstrong. Dr. Michael Dewar wrote the code using the Enthought Python software package and a 
Euclidian distance method. 
 b a 
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This resulted in a dendrogram and a heat map for each cluster, where the highest 
ratio between the maximum intensity and the remaining intensities represent the most 
selective peptide for the respective cell type (Figure 3.5a-b). The most selective 
clusters were selected and column diagrams of each of the peptides versus the cell 
types were generated. From this initial clustering it was evident that most of the 
highly selective peptide had maximum uptake in primary neutrophils. This was 
expected as this cell type is a ‘professional’ phagocyte183, which would lead to high 
uptake.  
 
In order to find the most selective peptide for each cell type, domination of the data 
set by highly endocytotic cell types must be avoided. This was achieved by dividing 
the 1296 normalised intensities into 9 groups whereby peptides with maximum 
uptake in one cell type were separately compiled (appendix II). This allowed 
clustering analysis to be performed on the basis of each individual cell type leading 
to a dendrogram and heat diagram for each cell type (Figure 3.5c-d; example of 
dendrograms and heat-maps shown for lymphocytes). The most selective tetramer for 
each cell type was identified from the heat maps by selecting the cluster with most 
significant “hot/cold” interface (Figure 3.5c, highlighted oval). In clusters with more 
than one peptide the peptide leading to the highest uptake level in the intended cell 
type was selected leading to a selective “hit”-peptide for each cell type (Figure 3.6 
and Table 3.2).  
 
Noticebly, the “hit”-tetramers identified for the neutrophils and the lymphocytes 
showed excellent selectivity, and the “hit”-tetramers identified for the monocytes, the 
SH-SY5Y, and the HEK293T cells showed moderate selectivity (Figure 3.6). The 
“hit”-tetramers identified for the E14, the K562, the HeLa and the ARN8 cells 
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All cell types 
a 
b 
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Figure 3.5: Clustering analysis of peptide-PNA/DNA microarray data identifies cell 
selective delivery agents. Dendrograns were derived from clustering analysis of the 
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cell types using Enthought Python and a Euclidean distance method. The 
dendrograms were cut such that ~20 clusters were produced. (a) Dendrogram 
obtained for combined data for all cell types. (b) Heat maps of clusters derived from 
the dendrogram. (c) Example of the dendrogram obtained for maximal uptake in 
primary lymphocytes. (d) Example of heat maps of clusters derived from the 
lymphocyte dendrogram. Red represents high relative intensity and blue represents 
low relative intensity. The number of horizontal bars across each cluster (different 
shade of coloured lines) depicts the number of peptides the respective cluster. In this 
heat map, cluster 11 (lymphocytes), which appears to have only one peptide, displays 










































































































































































































































































































































































































































































































































Figure 3.6: Column diagram of each of the peptide versus the cell types from the 
clusters exhibiting the greatest selectivity for each cell type using the original 
microarray data (before the internal normalisation).  
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3.3.4 Quantitative delivery of “hit” peptides 
To verify and quantitatively compare the cellular delivery abilities of the selected 
peptides, the sequences identified based on the microarray data were synthesised 
with a fluorescent tag: FAM-Ahx-AA4-AA3-AA2-AA1-NH2 (X-AA4-AA3-AA2-AA1-
NH2).
15,17 All the cell lines and the stem cells were incubated with the potential 
selective “hit”-tetramers and analysed by flow cytometry. To ensure that the 
experimental conditions are as close to in vivo conditions as possible the potential 
selective delivery agents were incubated with anticuagulated whole blood, followed 
by collection of the leukocytes and the neutrophils, monocytes and lymphocytes 
were separated by flow cytometry (Figure 3.7a).    
 
As expected, each of the “hit”-tetramers resulted in 100% uptake, i.e. the entire 
population is shifted in the histogram illustrating that all cells have internalised the 
respective peptide. In addition, a higher shift in fluorescence in the targeted cell type 
compared to the remaining 8 tetramers (Figure 3.7b).  
 
Comparison of each of the “hit”-tetramers across the cell types clearly demonstrated 
selectivity for the targeted cell type (Figure 3.8a). High-lighting this, X-Leu-Lys-
Lys-Pro-NH2 induced a 5-fold higher uptake in K562 cells compared to its uptake in 
all other cell types; X-Pro-Tyr-Glu-Glu-NH2 showed a 4-fold higher uptake in ARN8 
than in all other cell types; while X-Glu-Pro-Lys-Llp-NH2 under went a 3-fold higher 
uptake in E14 than in all other cell types (Figure 3.8a); wherease the remaining “hit”-
tetramers showed less selectivity for the targeted cell type (Figure 3.8a). 
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The myeloid leukaemia cell line, K562 has been reported to share some similar 
phenotypic characteristics to primary monocytes184,185. Selective uptake between 
circulating malignant and primary immune cells would be of great interest in 
targeting haematological cancers. In this regard, X-Leu-Lys-Lys-Pro-NH2 uptake in 
K562 cells was 6-fold higher than uptake in primary monocytes (Figure 3.8a). 
 
The uptake of some of the more unexpected “hit”-tetramers (X-Tyr-Pro-Lys-Leu, X-
Pro-Llp-Pro-Glu-NH2, and X-Pro-Tyr-Glu-Glu-NH2) were directly compared to the 
consensus sequence, X-Glu-Llp-Glu-Glu-NH2 and the positive control, X-Llp-Llp-
Llp-Llp-NH2 (Figure 3.7c and Figure 3.8b). The “hit”-tetramers had uptake levels 
equal to or higher than the positive control and also the consensus sequence in SH-
SY5Y and HeLa cells (Figure 3.7c and Figure 3.8b). X-Pro-Tyr-Glu-Glu-NH2
 had an 
uptake lever equal to or slightly lower than the positive control and the consensus 
sequence in ARN8 cells (Figure 3.7c and Figure 3.8b). This comparison illustrates 
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Figure 3.7: Flow cytometry analysis of the fluorescein-labelled “hit”-tetramers (X-
AA4-AA3-AA2-AA1-NH2 written as AA4-AA3-AA2-AA1) using a FACS Aria 
cytometer with FITC and PE-Texas-Red filters (a-c, 10,000 populations, n=3,) or a 
FACS Calibur cytometer with FITC and PE/PI filters (d, 10,000 populations, n=3). 
Any extracellular peptide was released by treatment with trypsin (which also served 
to detached the cells) while trypan blue was used to quench any extracellular 
fluorescence181, ensuring that any observed increase in fluorescence was from just 
the intracellular peptide. (a) Gating strategy for whole blood samples selecting 
populations of live single lymphocytes, monocytes and neutrophils. FITC filtered 
flow cytometry histograms gated for live, single cells following incubation with 
propidium iodide (selectively stains the nuclei of necrotic and apoptotic cells)182 to 
exclude dead cells as well as (b) cell selective “hit”-tetramers and (c) “hit”-tetramers 
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Figure 3.8: (a) Mean FITC filtered fluorescence of histograms versus the cell 
selective “hit”-tetramers (X-AA4-AA3-AA2-AA1-NH2). (b) Mean FITC filtered 
fluorescence of histograms versus the generic “hit”-tetramer compared to the cell 
selective “hit”-tetramers and positive control, X-Llp-Llp-Llp-Llp-NH2. Error bars 
indicate ± s.d. 
a 
b 
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3.4 Tetramer delivery is mediated by endocytosis 
To study compartmentalisation, the cells were incubated with their respective ‘hit’ 
tetramer and/or stained with LysoTracker red, and analysed by confocal microscopy. 
As a negative control for endocytosis, cells were also incubated with their respective 
‘hit’ tetramer and LysoTracker at 4 oC. Superimposed images of the red and green 
channels revealed co-localisation of the fluorescein label and LysoTracker red 
(yellow) illustrating that all the “hit”-tetramers incubated at 37 oC were 
compartmentalised into the lysosome. In contrast, only the LysoTracker fluorescence 
in the red channel and no fluorescence in the green channel were observed at 4 oC 
illustrating that internalisation of “hit”-tetramers was diminished by inhibition of 
active cellular uptake processes (Figure 3.9). Lysosome localisation and active-
transport dependence verifies that the all the “hit”-tetramers were taken up by 
endocytosis (Figure 3.9). 
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Figure 3.9: Selected Z-stacks of cells incubated with FAM-labelled “hit”-tetramer 
(X-AA4-AA3-AA2-AA1-NH2), followed by staining with LysoTracker Red, which 
specifically stains the lysosome. Confocal microscopy was performed using a 
Deltavision Tollervey microscope with FITC and TRITC filters. Red = LysoTracker 
red fluorescence, green is the fluorescein-labelled peptide. Yellow/orange colour is 
co-localisation of red and green fluorescence. Scale bars = 5 µm. 
 
3.5 Cytotoxicity 
In order for the peptides to have biological applications it is vital that they do not 
exhibit cellular toxicity. Cell viability upon treatment with the “hit”-tetramers (X-
AA4-AA3-AA2-AA1-NH2) was assessed with (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)186 assays. In living cells MTT is reduced to the 
purple formazan by mitochondrial reductase. As this enzyme is degraded in dead 
cells the colour intensisty is an expression of cell viability.  
 
Untreated cells were assumed to be 100% viable and the viability of peptide-treated 
cells was expressed as percentage live cells compared to untreated cells. All the 
“hit”-tetramers exhibited no cytotoxicity in all the tested cell types at 10 times the 
concentration of agent used for cell delivery (100 µM; Figure 3.10a).  
 
Additionally membrane toxicity was assessed using erythrocyte haemolysis assays. 
These demonstrated no evidence of haemolysis at 10 times the concentration of agent 
used for cell delivery (100 µM; Figure 3.10b). 
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Figure 3.10: (a) Cytotoxicity of hit-peptides assessed as cell viability by MTT 
assays (cell lines and stem cells). Cells were incubated with 100 µM “hit”-tetramer 
(X-AA4-AA3-AA2-AA1-NH2; 24 h) the media was changed and the incubation 
continued for 24 h and absorbance was measured at 580 nm. Untreated cells are 
assumed to be 100% variable. (b) Haemolysis assays showing no evidence of 
haemolysis at 100 µM of ‘hit’ tetramers on human erythrocytes. Untreated cells are 
assumed to be 100% variable. Error bars indicate ± s.d. n = 3.  
 
3.6 Conclusions 
Microarray analysis of a 1296 member PNA encoded peptide library identified an 
efficient generic delivery agent (Glu-Llp-Glu-Glu) for cervix epitheloid carcinoma 
(HeLa), erythroleukemic (K562), embryonic kidney cancer (HEK293T), 
a 
b 
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neuroblastoma (SH-SY5Y), amelanotic melanoma (ARN8) cells, stem cells (E14), 
and human primary lymphocytes, monocytes, and neutrophils.  
 
Clustering analysis of the microarray data identified selective delivery agents for all 
of the above cell types, excellent selectivity predicted for neutrophils and 
lymphocytes, moderate selectivity predicted for monocytes, SH-SY5Y, and 
HEK293T cells, and little selectivity predicted for E14, K562, HeLa and the ARN8 
cells. 
 
Flow cytometry analysis of the identified “hit”-peptides showed that X-Leu-Lys-Lys-
Pro-NH2 induced a 5-fold higher uptake in K562 cells compared to its uptake in all 
other cell types; X-Pro-Tyr-Glu-Glu-NH2 showed a 4-fold higher uptake in ARN8 
than in all other cell types; while X-Glu-Pro-Lys-Llp-NH2 under went a 3-fold higher 
uptake in E14 than in all other cell types; whereas the remaining “hit”-tetramers 
showed less selectivity for the targeted cell type. 
 
Comparison of the uptake of some of the more unexpected “hit”-peptides (X-Tyr-
Pro-Lys-Leu, X-Pro-Llp-Pro-Glu-NH2, and X-Pro-Tyr-Glu-Glu-NH2) with the 
consensus sequence, X-Glu-Llp-Glu-Glu-NH2 and the positive control, X-Llp-Llp-
Llp-Llp-NH2 revealed that the “hit”-peptides had uptake levels close to or higher than 
the positive control and the consensus sequence in SH-SY5Y, HeLa, and ARN8 
cells. This illustrates that these “hit”-peptides are not only selective but also very 
efficient cell delivery agents. 
 
Confocal microscopy revealed that the “hit”-peptides were taken up by a lysosome 
pathway, which verifies an endosomal mechanism for transfection of PNA by small 
peptide. The observed selectivity indicates that receptor mediated endocytosis is the 
mechanism for uptake of these peptides. Furthermore, the identified peptides showed 
no toxicity in the tested cell types.  
 
Noticeably, selective uptake between circulating malignant and primary immune 
cells, which would be of great interest in targeting haematological cancers, was 
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observed with 6-fold higher uptake of Leu-Lys-Lys-Pro in K562 cells compared to 
uptake in primary monocytes. 
 
This approach establishes a general strategy for the identification of small peptides as 
tools/reagents that allow selective delivery into any desired cell type. In addition, this 
technology presents and efficient and targeted delivery of PNA, this can enhance 
PNA’s antigene and antisense applications. This technology is not only limited to 
PNA delivery and will find applications in targeted delivery of potential drugs that 
do not have properties previously expected of drugs such as small size and cell 
permeability. 
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Chapter 4 Screening of an encoded 
peptide library to discover new cell 
binding ligands 
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4.1 Introduction to receptor mediated cellular attachment  
Through cell signalling pathways the integrins and GPCRs govern many vital 
cellular processes (section 1.4); thus integrins are involved in cell growth, division, 
apoptosis, survival, differentiation as well as viral binding and entry into cells.114,123 
GPCRs are involved in a wide range of functions115 such as binding of 
neurotransmitters regulating the nervous system controlling blood pressure, heart 
rate, and digestive processes, binding of chemokines regulating inflammatory 
responses, binding of opsins (visual sense) and odorants and pheromones (sense of 
smell), as well as sensing and regulating cell density (section 1.4). These essential 
biological functions make Integrins and GPCRs amongst the most heavily 
investigated drug targets in the pharmaceutical industry115,187,188. Thus, identification 
of new ligands could lead to the possibility of improved therapeutic targeting against 
these receptors. 
 
4.1.1 Previously reported integrin binding assays          
Several binding assays for integrins have been described to develop ligand arrays for 
integrin receptors and include the work by C. M. Niemeyer189, who recently 
developed a platform for DNA-directed immobilization of peptides, which allowed 
integrin mediated adhesion of fibroblast cells on RGD-features. Moreover, this 
method enables implementation of DNA microarrays as decoding tools in 
combinatorial synthesis and screening of cell surface receptor ligands.189 
Simultaneously in another example of integrin binding assays, L.L. Kiessling et al. 
developed peptide surfaces that support human embryonic stem cell growth and self-
renewal; although, no receptors responsible for the cell adhesion could be 
identified.190 However, Niemeyer and Kiessling demonstrated that peptide arrays 
supporting cell growth can used to identify ligands inducing cell migration, 
proliferation, and differentiation.  
 
C. Lethias et al. mapped cell adhesion sites and identified integrin receptors by cell 
binding to tenascin-X191. This demonstrated induction of cell attachment via binding 
of RGD (in tenascin-X) to integrin receptors. 
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K. S. Lam. et al. identified peptide ligands for cell surface receptors by the adhesion 
of human lung cancer cells onto a bead-based combinatorial library that allowed 
identification of a consensus sequence (cNGRGEQc) for the α3β1 integrin.
192 This 
work established the strategy of screening libraries for cell surface receptor binding; 
however, it lacks the advantages of high-throughput screening of an array. Y. 
Yamada and M. Nomizu et al. identified several metastasis promoting sequences by 
screening potential integrin peptide ligands.193,194      
 
L. G. Griffith et al. computed the effect of clusters of integrin ligands on integrin 
signaling and linkage between integrins and intracellular structures.195 This 
demonstrated that higher ligand densities increase adhesion strength by locally 
concentrating receptor in the membrane.  
 
4.2 Strategy of cell membrane-receptor screening 
Expanding on the previously reported integrin binding assays the aim of this project 
was to develop a microarray based high-throughput screening method for the 
identification of peptide ligands for cell surface receptors. This would achieve 
screening of human cells in a selective "cell-growth-on-microarray" design189  
(Scheme 4.1), allowing information on the interaction between the peptide-ligands 
and the cell surface receptors to be extracted on a single spot-by-spot (compound-by-
compound) basis. This technique would facilitate screening with cells with variations 
in surface-receptor ligand densities and/or receptor expression. 
 
Initially the PNA-encoded peptides Arg-Gly-Glu (RGD) and Leu-Asp-Val (LDV), 
which are perhaps the most studied integrin ligands118, well as Gly-Gly-Gly (GGG) 
were synthesised by microwave aided PNA and peptide couplings (Chapter 2). The 
PNA-tags were hybridised to complementary DNA microarrays specially designed 
with a “cell-repellent” surface and screened against HeLa cells (human epithelial 
cervix cancer). In addition, ligand binding was verified by flow cytometry. The 
overall strategy is shown in Scheme 4.1.  
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Scheme 4.1: Strategy of cell based microarray screening of a library of PNA-
encoded peptide ligands for binding to cell surface receptors. 
 
4.3 Cell microarray nomenclature 
The following nomenclature is assigned to cell binding on microarrays: specific 
binding refers to the attachment of cells only in printed areas, i.e. no unspecific 
binding to the microarray surface; selective binding refers to the attachment of cells 
only to receptor ligands, i.e. no unselective binding to negative controls.     
 
4.4 Production of cell specific microarray surface 
peptide-PNA/DNA microarrays were manufactured by contact printing amino 
modified DNA complementary the RGD-, LDV- and GGG-encoding PNA (Chapter 
2), TCTTA–PNA (negative control), and non-coding fluorescent DNA (positive 
control for printing and negative control for cell binding) on Codelink microarrays. A 
range of reaction conditions and compounds were tested to generate a novel cell 
repellent microarray surface (data not shown) and this was achieved by fabrication of 
fluorinated glass surfaces by capping unreacted active esters on the Codelink surface 
with perfluorooctyl propylamine. 
 
The PNA-encoded peptides were hybridised to their complementary partners on the 
array prior to screening with cells followed by high content microscopy and 
fluorescent scanning. This revealed a highly selective surface with attachment on 
RGD and LDV features with no cell attachment observed outside the printed regions 
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(Figure 4.1). Following adhesion, cells were observed to spread over the entire 
printed area of 80% of all RGD features, 70% of all LDV features, and 55% all GGG 
features (72 h, Figure 4.1). Slight cell attachment was also observed 10% of all 
features of non-coding DNA and PNA (72h, Figure 4.1). Following analysis the cells 
could be removed from the array by sonication in 10 mM Tris buffer (pH 8) for 10 
min, a gentle cell stripping procedure that removes all attached cells without 
removing the PNA or damaging the DNA microarray, allowing the cell binding 
microarrays to be re-used. 
 
                    RGD                                                                                  TCTTA (PNA) 
 
          non-coding DNA                                 LDV                                       GGG  
 
 
             
 
Figure 4.1: Microarray analysis of cell binding onto PNA-encoded peptides. DNA 
microarrays designed with 3 x 3 x 3 x 3 matrices of DNA oligonucleotides 
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complementary to and hybridised with RGD-PNA, LDV-PNA, GGG-PNA, TCTTA 
(PNA, negative control), non-coding DNA (negative control) and fluorinated surface 
modification. (a) HeLa cells were incubated 72 h and the cells fixed (4% 
paraformaldehyde) and stained with DAPI (blue) and phalloidin (red). (b) Brightfield 
and DAPI and phalloidin images of RGD features at 8 and 72 h.   
 
4.4.1 Verification of integrin-ligand binding by flow cytometry 
HeLa cells were analysed by flow cytometry to measure the relative binding affinity 
and to verify surface binding of the fluorescent peptide-PNA conjugates. Histograms 
of cell count vs. fluorescein isothiocyanate (FITC) fluorescence were created based 
on scatter plots gated for single, FITC-only positive, live cells (Figure 4.2). A similar 
increase in fluorescence was observed with the RGD-PNA and GGG-PNA treated 
cells compared to the untreated cells, whereas, LDV-PNA caused a slightly smaller 
increase in fluorescence. The relatively high level of fluorescence observed with 
GGG-PNA may be due to cellular uptake and/or unspecific cell surface interactions 
rather than integrin dependent binding. This would also explain the discrepancy 
between flow cytometry and microarray screening, where GGG features showed less 
cellular binding than RGD and LDV. Trypsin treatment after RGD-PNA incubation 
reduced the fluorescence signal to that of the untreated cells (Figure 4.2). Trypsin 
degrades surface receptor moieties and any bound peptide, which shows that the 
RGD-PNA is surface bound and not taken up by the cells.  
 
The cytotoxicity was evaluated by comparing the percentage of dead cells during 
flow cytometry in untreated cells and peptide-PNA conjugate treated cells. The 
relatively large number of dead cells (12%) in the untreated sample is expected due 
to the harsh detachment by scraping. RGD-PNA and LDV-PNA induced limited 
cytotoxicity (22% dead cells), whereas GGG-PNA had a greater cytotoxicity (26% 
dead cells). 
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Figure 4.2: Histograms of number of fluorescent cells versus fluorescence intensity 
of HeLa cells after incubation with 10 µM, RGD-, LDV-, GGG-PNA conjugates in 
DMEM CM + CaCl2 (50 µM) and MgCl2 (50 µM) at 37 
oC for 30 min.  
 
4.4.2 Conclusion 
The fluorinated surface provides a specific microarray platform for receptor 
mediated cell binding. This method of sorting of a library by the specific DNA and 
PNA-amino acid hybridisation enables screening of thousand member libraries with 
internal controls. In addition, this approach facilitates the study different cell types 
simultaneously and thereby screening for differences in surface-receptor ligands 
and/or receptor expression between diseased and normal cells or between various cell 
types. 
 
4.5 High throughput screening of receptor mediated 
cellular binding on microarray 
The aim of this project was screening of an immobilised 10,000 member PNA-
encoded peptide library (Library-229, Scheme 4.2) with human cells in a selective 
"cell-growth-on-microarray" design189. The PNA encoded peptide library was based 
on sequences reported by Y. Yamada et al.193 and designed to target integrins as well 






Nina Svensen                                                                                                   Chapter 4 
  86
   
long arms of mouse laminin 1 and found Phe-Gln-Val-Ala-Tyr-Ile-Ile-Ile-Lys 
(FQVAYIIIK) demonstrating strong B16-F10 cell adhesion.193 Consequently, 
Library-2 consisted of 10,000 nonapeptide-PNA conjugates with four variable 
positions each containing 10 different amino acids in the common sequence: Ac-Phe-
Gln-AA4-AA3-Tyr-AA2-AA1-Ile-Lys-PNA18-Fluorescein with each variable amino 
acid encoded by a PNA-triplet.29 The arrays used each contained 4 x 44K features, 
allowing 16 copies of each library member to be analysed per array. Cell lines used 
were D54 (αvβ5 and αvβ3 integrin overexpressing)
196,197 and HEK293T-CCR6 
(CCR6 GPCR overexpressing)134 allowing screening with cells with variations in 











Scheme 4.2: Generic structure of Library-2. AA1, AA2, and AA4 were Ile, Val, Phe, 
Pro, Arg, Glu, Lys, d-Pro, Ser or d-Val and AA3 Ile, Val, Phe, Ala, Pro, Arg, Glu, 
Lys, d-Ala, Ser or Pro. FAM is 5(6)-carboxyfluorescein amide. 
 
4.5.1 High throughput screening of cell/peptide-microarrays 
Library-2 was hybridised onto custom DNA microarrays (Agilent, 44k x 4, Figure 
4.3); which thereby renders the library of peptides available for receptor binding. 
Fluorescent microarray imaging and data analysis (BlueFuse; BlueGenome) 
confirmed the efficient hybridisation of the library onto the array (Figure 4.3). D64 
and HEK293T-CCR6 cells were incubated with the PNA hybridised microarrays in 
serum-free media to reduce non-specific adsorption of cell adhesive proteins. To 
minimize interference from cell secreted proteins incubation times were kept short (2 
h), while the surface of non-printed areas of the microarray was very hydrophobic 
surface and thus prevents cellular attachment and growth. The cells were fixed and 
nuclei stained with DAPI and fluorescent imaging was used to extract the intensity of 
the DAPI label (appendix III). This choice of fluorescent labels allows relative 
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quantification of the amount of peptide/PNA and cells (DAPI) on each spot, which 
enables accurate comparison of the receptor affinity for the peptides (Appendix III). 
Microarray imaging showed that attached D54 and HEK293T-CCR6 cells appeared 
to have a normal and healthy morphology (elongated and spread out shape, Figure 
4.3). 
 
4.5.2 “Hit” sequences allowing selective cell attachment  
Raw microarray data was obtained from Bluefuse, which allows grid alignment and 
signal estimation, in a Microsoft Excel format. In Microsoft Excel the top ~5% and 
the bottom ~5% of each of the replicate-sets were removed as outliers (erroneous 
values caused by dust, scrapes etc179,180). The average fluorescence intensities were 
calculated over each of the remaining 14 replicates and over the non-complementary 
negative control features. The average intensities were corrected for the background 
by subtracting the average intensity of the non-complementary negative control 
features. Thereafter, the data was normalised for the PNA hybridisation by 
calculating the ratio between the background corrected average intensities of the 
DAPI-label and the FAM-label for each of the background-corrected averages 
(appendix III).  
 
Scatter plots of the ratios of the DAPI and FAM background corrected average 
microarray intensities (cell binding) versus the variable amino acids for positions 
AA4 to AA1 were constructed (Figure 4.4) and showed that cells showed preference 
for some peptides over others and allowed consensus sequences for each cell line to 
be derived by combining the most preferred amino acids for each of the variable 
positions (Table 4.1). In the same manner, consensus sequences of non-binding 
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Figure 4.3: Microarray analysis of cell binding onto PNA-encoded peptides. DNA 
microarrays designed with 4 sub-arrays of 44,000 features each with 4 replicates of 
each oligonucleotide complementary to each member of the 10,000 member library 
as well as 4,000 non-coding negative controls. D54 and HEK293T-CCR6 cells 
incubated on Library-2 hybridised microarrays in serum free media (2 h) followed by 
a b 
c d 
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incubation in complete media (16 h) and fixation (4% paraformaldehyde) and nuclei 
staining with DAPI (blue). (a, c) FAM and DAPI fluorescent imaging and (b, d) 
Brightfield and DAPI fluorescent imaging of D54 and HEK293T-CCR6 cell arrays. 




Figure 4.4: Scatter plots of relative microarray intensities derived from the binding 
of D54 and HEK293T-CCR6 on Library-1 microarrays versus the variable amino 
acids for positions AA1-4. 
Nina Svensen                                                                                                   Chapter 4 
  90
   
Table 4.1: Consensus sequences derived from scatter plots based on microarray 





4.5.3 Synthesis and microarray printing of hit peptides 
To verify and quantitatively compare cellular affinities of the binding and non-
binding sequences the fluorescein (FAM) labelled peptides, FAM-Ahx-Phe-Gln-
dPro-Ile-Tyr-Ile-Ile-Ile-Lys-NH2 (X-FQpIYIIIK-NH2), FAM-Ahx-Phe-Gln-Ile-Pro-
Tyr-Ile-Ile-Lys-NH2 (X-FQIPYIIIK-NH2), FAM-Ahx-Phe-Gln-Lys-Lys-Tyr-Ser-
Arg-Ile-Lys-NH2 (X-FQKKYSRIK-NH2), and FAM-Ahx-Phe-Gln-Pro-Lys-Tyr-Ser-
Phe-Ile-Lys-NH2 (X-FQPKYSFIK-NH2) were synthesised.
15,17 As a positive control 
for integrin binding FAM-Ahx-Arg-Gly-Asp-NH2 (X-RGD-NH2) was also 
synthesised. 
 
Peptide arrays were generated by contact printing the FAM-labelled peptides onto 
succinimidyl-ester activated slides (750-900 µm spots) with a highly cell-repellent 
surface produced elsewhere on the slide by blocking unreacted regions with 
perfluorooctyl propylamine as described before ensuring that any cellular attachment 
on the arrays was peptide-mediated.  
 
4.5.4 Cell adhesion through specific peptide interactions 
D54 cells were incubated on the X-FQpIYIIIK-NH2 and X-FQKKYSRIK-NH2 
displaying array, whereas HEK293T-CCR6 cells were incubated on a X-FQIPYIIIK-
NH2 and X-FQPKYSFIK-NH2 displaying array as described above. As expected 
cells attached only on the printed regions of array and appeared to have a normal and 
healthy morphology (elongated and spread out shape, Figure 4.5). Substantially 
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greater cellular adhesion was observed on the “hit” binding peptides than on the non-
binding peptide controls (92% of all adhered D54 cells were on X-FQpIYIIIK-NH2 
compared to only 8% of all adhered cells on X-FQKKYSRIK-NH2, Figure 4.5).  
 
Likewise, more than 99% of all adhered HEK293T-CCR6 cells were on X-
FQIPYIIIK-NH2 compared to less than 1% of all adhered cells on X-FQPKYSFIK-
NH2 (Figure 4.5). This verifies that novel cell binding surface substrates can be 
identified by high-throughput screening of microarray supported PNA-encoded 
peptides and that cell adhesion is indeed peptide specific. 
 
4.5.5 Validation of receptor mediated cell adhesion 
To verify that cell adhesion was receptor mediated, a soluble modulator for the 
respective receptor was added to the media during microarray incubation. The D54 
cells over-express αvβ5 and αvβ3 integrins
196,197,198, which can be blocked by the 
natural ligand, RGD; whereas, the CCR6 receptor can be blocked by the agonist, anti 
human CCR6. Thus, D54 cells were incubated in the presence of X-RGD-NH2 (100 
µM) on the X-FQpIYIIIK-NH2-surface, which blocked cell adhesion by 98% in the 
number of cells bound compared to incubation without X-RGD-NH2, demonstrating 
that D54 binding to X-FQpIYIIIK-NH2 is integrin mediated (Figure 4.5).  
 
Similarly, HEK293T-CCR6 cells were incubated in the presence of peridinin 
chlorophyll protein complex (PerCP) anti human CCR6 on the X-FQIPYIIIK-NH2 
surface, which blocked cell adhesion by 98% demonstrating that HEK293T-CCR6 
binding to X-FQIPYIIIK-NH2 is GPCR mediated (Figure 4.5).  
 
As a negative control for CCR6 binding HEK293T cells were incubated on a X-
FQIPYIIIK-NH2 and X-FQPKYSFIK-NH2 surfaces, in the same manner. As 
expected, HEK293T adhesion was greatly reduced (~90%) compared to HEK293T-
CCR6 adhesion on the X-FQIPYIIIK-NH2 features, further illustrating that X-
FQIPYIIIK-NH2 binding is CCR6 mediated (Figure 4.5).   
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This study illustrates that peptide-ligands for cell surface receptors can be identified 




Figure 4.5: Verification of ligand binding by microarray analysis. Green (FITC) = 
peptide ligand, blue (DAPI) = nuclei staining of attached cells, and red (phalloidin) = 
actin-filament staining of attached cells visualization of cells incubated in serum free 
media (2 h) followed by incubation in complete media (16 h): (a) D54 cells 
incubated on X-FQpIYIIIK-NH2 (written as FQpIYIIIK) and X-FQKKYSRIK-NH2 
Nina Svensen                                                                                                   Chapter 4 
  93
   
(written as FQKKYSRIK; left) and in the presence of soluble X-RGD-NH2 (right). 
(b) HEK293T-CCR6 cells incubated on X-FQIPYIIIK-NH2 (written as FQIPYIIIK) 
and X-FQPKYSFIK-NH2 (written as FQPKYSFIK, left) and in the presence of 
soluble PerCP anti-human CCR6 (right). (c) HEK293T cells incubated on 
FQIPYIIIK and FQPKYSFIK. The cells were fixed (4% paraformaldehyde), the 
actin-filaments stained with phalloidin (red) and the nuclei stained with DAPI (blue). 
Scale bars = 10 µm.  
 
4.5.5.1 The agonist/antagonist binding-mode of the identified integrin 
ligand 
Agonist binding to integrins causes a conformational change in the receptor allowing 
phosphorylation and activation of focal adhesion kinase (FAK), which leads to 
formation of the adhesion complex attached to the actin-cytoskeleton117. Hereby, the 
actin filamentous system can be organized to induce cell migration by continuously 
binding new ligands at the front of the cell and releasing those at the rear199.  
 
Staining of the F-actin filaments in D54 revealed that cells attached to X-FQpIYIIIK-
NH2 had a high concentration of actin in one end of the axon and less in the 
remainder of the cell (Figure 4.5, white arrows). Contrarily, D54 cells adhered to X-
FQKKYSRIK-NH2 did not show the same localization of actin filaments towards 
either end of the cell. Noticeably, cells attached to X-FQpIYIIIK-NH2 in competition 
with soluble X-RGD-NH2 had a round morphology with no axon formation and no 
actin localization illustrating that the X-FQpIYIIIK-NH2 failed to induce focal 
adhesion formation when inhibited by X-RGD-NH2. These differences in cell 
morphology indicate that X-FQpIYIIIK-NH2 is binding as an agonist inducing 
conformational change in the receptor and ultimately linking the actin filaments. 
 
4.5.6 Cytotoxicity 
In order for the peptides to have biological applications it is vital that they do not 
exhibit cellular toxicity. Cell viability upon treatment with the “hit”-peptides was 
assessed with MTT186 assays as described before (section 3.5). Untreated cells were 
assumed to be 100% viable and the viability of peptide-treated cells was expressed as 
Nina Svensen                                                                                                   Chapter 4 
  94
   
percentage live cells compared to untreated cells. None of the “hit”-peptides showed 
cytotoxicity in any of the tested cell lines at 100 µM (Figure 4.6).  
 






















































        
 
Figure 4.6: Cytotoxicity of hit-peptides assessed as cell viability by MTT assays. 
Cells were incubated with X-FQAA4AA3YAA2AA1IK-NH2 (100 µM) or X-RGD-
NH2 (100 µM; 24 h), the media was changed and the incubation continued for 24 h 
and absorbance was measured at 580 nm. Untreated cells are assumed to be 100% 
variable. Error bars indicate ± s.d. (n = 3). 
 
4.5.7 Conclusion 
Microarray analysis of a 10,000 member PNA encoded peptide library identified new 
peptide ligands for αvβ5 and αvβ3 integrin and the CCR6 GPCR, namely FQpIYIIIK 
and FQIPYIIIK that demonstrated low cytotoxocity. Scatter plots of the microarray 
intensity versus the varying amino acid position in Library-2 showed preference for 
some amino acids over others, allowing consensus sequences for both receptor 
binding (FQpIYIIIK and FQIPYIIIK) and non-binding peptides (FQKKYSRIK and 
FQPKYSFIK) to be extracted for αvβ5 and αvβ3 integrins and CCR6 respectively.  
 
Synthesis followed by surface immobilisation of these “hit”-peptides with a 
fluorescent label allowed verification of receptor binding. Competition studies with 
the natural ligands for receptors demonstrated that binding of X-FQpIYIIIK-NH2 and 
D54
CCR6
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X-FQIPYIIIK-NH2 is integrin and CCR6-mediated respectively, whereas X-
FQKKYSRIK-NH2 and X-FQPKYSFIK-NH2 do not bind these receptors.  
 
This approach establishes a strategy for high-throughput screening for the 
identification of ligands for integrins and GPCRs offering and efficient approach to 
de-orphanise the many GPCRs, for which there are no known ligands. As integrins 
and GPCRs amongst the most heavily investigated drug targets in the pharmaceutical 
industry today115,137 identification of new agonist or antagonists of these receptors by 
this method can help identify new drug-targets as well as leads.  
 
The technology would also allow screening of a wide variety of cell surface receptors 
and offers a tool for investigating differences in membrane receptor expression 
between different cell types including diseased cells.  
 
Furthermore, this approach facilitates simultaneous screening of different cell types 
in a competition study simply by staining the different cells with different cell tracker 
dyes prior to screening. 
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Chapter 5 Microarray generation of 
10,000 oligonucleotides 
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5.1 Generation of DNA libraries 
As discussed in section 1.2.2.1 there are many examples of DNA being used as an 
encoding device for peptides or small molecules, enabling the high-throughput 
screening of peptide interactions with biological targets or screening of drug 
candidates. These DNA-encoding methods (section 1.2.2.1) rely on synthesis of 
DNA oligonucleotide libraries and development of methods for effective and 
economical generation of DNA libraries would be of great interest to this field. 
89,90,91,200,201 
Microarray based DNA libraries have been employed in gene expression profiling 
studies89-201, whereby cellular mRNA is extracted and the corresponding cDNA is 
hybridised onto a complementary DNA microarray. Hereby, the expression of 
thousands of genes is measured at once, to create a global picture of cellular function 
including identification of genes whose expression is changed in response to 
pathogens or other organisms200.  
 
Examples of the fabrication of DNA libraries include “PCR” on solid supported 
primers to enable high-throughput production of oligonucleotides202 Hereby, primers 
are covalently attached to microarrays allowing hybridisation of specific DNA 
targets and elongation of the primers generating microarray supported DNA libraries 
with high density of oligonucleotides of any length.202,203 This technique has been 
shown to reduce non-selective DNA oligonucleotide amplification and thereby 
enhancing identification of diagnostic targets204 and improving SNP detection205. 
Efforts have been made to synthesise oligonucleotide libraries from microarrays 
simply by cleaving the oligonucleotides off the array followed by PCR amplification 
of the cleaved oligonucleotides in solution. This generated multiplex DNA libraries 
for parallel genomic assays206, however, the technique is sacrificial, offering no 
means of reuse of the DNA array and it allows amplification of oligonucleotide 
libraries as mixtures only.  
 
However, the use of oligonucleotide libraries in chemical, biological and genetic 
research, including gene expression profiling, has its limitations in the expense of 
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vast numbers of DNA oligonucleotides. Thus, the aim of this project was to develop 
an approach to the generation of DNA libraries from DNA microarrays, while 
keeping the array intact and useable for subsequent applications, allowing the 
efficient and inexpensive production of custom made thousand-member DNA 
libraries. This was achieved using 10,000 oligonucleotides, which were “read-off” 
the array by a polymerase and subsequently amplified by PCR (Scheme 5.1). The 
generated DNA libraries were evaluated by Solexa sequencing as well as 
conventional microarray analysis.   
 


































Scheme 5.1: Concept of generation of DNA oligonucleotides from microarrays and 
parallel analysis. FAM = 5(6)-carboxyfluorescein. 
 
5.2 Microarray design  
In order to explore the fidelity of the approach microarrays were designed to contain 
an increasing number of different DNA oligonucleotides (1, 10, 3875, or 10,000) and 
were based on the 17 base pair (bp) sequences complementary to a previously 
reported 10,000 member PNA-encoded peptide library29.  
  
The 1-member oligonucleotide array was designed to contain just one sequence 
(Table 5.1a), which included two domains complementary to primer-1 and primer-2 
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(Table 5.1a, red domains), in a 10 x 10 pattern. The 10-member oligonucleotide array 
was designed with the variable domain (17 bp; Table 5.1a, black) flanked by 
domains complementary to primer-1 and primer-2 (Table 5.1a, red). The 
oligonucleotides were randomly organised with 4,000 replicates in 4 x 44,000 
subarrays. In addition, each subarray included 4,000 non-complementary DNA 
oligonucleotides as negative controls. 
 
The 3,875 and 10,000-member oligonucleotide arrays were designed with the 
variable domain (17 bp; Table 5.1a, black) flanked by domains complementary to 
Solexa-primer-1 and 2 (Table 5.1a, blue/green) to allow subsequent DNA 
sequencing. In order to quantitatively assess the amplification of each 
oligonucleotide on the array the 3,875 oligonucleotide array was designed with 
scaling of the content of the oligonucleotides with either 1, 2, 4, 8, or 16 replicates of 
each oligonucleotide in each of the 4 x 44,000 subarrays (Table 5.1b). In addition, 
each subarray included 1,375 non-complementary DNA oligonucleotides as negative 
controls. The 10,000 oligonucleotides were organised randomly with 4 replicates of 
each in 4 x 44,000 subarrays and each subarray included 4,000 non-complementary 
DNA oligonucleotides as negative controls. 
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Table 5.1: (a) General microarray supported oligonucleotide sequences and primer 
sequences. X is A, C, or T. (b) Number of replicates of oligonucleotides on the 
scaled content 3,875-member oligonucleotide microarray.  
 
 
1-member oligonucleotide microarray 
5’-TCCCAGGGAAAGCATGGAAGAAGGAGAACCTTCTCTCTCTCTCTCTCTCT-3’ 
10-member oligonucleotide microarray  
5’-TCCCAGGGAAAGCATGGXXXXXXXXXXXXCTTCTCTCTCTCTCTCTCTCT-3’ 














5' CTACACGACGCTCTTCCGATCTGG 3’ 
Primer-4-FAM 
FAM- 5' GCATACGAGCTCTTCCGATCTAAG 3’ 
 
 
Number of oligonucleotides x 
number of replicates  
2000 oligonucleotides x 16: 32,000 
1000 oligonucleotides x 8:   8,000 
500 oligonucleotides x 4:  2,000 
250 oligonucleotides x 2:  500 
125 oligonucleotides x 1:  125 
3,875 oligonucleotides in total: 42,625 
 
5.3 PCR “read-off” microarrays 
The first steps in the process involved primer hybridisation and elongation on the 
solid support and required extended hybridisation and elongation times for efficient 
production of a double stranded DNA microarray, with one DNA strand covalently 
attached to the surface. The newly synthesized DNA strand could then function as a 
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PCR “read-off” the 1-member oligonucleotide array gave a 50 bp band by DNA gel 
electrophoresis (Figure 5.1a). Conventional Sanger sequencing of the PCR amplified 
product showed the expected oligonucleotide sequence (Table 5.1a). PCR “read-off” 
the 10-member oligonucleotide microarray (Table 5.1a) also gave the expected 50 bp 
band by gel electrophoresis (DNA-10), while the larger 3,875 and 10,000-member 
oligonucleotide microarrays gave the expected 107 bp band (DNA-3,875 and DNA-
10,000 respectively; Figure 5.1a). Furthermore, enzymatic digestion with EcoICRI 
(recognition sequence: 5’-GAGCTC-3’) of DNA-3,875 and DNA-10,000 resulted 
in the two expected fragments (85bp and 22bp; Figure 5.1c). 
 
PCR on the 10,000-member oligonucleotide microarray was repeated 5 times after 
the initial round of primer hybridisation, extension, and washing but without 
stripping the newly synthesized DNA. This resulted in similar isolated yields (39-
40%, equation 7.1) illustrating that PCR can be performed multiple times without 
damaging the array (Figure 5.1b). No DNA was observed when the PCR “read-off” 





Figure 5.1: DNA gel electrophoresis of: (a) PCR products from 1, 10, 3,875, 10,000-
member oligonucleotide arrays; (b) 5 repeats of PCR products from the 10,000-
member oligonucleotide array; (c) DNA-10,000 and DNA-3875 and EcoICRI 
digestion. 
 
a b c 
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5.4 Microarray hybridisation of PCR products 
To allow microarray quantification of the DNA microarray “read-off” libraries these 
were further amplified by PCR with a FAM labelled primer and an unlabelled primer 
(primer-1 and primer-2-FAM for DNA-10; primer-3 and primer-4-FAM for DNA-
3,875 and DNA-10,000) producing FAM-labelled dsDNA libraries (DNA-10-FAM, 
DNA-3,875-FAM, DNA-10,000-FAM; Table 5.1 and Figure 5.2).  
 
The doublestranded DNA-3,875 and DNA-10,000 libraries were sought to be 
hybridised to DNA microarrays that encode only the variable domain of the DNA-
10,000 library (17 bp; Table 5.1a, black). However, hybridisation of the 17 bp 
microarray supported oligonucleotides with the 107 bp dsDNA libraries is very 
challenged due to the competition between the non-microarray complementary 107 
bp DNA strands and the 17 bp strands. Thus, to improve the efficiency of microarray 
hybridisation single stranded DNA libraries were synthesised by PCR with a single 
primer (primer-4-FAM) producing microarray complementary ssDNA libraries 




Figure 5.2: DNA gel electrophoresis of products from PCR with two primers 
producing dsDNA-10,000-FAM and dsDNA-3,875-FAM (primer-3 and primer-4-
FAM), and dsDNA-10-FAM (primer-1 and primer-2-FAM) and products from PCR 
with a single primer producing ssDNA-10,000-FAM and ssDNA-3,875-FAM 
(primer-4-FAM). 
 
dsDNA-10-FAM was then hybridised onto a complementary DNA microarray 
identical to the “read-off” DNA microarray (above); whereas the ssDNA-3,875-FAM 
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and ssDNA-10,000-FAM libraries were hybridised onto microarrays that were 
complementary the 17 bp variable domain (Table 5.1a, black). Fluorescent 
microarray imaging in combination with BlueFuse technology (BlueGenome) was 
used to quantify the intensity of the FAM-label and thereby determine the amount of 
DNA hybridised to each spot (Figure 5.3 and appendix IV). Note that the observed 
differences in spot intensities on the 10 and 10,000-member oligonucleotide 
microarrays are due the differences in hybridisation efficiencies of the 





Figure 5.3: Microarray analysis of FAM-labelled oligonucleotide libraries generated 
by “read-off” DNA microarrays. FITC-filtered fluorescence of 44,000 feature DNA 
microarrays with variable number of replicates of each oligonucleotide as well as 
non-coding negative controls. (a) 10 oligonucleotide array hybridised with dsDNA-
10-FAM. (b) Array complementary to the varying 17 bp region of the DNA-10,000 
library hybridised with ssDNA-3,875-FAM. (c) Array complementary to the varying 
17 bp region of the DNA-10,000 library hybridised with the dsDNA-10,000-FAM. 
Hybridisations were in 0.1% SDS in 4 x SSPE buffer (110 µL) from 65 oC to 27 oC.  
 
a b 
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5.4.1 Quantification of microarray hybridisations 
Raw microarray data was obtained from Bluefuse, which allows grid alignment and 
signal estimation, in a Microsoft Excel format. In Microsoft Excel the top ~5% and 
the bottom ~5% of each of the replicate-sets were removed as outliers (erroneous 
values caused by dust, scrapes etc179,180). The average intensity was calculated for all 
of the replicate sets and of the intensity of the non-coding negative control features 
on each microarray. The average intensities were corrected for the background by 
subtracting the average intensity of the non-coding negative control features 
(appendix IV). In order to assess the efficiency of the microarray “read-off” and 
subsequent PCR amplification the background-corrected average microarray 
intensities were plotted versus the number of replicates (Table 5.1 and Figure 5.4).  
 
The slight differences in background-corrected average intensities in the 10 
oligonucleotide graph (Figure 5.4a) arise from the differences in secondary structures 
and Tm of the oligonucleotides as these properties greatly affect the hybridisation 
efficiency. Thus, a curved normal distribution of microarray intensity versus the 
oligonucleotide sequences is expected.207 The relatively similar average intensities 
and curved distribution of the 10 oligonucleotide graph illustrate that the amounts of 
DNA targets in the hybridisation mixture were close to equivmolar and that the 
microarray “read-off” had occurred uniformly over the whole array.   
 
The graph for the 3,875 oligonucleotides shows a linear relationship between the 
microarray intensities versus the number of replicates illustrating that the 3,875 DNA 
templates had been “read-off” and amplified relative to the number of replicates of 
probes on the microarray (Figure 5.4b). Each data point in the 3,875 oligonucleotides 
graph represents the average of many different oligonucleotides (Table 5.1b) with 
different Tm and secondary structures. Consequently, the effects of Tm and secondary 
structures on the hybridisation efficiency are evened-out resulting in a smoother 
graph of the 3,875 oligonucleotides compared to that of the 10 oligonucleotides. 
 
The average intensity versus the number of replicates graph for the 10,000 
oligonucleotides shows a curved normal distribution similar to that of the 10 
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oligonucleotides illustrating that also the microarray “read-off” occurs uniformly 




Figure 5.4: The background corrected average intensities were plotted versus the 
number of replicates for: (a) the dsDNA-10-FAM library, (b) the ssDNA-3,875-
FAM library, and (c) the ssDNA-10,000-FAM library. Error bars indicate ± s.d. 
  
5.4.2 Solexa sequencing 
Solexa sequencing of the DNA-10,000 oligo-pool identified 9976 sequences from the 
possible 10,000 DNA oligonucleotides synthesised on the DNA microarray giving an 
error rate of 0.2% (24 oligonucleotides out of 10,000 not seen; Table 5.2). 
Noticeably, the oligonucleotides not seen via sequencing all had one of the following 
I0,000 oligonucleotide sequences 
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consensus sequences (X = any base): CGC-XXX-XXX-CGC, CGC-XXX-CGC-
XXX, CGC-CGC-XXX-XXX, CAC-GAX-XAG-TGC (Table 5.2).  
 
The 9976 sequences were each seen between 1 to 4837 times (Figure 5.5). This 
significant difference in the number of reads of each oligonucleotide was initially 
thought to correspond to an unexpected large difference in the actual amount of the 
respective oligonucleotide in the library. Closer examination of the sequences 
revealed that the oligonucleotides that had poor frequencies of observation had the 
same consensus sequences as the non-identified oligonucleotides (Table 5.2). All of 
the oligonucleotides not seen by sequencing were observed by microarray 
hybridisation in substantial amounts, i.e. microarray intensities in the range of 6,000-
38,000 compared to the full intensity range of the microarray of 2,700-55,000 (Table 
5.2 and appendix V).  
 
Table 5.2: Oligonucleotide sequences not seen by Solexa sequencing and their 
background-corrected average microarray intensities (10,000-member 
oligonucleotide microarray). 
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Figure 5.5: Graph of the number of times each of the 9976 sequences was seen by 
Solexa sequencing versus the oligonucleotide sequences. 36-bp reads of the Solexa 
primer of the dsDNA-10,000 oligo-pool generated by “read-off” the 10,000 
oligonucleotide microarray. 
 
Based on the data from sequencing and the microarray screening it can be assumed 
that the relative amounts observed by sequencing are an effect of the actual amounts 
of the oligonucleotides in the sample, but that this is probably secondary to the 
efficiency of the base calling of the respective sequence. 
 
5.5 Conclusion 
Four microarrays with 1, 10, 3875 or 10,000 different oligonucleotide sequences 
were utilised to determine whether they could be used as platforms for large scale 
DNA synthesis. Hereby a novel microarray “read-off” technology was established 
that allows high-throughput amplification of microarray supported DNA probes 
producing tens of thousands member DNA libraries.   
 
Microarray hybridisation of 1, 10, 3875, and 10,000 DNA oligonucleotide “read-off” 
libraries illustrated that microarray “read-off” had occurred uniformly over the whole 
of high-content DNA microarrays with only few replicates of each probe, and that 
the amount of oligonucleotide in the library mixture was relative to the content of 
each oligonucleotide on the “read-off” array.  
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Solexa sequencing identified 9976 sequences (error rate of 0.2%). However, there 
were significant differences in the number of reads of each oligonucleotide. 
Examination of the oligonucleotides with poor frequencies of observation revealed a 
set of consensus sequences, indicating that the relative amounts observed by 
sequencing are an effect of the actual amounts of the oligonucleotides in the sample, 
but that this is probably secondary to the efficiency of the base calling of the 
respective sequence. This also explains the discrepancy observed between DNA 
sequencing and microarray data. 
 
This technique establishes an economical and efficient way of producing thousand 
member DNA oligonucleotide libraries. In addition, this technique would also allow 
production of DNA libraries as separate oligonucleotides rather than mixtures simply 
by employing an appropriate microarray design. For example, a microarray with 100 
subarrays, each with repeats of a single oligonucleotide, would enable synthesis of 
100 separate oligonucleotides using matching coverslide with 100 “wells”.  
 
This process offers an efficient technique for the generation of thousands of 
oligonucleotides allowing the rapid synthesis of specific primers for use in genome 
sequencing and genotyping assays.208 Another application of the technique is the 
synthesis of siRNA by employing an RNA polymerase209 rather than DNA 
polymerase, which would allows pools of siRNA to be synthesised from DNA 
microarrays.210-214 210,211,212,213,214 
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Chapter 6     Screening of an encoded 
peptide library to discover new 
ligands for cell surface receptors 
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6.1 Introduction to microarray screening post cellular 
selection 
In the approach described in Chapter 4,  “screening of an encoded peptide library to 
discover new cell binding ligands” and several other integrin binding assays189-195 
two potential complications were identified: 1) unspecific binding of the cells to the 
surface mediated by cell secreted adhesive proteins and 2) degradation of the 
microarray due to exposure to cell adhesion and proteases. The aim of this project 
was to avoid false positives from unspecific cell-surface adhesion and to prevent 
microarray degradation by development of an alternative approach to the high 
throughput screening of PNA-encoded peptide libraries against cell surface 
receptors. 189,190,191,192,193,194,195 
 
The 10,000 member PNA-encoded peptide library described in section 4.2 (Library-2 
29) was screened against human cells followed by extraction of the surface bound 
library members and microarray hybridisation of the PNA tags (Scheme 6.1). 
Hereby, allowing information on the interaction between the peptide-ligands and the 
cell surface receptors to be extracted on a single spot-by-spot (compound-by-
compound) basis. The arrays used each contained 4 x 44K features, allowing 16 
copies of each library member to be analysed per array. Cell lines used were D54 
(αvβ5 and αvβ3 integrin overexpressing)
196,197 and HEK293T-CCR6 (CCR6 GPCR 
overexpressing)134 as well as unmodified HEK293T allowing screening with cells 






































Scheme 6.1: Concept of identification of ligands for cell surface receptors by 
microarray analysis of a library of PNA-encoded peptide ligands.  
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6.2 Amplification of the PNA tags 
Following cellular incubation with Library-2 the cell surface bound peptide-PNAs 
were extracted by pronase degradation of the extracellular receptor moieties as well 
as the bound peptide ligands releasing the PNA tags (Scheme 6.1). The extracted 
PNA was purified by membrane filtration but produced only small amounts of PNA 
(pmol scale) due to the limited number of cells and receptors expressed in the cell 
surface. Theoretically, the maximum amount of PNA-peptide that could be obtained 
from the 106 cells (assuming that there are ~3 x 106 target receptors per cell and 
100% yield) is ~5 pmol. This comprises just 1% of the amount of Library-2 required 
for efficient hybridisation (~500 pmol; section 0), thus, necessitating the 
development of a PNA amplification methodology. PNA is not recognized by DNA 
polymerase or other enzymes,6,28 which complicates its amplification by traditional 
DNA amplification methods, and no amplification method of PNA has been 
described in the literature. The approach developed in this context was indirect 
amplification of PNA by amplification of a complementary DNA strand (Scheme 
6.2). In this approach the double stranded (ds) DNA library with one strand 
complementary to the desired PNA library was obtained as discussed in Chapter 5 


































dsPNA/DNA sub-library  
 
Scheme 6.2: Concept of indirect amplification of a PNA library by amplification of 
the complementary DNA library. 
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Hybridisation of the 17 bp PNA-Library-229 with the 64 bp dsDNA-Library-2 (Table 
6.1) is very challenged due to the competition between the non-PNA complementary 
64 bp ssDNA and the 17 bp PNA. Thus to improve the efficiency of PNA/DNA 
hybridisation the single stranded (ss) DNA library complementary to the PNA-
Library-2 was synthesised by PCR with a single primer (ssDNA-Library-2; Scheme 
6.2). 
 
To investigate the efficiency of the PNA amplification strategy a single DNA 
oligonucleotide (oligonucleotide-1; Table 6.1) was hybridised with a previously 
reported single strand of PNA17 (TGTTTGTTTGTT; Chapter 2; Table 6.1 black) as 
well as oligonucleotides-2 and 3 (Table 6.1, red; Scheme 6.2). Hereby, a fully double 
stranded DNA/PNA duplex was formed. The unhybridised ssDNA could then be 
degraded by a single strand specific DNase, eliminating PCR amplification of any 
ssDNA not associated with PNA. Oligonucleotide-2 and 3 protected the primer 
binding domains of oligonucleotide-1 (Table 6.1, red) from nuclease degradation, 
rendering these domains intact for PCR amplification. DNA gel electrophoresis 
identified oligonucleotide-2 and 3 (below 25 bp band, Figure 6.1), oligonuleotide-1 
(~30 bp band, Figure 6.1), the ssDNA/dsDNA hybrid complex (~45 bp band, Figure 
6.1; Scheme 6.2), and the dsDNA/PNA complex (~45 bp band, Figure 6.1). After 
nuclease degradation the ssDNA/dsDNA hybrid complex band had disappeared 
leaving the only the dsDNA/PNA complex. This demonstrates that DNA hybridised 
to PNA can be separated from unhybridised DNA. 
   
Table 6.1: General oligonucleotide sequences and primer sequences. 
dsDNA-Library-2 
5' CTACACGACGCTCTTCCGATCTGGXXXXXXXXXXXXCTTAGATCGGAAGAGCTCGTATGC 3' 
Oligomucleotide-1 
5’ CTACACGACGCTCTTCCGATCTGGAACAAACAAACAAACACTTAGATCGGAAGAGCTCGTATGC 3’ 
Oligonucleotide-2 
5' CCAGATCGGAAGAGCGTCGTGTAG 3' 
Oligonucleotide-3 
5' GCATACGAGCTCTTCCGATCTAAG 3’ 
Primer-3 
5' CTACACGACGCTCTTCCGATCTGG 3’ 
Primer-4-FAM 
FAM- 5' GCATACGAGCTCTTCCGATCTAAG 3’ 
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Figure 6.1: DNA gel electrophoresis of hybridisation of oligonucleotide-1 with 
oligonucleotide-2 and 3 with or without peptide-TGTTTGTTTGTT. Half of each 
hybridisation solution was treated with single strand specific nuclease.  
 
Similarly, PNA purified from cells and the PNA-Library-2 was hybridised to the 
ssDNA-Library-2 as well as oligonucleotide-2 and 3, followed by nuclease 
degradation, and purification of the dsDNA/PNA complexes by gel column filtration. 
The purified dsDNA/PNA complexes were amplified by PCR with a FAM-labelled 
primer (Table 6.1) as previously described (section 5.4) producing FAM-labelled 
ssDNA libraries complementary to custom made DNA microarrays (ssDNA-Library-




Figure 6.2: DNA gel electrophoresis of PCR amplification of dsDNA-Library-2-
FAM, dsDNA-D54-FAM, and dsDNA-HEK293T-CCR6-FAM with a single primer 
producing ssDNA-Library-2-FAM, ssDNA-D54-FAM, and ssDNA-HEK293T-
CCR6-FAM respectively. 
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6.3 Microarray hybridisation of amplified ssDNA 
The ssDNA-FAM libraries were hybridised to a DNA-microarray complementary to 
the 17 bp PNA encoding domains. Fluorescent microarray imaging in combination 
with BlueFuse (BlueGenome) technology was used to extract the intensity of the 
FAM-label and thereby determine the amount of FAM labelled ssDNA hybridised to 
each spot (Figure 6.3 and appendix VI). The FITC-filtered images of the Library-2 
microarray illustrates that the ssDNA-Library-2-FAM hybridisation had been 
efficient (i.e. most spots are very intense, Figure 6.3) demonstrating efficient indirect 
amplification of the PNA-Library-2 through amplification of the complementary 
ssDNA-Library-2. The FITC-filtered images of the D54 and HEK293T-CCR6 
microarrays illustrate that only some spots had been hybridised, indicating that the 
cells had selected certain peptide-PNA conjugates and that the indirect amplification 





Figure 6.3: Microarray analysis of receptor ligand PNA-encoded peptides. DNA 
microarrays were designed with 4 replicates of each oligonucleotide complementary 
to each member of the 10,000 member library as well as 4,000 non-coding negative 
controls resulting in a 44,000 feature microarray. Microarrays hybridised with (a) 
ssDNA-Libaray-2 and (b) ssDNA-FAM from amplification of PNA signal from D54 
a b 
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and HEK293T-CCR6 cells in 110 µL 0.1% SDS, 4 x SSPE buffer from 65 oC to 27 
oC overnight.  
 
6.3.1 Quantification of microarray hybridisations 
Raw microarray data was obtained from Bluefuse, which allows grid alignment and 
signal estimation, in a Microsoft Excel format. The average fluorescence intensity 
was calculated over each of the 4 replicates and over the non-complementary 
negative control features. The average intensities were corrected for the background 
by subtracting the average intensity of the non-complementary negative control 
features. Thereafter, the D54 microarray data was normalised for the Library-2 
hybridisation by calculating the ratio between the background corrected average 
intensities of the ssDNA-D54-FAM hybridisation and the background corrected 
average intensities of the ssDNA-library-2-FAM hybridisation (appendix VI). The 
HEK293T-CCR6 microarray data was normalised in the same manner.  
 
Scatter plots of the normalised microarray intensities versus the variable amino acids 
for positions AA4 to AA1 were constructed (Figure 6.4) allowing cellular preference 
for specific peptides to be elucidated, or indeed consensus sequences of non-binding 
peptides (negative controls) for each cell line to be obtained (Table 6.2). 
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Figure 6.4: Scatter plots of the background-corrected mean FITC microarray 
intensities versus the variable amino acids for position AA1-4 of PNA derived from 
D54 and HEK293T-CCR6 cells hybridised on complementary DNA microarrays.  
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Table 6.2: Consensus sequences derived from scatter plots based on microarray 
analysis by combining either the most or the least preferred amino acid in each 




6.4 Synthesis of “hit” peptides  
To verify and quantitatively compare cellular affinities of the identified binding and 
non-binding sequences the fluorescein labelled peptides, FAM-Ahx-Phe-Gln-Ser-Ile-
Tyr-Pro-dPro-Ile-Lys-NH2 (X-FQSIYPpIK-NH2), FAM-Ahx-Phe-Gln-Lys-Glu-Tyr-
Lys-Phe-Ile-Lys-NH2 (X-FQKEYKFIK-NH2), and FAM-Ahx-Phe-Gln-Pro-dAla-
Tyr-Pro-Phe-Ile-Lys-NH2 (X-FQPaYPFIK-NH2) were synthesised.
17,87 As a positive 
control for integrin binding Rhodamine-Ahx-Arg-Gly-Asp-NH2 (Z-RGD-NH2) was 
also synthesised. 
 
6.5 Evaluation of selective cell binding of “hit” peptides 
D54, HEK293T, and HEK293T-CCR6 cells were analysed by flow cytometry 
following incubation with the fluorescently labelled peptides or a CCR6 antibody, 
anti-human CCR6. 
 
6.5.1 Peptide-cell interactions are peptide specific 
In D54 cells the identified peptide integrin ligand, X-FQSIYPpIK-NH2 induced a 
significantly higher shift in the level of fluorescence compared to that of the 
untreated cells similar to the shift induced by the positive control, X-RGD-NH2
 
(section 4.5.3; Figure 6.5 and appendix VII). The identified non-binding peptide, X-
FQKEYKFIK-NH2 caused a smaller increase in fluorescence compared to X-
FQSIYPpIK-NH2. This illustrates that binding of X-FQSIYPpIK-NH2 is peptide 
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specific and that this peptide has a similar affinity for the binding receptors as X-
RGD-NH2. Treatment with pronase/EDTA greatly reduced the fluorescence signal of 
all peptides illustrating that the peptides are associated with the cell surface and not 
taken up by the cells (Figure 6.5 and appendix VII).  
 
 

























































































































Figure 6.5: Flow cytometry analysis of peptide ligands. (a) FAM versus Rho-filtered 
scatter plots gaited for live, single cells following incubation with X-
FQAA4AA3YAA2AA1IK-NH2, X-RGD-NH2, and Z-RGD-NH2 using a FACS Aria 
cytometer with FITC and PE-Texas-Red filters (10,000 populations, n=3). D54 cells 
were detached by scraping for minimal destruction of the extracellular receptor 
moieties or by trypsin/EDTA as a control for extracellular binding of peptides. 
Peptides are written as simplified sequences. (b) Mean FAM-filtered fluorescence of 
scatter plots versus the labelled peptides and antibodies. Compensation was applied 
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In HEK293T-CCR6 cells the identified peptide CCR6 ligand, X-FQIPYIIIK-NH2
 
(section 4.5.3) induced a significantly higher shift in the level of fluorescence 
compared to that of the untreated cells but slightly smaller than the shift induced by 
the positive control, FAM-anti-human CCR6 (Figure 6.6 and appendix VII). The 
identified non-binding peptide, X-FQPaYPFIK-NH2 caused a smaller increase in 
fluorescence compared to X-FQIPYIIIK-NH2 (Figure 6.6 and appendix VII). This 
illustrates that binding of X-FQIPYIIIK-NH2 is peptide specific and that this peptide 
has a similar affinity for the binding receptor as FAM-anti-human CCR6. Treatment 
with pronase/EDTA greatly reduced the fluorescence signal of all peptides 
illustrating that the peptides are associated with the cell surface and not taken up by 
the cells (Figure 6.6 and appendix VII). 
 
 







































































































































Figure 6.6: Flow cytometry analysis of peptide ligands. (a) FAM versus PerCP-
filtered scatter plots gaited for live, single cells following incubation with X-
a 
b 
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FQAA4AA3YAA2AA1IK-NH2 or anti-human CCR6 using a FACS Aria cytometer 
with FITC and PE-Texas-Red filters (10,000 populations, n=3). HEK293T-CCR6 
cells were detached by scraping for minimal destruction of the extracellular receptor 
moieties or by trypsin/EDTA as a control for extracellular binding of peptides. 
Peptides are written as simplified sequences. (b) Mean FAM and PerCP-filtered 
fluorescence of scatter plots versus the labelled peptides and antibodies. 
Compensation was applied between FAM/PerCP fluorophore pair. Error bars 
indicate ± s.d. (n=3). 
 
6.5.2 Peptide-cell binding is receptor mediated  
To verify that binding of the identified ligands was mediated by the receptor in 
question, a soluble inhibitor for the respective receptor labelled with a different 
fluorophore than the peptides were co-incubated with the peptides. The D54 cells 
overexpress αvβ5 and αvβ3 integrins
196,197,198, which can be blocked by the natural 
ligand, RGD; whereas, the CCR6 receptor can be blocked by the agonist, anti-human 
CCR6.  
 
Thus, D54 cells were incubated with equimolar Z-RGD-NH2 and X-FQSIYPpIK-
NH2, which blocked X-FQSIYPpIK-NH2 binding by 55% and Z-RGD-NH2 binding 
by 57% (Figure 6.5 and appendix VII). Z-RGD-NH2 binding could almost be 
completely blocked (80%) by addition of 10 equivalents of X-FQSIYPpIK-NH2 
(appendix VII). Whereas, incubation with X-FQKEYKFIK-NH2 and Z-RGD-NH2 
had no effect on binding of either peptide (Figure 6.5 and appendix VII). This 
illustrates that X-FQSIYPpIK-NH2 binding to D54 is integrin mediated, whereas X-
FQKEYKFIK-NH2 binding is not. 
 
Similarly, HEK293T-CCR6 cells were incubated with equimolar PerCP-anti human 
CCR6 and X-FQIPYIIIK-NH2, which inhibited X-FQIPYIIIK-NH2 binding by 56% 
and PerCP-anti human CCR6 binding by 58%, and 10 equivalents of X-FQIPYIIIK-
NH2 completely blocked anti human CCR6 binding (Figure 6.6 and appendix VII). 
Whereas, incubation with X-FQPaYPFIK-NH2 and PerCP-anti human CCR6 had no 
effect on binding of either peptide (Figure 6.6 and appendix VII). This demonstrates 
that X-FQIPYIIIK-NH2 binding to HEK293T-CCR6 is CCR6 mediated, whereas X-
FQPaYPFIK-NH2 binding is not.  
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As a negative control for CCR6 binding unmodified HEK293T cells were also 
incubated with X-FQIPYIIIK-NH2, X-FQPaYPFIK-NH2, and PerCP-anti human 
CCR6 in the same manner as the HEK293T-CCR6 cells. As expected, much smaller 
shifts in the levels of fluorescence was induced in the HEK293T cells compared to 
the HEK293T-CCR6 cells and no competition between the peptides and the antibody 
was observed (Figure 6.7 and appendix VII). In addition, the fluorescence signals 
could not be significantly reduced by pronase/EDTA treatment (Figure 6.7 and 
appendix VII). These differences in binding of X-FQIPYIIIK-NH2 in HEK293T-











































































































































Figure 6.7: Flow cytometry analysis of peptide ligands. (a) FAM versus PerCP-
filtered scatter plots gaited for live, single cells following incubation with X-
FQAA4AA3YAA2AA1IK-NH2 or anti-human CCR6 using a FACS Aria cytometer 
b 
a 
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with FITC and PE-Texas-Red filters (10,000 populations, n=3). HEK293T cells were 
detached by scraping for minimal destruction of the extracellular receptor moieties or 
by trypsin/EDTA as a control for extracellular binding of peptides. Peptides are 
written as simplified sequences. (b) Mean FAM and PerCP-filtered fluorescence of 
scatter plots versus the labelled peptides and antibodies. Compensation was applied 
between FAM/PerCP fluorophore pair. Error bars indicate ± s.d. (n=3). 
 
6.6 Cytotoxicity 
In order for the peptides to have biological applications it is vital that they do not 
exhibit cellular toxicity. Cell viability upon treatment with the “hit”-peptides was 
assessed with standard MTT186 assays demonstrating no cytotoxicity was exhibited 
by any of “hit”-peptides in the tested cell lines at 100 µM (Table 6.3). 
 





















































Table 6.3: Cytotoxicity of “hit”-peptides assessed as cell viability by MTT assays. 
Cells were incubated with X-FQAA4AA3YAA2AA1IK-NH2 (100 µM) or X-RGD-
NH2 (100 µM; 24 h) the media was changed and the incubation continued for 24 h 
and absorbance was measured at 580 nm. Untreated cells are assumed to be 100% 
variable. Error bars indicate ± s.d. (n = 3). 
 
6.7 Conclusion 
Microarray analysis of a 10,000 member PNA encoded peptide library followed by 
scatter plot analysis allowed consensus sequences for both receptor binding 
(FQSIYPpIK and FQIPYIIIK) and non-binding peptides (FQKEYKFIK and 
D54
CCR6
Nina Svensen                                                                                                   Chapter 6 
  123
   
FQPaYPFIK) to be extracted for αvβ5 and αvβ3 integrins and CCR6 respectively that 
demonstrated low cytotoxicity.  
 
Synthesis followed by flow cytometry analysis of these “hit”-peptides allowed 
verification of receptor binding. Competition studies with the natural ligands for 
integrins and CCR6 demonstrated that binding of X-FQpIYIIIK-NH2 and X-
FQIPYIIIK-NH2 is αvβ5 and αvβ3 integrin and CCR6-mediated respectively, whereas 
X-FQKKYSRIK-NH2 and X-FQPKYSFIK-NH2 do not bind to these receptors.  
 
This “microarray-screening-post-cellular-selection” approach to screening of 
encoded peptide ligands for cell surface receptors has a number of advantages: 1) 
exclusion of false positives from to unspecific cellular attachment to solid supported 
ligands; 2) the method allows ligand binding to both adherent and suspension cells. 
However, this technique is based of screening of ligands in suspension, and hence, 
does not allow screening for ligands promoting cell adhesion and cell migration.  
 
In contrast, the previously reported “microarray-screening-of-cell-binding-ligands” 
approach to screening of encoded peptide ligands for cell surface receptors (Chapter 
4) has the advantages of allowing: 1) screening of ligands that promote cell adhesion; 
2) screening of ligands that induce cell migration (by measuring the exact microarray 
location of each adhered cell at different time points); 3) screening of both adherent 
and suspension cells. Though, this method is based on screening of microarray 
supported ligands, which may lead to false positives due to unspecific cellular 
adhesion caused by cell secreted proteins.  
 
In conjunction, the two approaches can complement each other as illustrated with the 
identification of two different ligands for αvβ5 and αvβ3 integrins, X-FQpIYIIIK-NH2 
and X-FQpIYIIIK-NH2 by “microarray-screening-post-cellular-selection” and 
“microarray-screening-of-cell-binding-ligands” respectively. 
 
Moreover, the two methods independently identified X-FQIPYIIIK-NH2 as the best 
CCR6 ligand, which further establishes both of these screening strategies as reliable 
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methods for high-throughput screening for the identification of ligands for cell 
surface receptors and offers a tool for investigating differences in membrane receptor 
expression between different cell types including diseased cells.   
 
 
This approach establishes a strategy for high-throughput screening for the 
identification of ligands for integrins and GPCRs offering and efficient approach to 
de-orphanise the many GPCRs, for which there are no known ligands. As integrins 
and GPCRs amongst the most heavily investigated drug targets in the pharmaceutical 
industry today115,137 identification of new agonist or antagonists of these receptors by 
this method can help identify new drug-targets as well as leads.  
 
The technology would also allow screening of a wide variety of cell surface receptors 
and offers a tool for investigating differences in membrane receptor expression 
between different cell types including diseased cells.  
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Chapter 7 Experimental 
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7.1 General reaction conditions 
All reactions were carried out at room temperature under N2 unless otherwise stated. 
All solvents including those for flash chromatography and crystallisation were HPLC 
grade. Commercially available reagents were used as delivered unless otherwise 
described.  
 
1H nuclear magnetic resonance (NMR) and 13C NMR spectra were obtained for all 
isolated organic compounds using a Bruker DP360 spectrometer operating at 360 
MHz for 1H NMR and 90 MHz for 13C NMR, chemical shifts, δ are in ppm relative 
to internal standard CHCl3 (residual, 7.27 ppm for 
1H NMR) and CDCl3 (77.0 ppm 
for 13C NMR) in the solvents indicated at 298 K. Coupling constants (J) are reported 
in Hz.  
 
Infrared (IR) spectroscopy was recorded on a Fourier transform Bruker Tensor 27 
fitted with a Specac single reflection diamond attenuated total reflection Golden 
Gate. All samples were run neat, frequencies are reported in cm-1 and only 
frequencies corresponding to significant functional groups are reported.  
 
Thin layer chromatography (TLC) analysis was performed with aluminium backed 
silica plates (Merk: Silica gel 60 F254). The TLC plates were visualised by ultraviolet 
(UV) detection at 254 nm or by dipping in 5 % phosphormolybdic acid in ethanol 
(PMA-DIP), or 0.6 (w/w)% ninhydrin in ethanol (ninhydrin-DIP), or 1 % Ce(SO4)2, 
2.5% (NH4)Mo6O24, and 10% H2SO4 (CEMOL-DIP), or 1% KMnO4, 6.7% K2CO3, 
and 0.08% NaOH in water (KMnO4-DIP) and developed with a heat-gun.  
 
Flash chromatography was carried out as described by Still et al.215 by use of silica 
gel 60 Å (Amicon 85040, 35-70 µ). Solvents were evaporated by concentration in 
vacuo at ~ 2-800 mmHg and 40 oC. Single peptides and peptide-PNA conjugates 
were characterised by RP-HPLC performed on an Agilent Technologies 1100 
modular HPLC system with detection by UV-absorbance according to the following 
methods:  
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HPLC method 1: Supelco Discovery C18 Column, 5 cm x 4.6 nm x 5 µm; solvent A: 
H2O with 0.1% TFA; solvent B: CH3CN with 0.1% TFA, eluting with 10% B to 90% 
B over 3 min; 90% B for 1 min; 
HPLC method 2: Phenomenex Luna Column, C18, 15 cm x 1.00 cm, 5 µm; λ = 220 
nm; solvent A: H2O with 0.1% TFA; solvent B: CH3CN with 0.1% TFA, eluting with 
A for 5 min; 100% A to 100% B over 20 min; 100% B for 5 min;  
HPLC method 3: Phenomenex Luna Column, C18, 15 cm x 1.00 cm, 5 µm.; λ = 254 
nm; solvent A: H2O with 0.1% formic acid; solvent B: MeCN with 0.1% formic acid, 
eluting with 95% A to 95% B over 3 min; 100% B for 1 min. 
 
Electronspray mass spectrometry (MS) performed on an Agilent Technologies 
LC/MSD Series 1100 quadrupole mass spectrometer, equipped with an electronspray 
ion source.  MALDI-TOF spectrometry performed on an Applied Biosystems 
Voyager DESTR MALDI-TOF mass spectrometer (matrix: sinapinic acid in 
CH3CN/H2O 1:1).  
 
UV-visible spectroscopy was performed on an 8453 Agilent UV-Visible 
spectrophotometer. Fluorescence measurements were performed on a Jobin Yvon 
Spex Fluoromax spectrofluorometer or a FS900 spectrofluorometer.  
 
Microwave irradiated reactions were carried out in a Biotage Initiator Sixty 
microwave chamber. Peptides, and in some cases PNA, were synthesised in a CEM 
Liberty Microwave peptide synthesiser.  
 
PCR was performed in a Techne TC-312 PCR cycler unless otherwise stated. DNA 
gel electrophoresis was carried out on a Bio-Rad PowerPac 300 at 90 V. PCR on 
microarrays was performed using a GeneMachines Hyb4 automated station 
(Genomic Solutions, UK). DNA Illumina Solexa Sequencing was performed by the 
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7.1.1 Qualitative Ninhydrin test 
5-20 resin beads were washed with MeOH (x 3) and 6 drops of reagent A [50 mg/mL 
of ninhydrin (1,2,3-indanetrione monohydrate, Sigma-Aldrich) in EtOH] was added 
followed by 3 drops of reagent B [2 g/mL phenol (Sigma-Aldrich) and 10 µM KCN 
(Sigma-Aldrich) in EtOH/pyridine 1:1] and the sample was heated to 100 oC for 5 
min. A blue colour solution was indicative of primary amines (positive) and a yellow 
colour indicative of no primary amines present (negative).  
 
7.1.2 Preparation of samples for MALDI-TOF 
Samples in H2O (1 µL of ~1 µg/mL) was mixed with matrix [1 µL, 15% sinapic acid 
(Sigma-Aldrich) in H2O/AcN 1:1] and the resulting suspension was loaded onto a 
stainless steel MALDI-TOF plate and allowed to dry for at least 1 h before running 
MALDI-TOF. 
 
7.1.3 DNA gel electrophoresis and purification of DNA 
Samples (20-30 µL) were prepared with 6 x Blue/Orange Loading Dye (5 µL, 
Promega) and DNA grade H2O were run on a 5 (wt)% agarose gel (Promega 
Preparative grade for small fragments) with either 600 ng/mL ethidium bromide 
(EtBr, for dsDNA) or 1 x SYBR Green II RNA Gel Stain (for ssDNA) in 1 x Tris 
Borate Ethylenediaminetetraacetatic acid (pH 8.3, TBE, Fisher Scientific) buffer for 
approximately 1 h. The gel was analysed under UV light and the appropriate bands 
were excised with a scalpel.   
 
DNA was purified using a QIAEX II Agarose Gel Extraction Kit (Qiagen) according 
to the manufacturer’s protocol. 600 l of buffer QX1 per each 100 mg of agarose gel 
was added to the gel followed by addition of 30 l QIAEX II per 10 g DNA and the 
suspension was incubated at 50°C for 10 min and vortexed every 2 min for 15 s to 
solubilise the agarose and bind the DNA. The samples were centrifuged at maximum 
speed for 30 s and the supernatant discarded. The pellet was washed with 500 l of 
buffer QX1 and 500 l of buffer PE x 2, during which the beads were pelleted by 
centrifugation at maximum speed and the pellet was resuspended by vortexing for 15 
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s. The pellet was air dried for 30-60 min and the DNA was eluted with 2 x 20-40 mL 
Tris·Cl (10 mM), pH 8.5 following 5 min incubation and recovery of the supernatant 
after centrifugation at maximum speed. Samples were stored at -20 oC. 
 
7.2 General microarray procedures 
All buffers and washing solutions were made up with cell tissue culture H2O and all 
DNA work was carried out with DNA grade H2O (Promega). Printing was carried 
out on a Genetix QArray Mini with Genetix Qsoft Microarraying software in 70% 
humidity. Hybridisations were carried out in 1 x GenHyb buffer (Genetix) in an 
Agilent Hybridisation Chamber in the oven or in an automated GeneMachines Hyb4 
automated hybridiser with Hyb4 Editor (Genomic Solutions) software. PCR on 
microarrays were also carried out in the GeneMachines Hyb4 automated hybridiser. 
Customised microarrays were purchased from OGT. All arrays were sterilised under 
UV light for 5 min before cellular incubation. The microarrays were imaged using a 
Nikon Eclipse 50i microscope with FITC, DAPI, and tetramethyl rhodamine 
isothiocyanate (TRITC) filters and Pathfinder software (Imstar) or a Tecan LS 
Reloaded microarray scanner with ArrayPro 32 Analyser (Media Cybernetics Inc) 
software, or a CCD based microarray scanner (BioTEc LaVision BioAnalyser) using 
FITC, DAPI and Cy3 filters. Image analysis was performed using Bluefuse software 
(BlueGnome, Cambridge) and data analysis was performed using Microsoft Excel 
and clustering analysis was performed using Enthought Python software.  
 
7.2.1 Stringency washes after DNA microarray hybridisation  
OGT arrays were washed according to standard protocols: 1) Washed with OGT 
recommended buffer [20 mL, 100 mM NaCl (Fisher Scientific), citric acid (40 mM, 
Acros), 0.7% (w/v) N-lauroylsarcosine sodium salt (Aldrich), EGTA (0.1 mM, Fisher 
Scientific), pH 7.5] at the hybridisation temperature for 10 min, rinsed with H2O (20 
mL x 3), rinsed with Tris buffer at pH 8.0 (20 mL, 50 mM, Fisher), and dried under a 
N2 flow; or 2) washed with Gene Expression Wash buffer I (20 mL, Agilent) at room 
temperature for 2 min, washed with Gene Expression Wash buffer II (20 mL, 
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Agilent) at 37 oC for 2 min, rinsed with H2O (20 mL x 3), rinsed with Tris buffer at 
pH 8.0 (20 mL, 50 mM, Fisher), and dried under a N2 flow; or 3) washed with 0.2% 
Sodium Dodecyl Sulphate (SDS, Promega) in 2 x Saline-Sodium Citrate (SSC, 20 
mL, Promega) for 5 min, 0.2 x SSC (20 mL) for 5 min, 0.1 x SSC (20 mL) for 5 min, 
and briefly rinsed in DNA grade H2O (20 mL) and Tris buffer at pH 8.0 (20 mL, 10 
mM) and dried under a N2 flow. Codelink (Amersham Biosciences) arrays were 
washed acetonitrile (20 mL x 2) briefly, H2O (20 mL x 2) briefly, 0.1% SDS in 4 x 
(20 mL) at 50 oC for 30 min, H2O briefly (20 mL x 2), 10 mM Tris pH 8 (20 mL) 
briefly, and dried under a N2 flow. 
 
7.3 General biological work 
Cells were cultured in a Heraeus HERAcell 150 incubator and cell experiments were 
performed in a Heraeus HERAsafe KS 18 class II negative flow cabinet. Flow 
cytometry was performed on a BD Biosciences FACSAria system with the BD 
FACSDiva software or a BD Biosciences Calibur system with BD CellQuest 
software and FlowJo software was used for analysis. Confocal microscopy was 
performed on a Deltavision Tollervey microscope with a Photometrics Coolsnap HQ 
camera, SoftWoRx (Applied Precision) software using FITC (Ex = 490/20 nm, Em = 
528/38 nm) and TRITC (Ex = 545/30 nm, Em = 610/75 nm) filters (100 x 
magnification). Cell viability was assessed recording absorbance at 570 nm using a 
Bio-Rad 1.15 microplate reader.  
 
7.3.1 Cell culture  
HeLa and K562 (courtesy of Prof. Tim Elliot, Cancer Research UK, University of 
Southampton) cells were maintained in Roswell Park’s Memorial Institute (RPMI) 
1640 (Sigma-Aldrich) complete media [CM: 10% foetal bovine serum (FBS, 
Biosera), 2 mM L-glutamine, 100 mg/mL streptomycin, and 100 U/mL penicillin 
(Gibco)]. HEK293T (ECACC), HEK293TCCR6 (courtesy of Dr. Dominic 
Compopiano, University of Edinburgh, UK), D54 (courtesy of Dr. Darell D. Bigner, 
Duke University Medical Centre, California), and ARN8 (courtesy of Prof. Ted 
Hupp, The Edinburgh Cancer Research Centre, The University of Edinburgh) were 
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maintained in Dubelco’s Modified Eagle Medium CM (DMEM CM, Sigma-
Aldrich). SH-SY5Y (European Collection of Cell Cultures) were maintained in 
Ham's F12: Eagle’s Minimum Essential Medium (EMEM, Sigma-Aldrich) (1:1) 
supplemented with 15% FBS (Biosera); 2 mM L-glutamine, 100 mg/mL 
streptomycin, 100 U/mL penicillin (Gibco); and 1% Non Essential Amino Acids 
(NEAA, Gibco). E14 cells (mouse embryonic stem cells, courtesy of Prof. Joshua 
Brickman, The Institute for Stem Cell Research, The University of Edinburgh, UK) 
were grown on gelantine-coated polystyrene (polystyrene was treated with 3% 
gelatine in  phosphate buffered saline (PBS) for 5 min prior to seeding the cells) in 
Glasgow Minimum Essential Medium (GMEM, Sigma-Aldrich) CM supplemented 
with 1 mM sodium pyruvate (Gibco), 1% NEAA (Gibco), 0.1 mM β-
mercaptoethanol, and 100 U/mL leukaemia inhibitory factor (Gibco). All cells were 
grown in T-75 or T-25 flasks (Nunc) in 5% CO2 at 37 
oC.  
 
Adherent cell lines were passaged by removing the old media from the flask, 
washing the surface with PBS (5 mL, Oxoid), and detached by standard trypsination 
(incubating the cells with a minimal amount of 0.05% trypsin and 0.53 mM 
ethylenediaminetetraacetatic acid (EDTA) in PBS, Fisher Scientific), or by scraping. 
Suspension cell lines were passaged by collecting the cells by centrifugation (1100 
rpm for 5 min) and the old media was removed. Hereafter, the cells were suspended 
in appropriate media and transferred to a sterile tube, a fraction was left in the flask 
and fresh media was added. The cells were used within an hour after they were 
transferred to the tube. Before microarray incubation, the cells were counted 
following 4 x dilution in trypan blue (0.4 mM, Sigma-Aldrich). 
 
Primary cells were isolated and purified as previously reported216 and subsequently 
maintained in Improved Modified Eagle Medium (IMEM, Invitrogen). Briefly, with 
local ethical approval, freshly obtained anticoagulated blood was centrifuged, plasma 
removed and the white cell fraction was separated using Percoll density gradient 
centrifugation. Neutrophils were obtained from the granulocyte layer and washed and 
confirmed to be 95% pure by flow cytometry. The mononuclear cells were enriched 
for monocytes by adherence for one hour on treated sterile culture plates. 
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Lymphocytes were obtained from the non-adherent fraction. Flow cytometry 
confirmed that the monocytes were >80 % pure and the lymphocytes >80% pure.§ 
 
7.3.2 Fixing and microscopy analysis of cells 
Cells were fixed with 4% para-formaldehyde (Sigma-Aldrich) in PBS for 15-30 min 
and washed with PBS x 3. The attached cells were stained with DAPI (20 µL/mL, 
Sigma-Aldrich) in PBS for 15 min and washed with PBS and/or stained with 
AlexaFluor 568 phalloidin (1 µL/mL, Invitrogen) in PBS for 15 min and washed 
with PBS x 3. 
 
7.3.3 MTT Cytotoxicity assays 
Cells were grown to ~50% confluence (to avoid cells reaching complete confluence 
during the 48 h experiment) in 96-well plates and incubated with FAM-labelled 
peptide (100 µM) in appropriate growth media for 24 h at 37 oC and the media was 
removed and fresh media was added and the incubation continued for 24 h with the 
last row was used as a blank (no cells seeded). Cells were washed with PBS and 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 50 µL, 1mg/mL, 
Sigma-Aldrich) in Iscove's Modified Dulbecco's Media (IMDM) was added and 
incubated for 4 h at 37 oC. Hereafter, MTT solubilising solution [60 µL, 10 % Triton-
X 100 (Sigma-Aldrich), 0.1 N HCl (Fisher Scientific) in isopropanol] was added and 
the well-plate was shaken until complete dissolution of the formazan crystals. 
Absorbance was measured at 570 nm in a Bio-Rad Benchmark microplate reader.  
 
Untreated cells were considered to be 100% viable and cell viability was calculated 







⋅=                                                    (Equation 7.1) 
 
                                                 
§ Performed by Dr. Kevin Dhaliwal 
Nina Svensen                                                                                                   Chapter 7 
  133
   
7.4 Experimental for Chapter 2 
All counpounds described in the following sections (7.4.1-7.4.14) were synthesised 
according to previously reported procedures14 and unless otherwise described the 
obtained TLC, NMR, HPLC, and LCMS data of the products is consistent with the 
published data.   
 








Chloroacetic acid (105.82 mmol, 10.00 g, Sigma-Aldrich) was added portion-wise to 
ethylenediamine (60 mL, Sigma-Aldrich) at 4 oC and the reaction was allowed to 
warm to room temperature while stirring for 16 h. The solvent was removed by 
concentration in vacuo (<50 oC). This gave a crude yellow oil, which was further 
purified by crystallisation from dimethylsulfoxide (DMSO). The resulting white 
crystals were collected by filtration and washed with DMSO (3 x 50 mL), THF (3 x 
50 mL), and diethyl ether (3 x 50 mL) and dried in vacuo at 50 oC overnight to give a 
white crystalline compound 10.56 g (84%), which was carried directly into the next 
step without further purification.  
 
The product (84.65 mol, 10.00 g) was added to MeOH (300 mL) at 0 oC followed by 
drop wise addition of SOCl2 (846.5 mol, 61.8 mL, Sigma-Aldrich) and the reaction 
was warmed to reflux temperature and stirred for 16 h. The product was filtered and 
washed with MeOH and dried in a vacuum oven overnight to yield 7.1 as a white 
solid 10.84 g (62%).  
 Rf (EtOAc) = 0.31. 
1H NMR (250 MHz, DMSO):  δ 9.82 (s, 1H, NH), 8.50 (s, 2H, NH2), 4.06 (s, 2H, 
CH2CO), 3.75 (s, 3H, CH3), 3.41-3.11 (m, 4H, 2 CH2). 
 
13C NMR (62.5 MHz, DMSO): δ ppm 167.28 (C=O), 52.97 (CH2C=O), 46.93 (C 
H2NH), 44.36 (C H2N H2), 35.34 (CH3O).  
RP-HPLC (method 1): 0.9 min (254 nm, 81.1% purity).  
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LRMS (ES+): m/z (%)133.0 [M+H]+ (100). 
 






Acetic acid (99.92mmol, 5.72 mL) was added to DMF (500 mL) at room temperature 
followed by  dimedone (109.9 mol, 15.41 g, Sigma-Aldrich), DCC (99.92 mol, 20.62 
g, Sigma-Aldrich), and 4-dimethylaminopyridine (DMAP, 99.92 mol, 12.21 g, 
Sigma-Aldrich) and the reaction was stirred for 48 h. Precipitated DCU was removed 
by filtration and the precipitate was washed with DMF. The combined organic 
phases were concentrated in vacuo and the residue was dissolved in EtOAc (800 
mL). The organic solution was washed with KHSO4 (100 mL, 1 M) and the product 
extracted with NaHCO3 (100 mL). The aqueous solution was extracted with DCM 
and the solution was concentrated in vacuo to give a crude product, which was 
precipitated from MeOH/H2O 1:1 to afford Dde-OH as a yellow oily solid 11.19g 
(56%). Alternatively, the product could be purified by flash chromatography with 
eluent DCM/MeOH 97:3 to give 7.2 11.2 g (62%).  
Rf (EtOAc) = 0.70  
1H NMR (250 MHz, CDCl3): δ ppm 2.53 (s, 3H, CH3), 2.38 (s, 4H, 2 CH2), 1.01 (s, 
6H, C(CH3)2). OR 
1H NMR (250 MHz, CDCl3) : δ ppm 2.54 (s, 3H, CH3), 2.47 (s, 
2H, CH2), 2.29 (s, 2H, CH2), 1.01 (s, 6H, C(CH3)2).  
13C NMR (62.5 MHz, CDCl3): δ ppm 202.74 (C=C), 197.00 (C=O), 112.70 
(C=COH), 49.50 (C(CH3)2), 30.97 (C H2), 28.82 (CH3C=C), 28.53 (CH3).   
RP-HPLC (method 1): 3.76 min (254 nm, 73.7% purity).  
LRMS (ES+): m/z (%) 183.1 [M+H]+ (100). 
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7.4.3  Synthesis of N-{2-[1-(4,4-dimethyl-2,6-dioxocyclohexyliden) 










7.2 (47.9 mol, 9.83 g) was added to DCM/EtOH 1:1 (200 mL) at room temperature 
followed by N,N-diisopropylethylamine (DIPEA, 95.87 mol, 16.20 mL, Sigma-
Aldrich) and 7.1 (47.9 mol, 8.74 g) and the reaction was stirred at room temperature 
for 16 h. The solvent was evaporated in vacuo and the crude solid was dissolved in 
EtOAc (200 mL) and extracted with KHSO4 (4 x 60 mL, 1M). The aqueous phase 
was brought to pH 9 with NaHCO3 and the aqueous phase was extracted with EtOAc 
(5 x 60 mL). The combined organic phases were washed with brine (60 mL) and 
dried over MgSO4 and concentrated in vacuo to yield 7.3 as a yellow oily solid 12.1 
g (85%).  
Rf (MeOH/EtOAc 1:9) = 0.41. 
1H NMR (250 MHz, DMSO): δ ppm 3.85 (s, 3H, OCH3), 3.68 (dd, J = 11.44, 5.68 
Hz, 2H, NHCH2), 3.61 (s, 2H, NHCH2CO), 2.99 (t, J = 5.99, 5.99 Hz, 2H, NHCH2), 
2.69 (s, 3H, CCH3), 2.47 (s, 4H, (CH2)2-Dde), 1.16 (s, 6H, (CH3)2-Dde). 
 
13C NMR (62.5 MHz, CDCl3): δ ppm 173.81 (C=O), 173.13 (C=O), 108.38 
(HNC=C), 52.25 (CH3C=C), 50.66 (HNCH2C=O), 48.04 (HNCH2), 43.82 (HNCH2), 
30.43 (C(CH3)2), 28.64 (CH3O), 18.50 (CH3).  
RP-HPLC (method 1): 2.31 min (ELSD, 100% purity).  
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Adenine (103.6 mmol, 14.0 g, Acros) was added to dry DMF (400 mL) at room 
temperature under N2 followed by NaH (114.0 mmol, 4.56 g, 60% in mineral oil, 
Sigma-Aldrich) and the reaction was stirred for 1 h. The reaction was cooled to 0 oC 
and methyl 2-bromoacetate (103.6 mmol, 9.81 mL, Fluka) was added drop wise and 
the reaction was stirred for 4h. The solvent was evaporated in vacuo, and the crude 
solid was washed with H2O, sonicated for 5 min, and filtered. The solid was dried 
over P2O5 overnight in a vacuum oven to give 7.4 as a white solid 15.01 g (69%).  
Rf (MeOH/EtOAc 1:1) = 0.67. 
1H NMR (250 MHz, DMSO) δ ppm 8.14 (s, 1H, CH), 8.12 (s, 1H, CH), 7.29 (s, 2H, 
NH2), 5.09 (s, 2H, CH2), 3.71 (s, 3H, CH3).  
13C NMR (62.5 MHz, DMSO): δ ppm 186.83 (H2NC=N), 156.34 (C=O), 153.02 
(=NCH=N), 150.06 ((N)2C=C), 141.57 (-NCH=N), 118.62 (-NC=C), 52.78 (CH3), 
44.17 (C H2).  
RP-HPLC (method 1): 3.69 min (ELSD, 93.1% purity).  











7.4 (67.57 mmol, 14.00 g) was added to dry DCM/pyridine 1:1 (500 mL) at room 
temperature under N2, followed by Mmt-Cl (101.36 mmol, 31.3g, Sigma-Aldrich) 
and NEM (67.57 mmol, 8.55mL, Sigma-Aldrich). The reaction was heated to 40 oC 
and stirred for 3 h and then cooled to room temperature and stirred for 16 h. The 
solvent was evaporated in vacuo and the residue was dissolved in EtOAc (800 mL) 
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and washed with 1 N KHSO4 (300 mL), 10% NaHCO3 (300 mL), and brine (300 
mL) and dried over MgSO4. The solvent was evaporated in vacuo and the solid was 
washed with petroleum ether and resulting precipitate was treated with NaOH (250 
mL, 1M) and refluxed for 2 h. The temperature was lowered to room temperature 
and the reaction was stirred for 2 h. The reaction was cooled to 0 oC and treated with 
KHSO4 (350 mL, 1 N) and stirred for 30 min. The precipitate was filtered and 
washed with small portions of water until the filtrate was neutral and the solid was 
dried in vacuo to give 7.5 as a white solid 19.5 g (58% over two steps).  
Rf (MeOH) = 0.67.  
1H NMR (250 MHz, DMSO: δ ppm 8.37 (s, 1H, CH-pur), 8.08 (s, 1H, CH-pur), 
7.51-7.32 (m, 10H, CH-Mmt), 7.27 (d, J = 8.68 Hz, 2H, CHCOCH3-Mmt), 7.03 (d, J 
= 8.74 Hz, 2H, CH-Mmt), 5.13 (s, 2H, CH2), 3.90 (s, 3H, OCH3-Mmt).  
RP-HPLC (method 1): 2.60 min (ELSD, 98% purity).  
LRMS (ES+): m/z (%) 466.1 [M+H]+ (100). 
Mp: 114-121 oC. 
 









6-chloroguanine (103.6 mmol, 17.6 g, Sigma-Aldrich) was added to dry DMF (400 
mL) at room temperature under N2 followed by NaH (114.0 mmol, 4.56 g, 60% in 
mineral oil) and the reaction was stirred for 1 h. The reaction was cooled to 0 oC and 
methyl 2-bromoacetate (103.6 mmol, 9.81 mL) was added drop wise and the reaction 
was stirred for 6 h. The solvent was evaporated in vacuo, and the crude oil 
precipitated with H2O and the precipitate was filtered and washed with H2O to yield 
7.6 as a white solid 17.85 g (71%).  
Rf (EtOAc) = 0.54.  
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H NMR (250 MHz, CDCl3): δ ppm 7.77 (s, 1H, CH), 4.80 (s, 2H, CH2), 3.75 (s, 3H, 
CH3).  
RP-HPLC (method 1): 4.73 min (ELSD, 95.8% purity).  










7.6 (71.82 mmol, 17.50 g) was added to dry THF (200 mL) at room temperature 
under N2, followed by Mmt-Cl (107.74 mmol, 33.3g) and DIPEA (71.82 mmol, 9.28 
g) and stirred for 16 h at rt. The solvent was evaporated in vacuo and the residue was 
dissolved in ether (400 mL) and washed with 1 N KHSO4 (50 mL), 10% NaHCO3 
(50 mL), and brine (50 mL) and dried over MgSO4. The solvent was evaporated in 
vacuo and the resulting crude product was precipitated from DCM/warm petroleum 
ether (46-60 oC) and the residue was treated with NaOH (400 mL, 1 M) and refluxed 
for 4 h. The temperature was lowered to room temperature and the reaction acidified 
with HCl (2 N) to pH = 2. The precipitate was filtered and washed with small 
portions of water until the filtrate was neutral. The solid was dried in vacuo for 16 h 
and washed with diisopropyl ether (30 mL) and dried in vacuo to give 7.7 as a white 
solid 7.33 g (49% over two steps).  
Rf (MeOH) = 0.63.  
1H NMR (250 MHz, DMSO): δ ppm 10.79 (s, 1H, NH-pur), 7.84 (s, 1H, NH-Mmt), 
7.79 (s, 1H, CH-pur), 7.56-7.38 (m, 12H, CH-Mmt), 7.09 (d, J = 8.89 Hz, 2H, 
CHCOCH3-Mmt), 4.46 (s, 2H, CH2), 3.96 (s, 3H, CH3).  
RP-HPLC (method 1): 2.67 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 505.0 [M+Na]+ (100). 
Mp: 200-220 oC (decomposed). 
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Thymine (103.6 mmol, 13.1 g, Acros) was added to dry DMF (400 mL) under N2 at 
room temperature followed by K2CO3 (113.96 mmol, 26.3 g) and methyl 
bromoacetate (113.96 mmol, 10.8 mL) and the reaction was stirred for 16 h, which 
lead to formation of a crude precipitate. The precipitate was collected by filtration 
and dried in vacuo. The precipitate was cooled to 0 oC and treated with H2O (125 
mL) and HCl (5 mL, 4 M) and stirred for 30 min. The precipitate was collected by 
filtration, washed with H2O (75 mL x 3), and treated with H2O (125 mL) and NaOH 
(75 mL, 2 M) and refluxed for 10 min. The reaction was cooled to 0 oC and treated 
with HCL (110 mL, 4 M) and stirred for 30 min. The resulting precipitate collected 
by filtration and washed with H2O until the filtrate was neutral and dried over P2O5 
to yield 7.8 as a white solid 11.22 g (59% over two steps).  
Rf (MeOH) = 0.61  
1H NMR (250 MHz, DMSO): δ ppm 13.26 (s, 1H, CO2H), 11.50 (s, 1H, NH), 7.66 
(d, J = 1.18 Hz, 1H, CH), 4.53 (s, 2H, CH2), 1.91 (s, 3H, CH3).  
RP-HPLC (method 1): 1.64 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 185.0 [M+H]+ (100). 
 







Cytosine (88.56 mmol, 9.84 g, Acros) was added to dry DCM/pyridine (500 mL) at 
room temperature under N2, followed by Mmt-Cl (132.85 mmol, 29.7 g) and N-
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ethylmaleimide (NEM, 88.56 mmol, 10.20 mL). The reaction was heated to 50 oC 
and stirred for 16 h. Note some batches of cytosine were so insoluble that the 
reaction could not take place. In these cases the cytosine was dissolved in H2O with 
1.1 equiv. HCl and freeze dried overnight. Hereby the much more soluble 
cytosine·HCl salt was formed. However, in reaction of this compound 2 equiv. NEM 
were added to the reaction. The solvent was evaporated in vacuo and the residue was 
dissolved in EtOAc (800 mL) and washed with 1N KHSO4 (300 mL), 10% NaHCO3 
(300 mL), and brine (300 mL) and dried over MgSO4. The solvent was evaporated in 
vacuo and the solid was washed with petroleum ether to give 7.9 as a white solid 
23.61 g (70%).  
Rf (EtOAc) = 0.65  
1H NMR (250 MHz, DMSO):  δ ppm 10.17 (s, 1H, NH), 7.45 (d, J = 7.26 Hz, 1H, 
NHCH), 7.30-6.92 (m, 12H, CH-Mmt), 6.80 (d, J = 7.69 Hz, 2H, CHCOCH3-Mmt), 
4.86 (d, J = 7.17 Hz, 1H, CH), 3.59 (s, 3H, CH3).  
RP-HPLC (method 1): 3.99 min (ELSD, 100% purity).  









7.9 (60.00 mmol, 23.00 g) was added to dry DMF (200 mL) at room temperature 
under N2 followed by NaH (66.00mmol, 2.64g, 60% in mineral oil) and the reaction 
was stirred for 1 h. The reaction was cooled to 0 oC and methyl 2-bromoacetate 
(60.00 mmol, 5.7 mL) was added drop wise and the reaction was stirred for 4 h. The 
solvent was evaporated in vacuo and the resulting crude product was precipitated 
from H2O, collected by filtration, and treated with NaOH (500 mL, 2 M) and 
refluxed for 2 h. The temperature was lowered to room temperature and solution was 
washed with DCM (100 mL x 3) and acidified with HCl (2 N) until pH = 2. The 
precipitate was filtered and washed with small portions of water until the filtrate was 
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neutral. The solid was dried in vacuo overnight to give 7.10 as a white solid 26.07g 
(98% over two steps).  
Rf (EtOAc/MeOH 1:1) = 0.47.  
1H NMR (250 MHz, DMSO): δ ppm 12.81 (s, 1H, CO2H), 8.32 (d, J = 7.90 Hz, 1H, 
CH-Cyt), 7.46-7.08 (m, 12H, CH-Mmt), 6.81 (d, J = 7.90 Hz, 2H, CHCOCH3-Mmt), 
6.15 (d, J = 7.55 Hz, 1H, CH-Cyt), 4.21 (s, 2H, CH2), 3.70 (s, 3H, CH3).  
RP-HPLC (method 1): 4.21 min (ELSD, 100% purity). 
LRMS (ES+): m/z (%) 273 [Mmt]+ (100), 442.0 [M+H]+ (4). 
Mp: 207-209 oC 
 







Aminomethyl PS-resin (16 mmol, 10.0 g, GLS Biochem) was swollen in dry THF 
(40 mL) and cyclohexyl isocyanate (80 mmol, 10.2 mL, Sigma-Aldrich) was added 
and the reaction was shaken overnight. The reaction was monitored by ninhydrin 
test. The resin was filtered, washed with DCM (x 3), DMF (x 3), MeOH (x 3) and 
dried in a vacuum oven overnight at 40 °C to yield 7.11 11.85 g (99%). IR (neat): 
νmax / (cm
-1) 2925s, 1627s, 1552s, 1449m, 1251m, 758m, 699s. 
N N•
7.12  
7.11 (4.6 mmol, 3.46 g) was swollen in DCM (30 mL) and triphenylphosphine (13.2 
mmol, 3.50 g, Sigma-Aldrich) was added. The mixture was stirred for 10 minutes 
and CBr4 (13.2 mmol, 4.42 g, Sigma-Aldrich) was added, immediately followed by 
drop wise addition of anhydrous TEA (43 mmol, 5.82 mL). The dark reaction 
mixture was shaken overnight, the resin was filtered and washed with DCM (x 3), 
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DMF (x 3), DCM (x 3), and dried overnight in a vacuum oven at 40 °C to give 7.12 
(PS-DCC) 3.44 g (99%).  
IR (neat): νmax / (cm
-1) 2930m; 2117s; 1450m; 1338m; 1020m; 813m; 759s.  
13C-NMR (250 MHz, CDCl3) δ ppm: 145.1, 55.6, 50.5, 34.8, 25.5, 24.5. 
 

















7.5 (2.15 mmol, 1.00 g) was added to dry DMF (25 mL) under N2 followed by HOBt 
(1.93 mmol, 0.30 g, Sigma-Aldrich) and the reaction was stirred for 10 min. 
Thereafter the reaction was added to 7.12 (3.86 mmol, 2.84 g, 1.36 mmol/g) pre-
swollen in DCM and the reaction was stirred for 15 min. Then 7.3 (1.9 3mmol, 0.57 
g) was added and the reaction was microwave irradiated for 30 min at 60 oC. PS-
DCC/DCU was removed by filtration. The solvent was removed in vacuo and the 
residue was dissolved in DCM (100 mL) and the organic phase was washed with 
KHSO4 (30 mL, 1 M), 10% NaHCO3 (30 mL), and brine (30 mL). The organic phase 
was dried over MgSO4 and concentrated in vacuo, which gave a brown oily solid, 
which was added to MeOH (20 mL) and Cs2CO3 (aq, 20 mL, 2 M) was added drop 
wise and the reaction was stirred for 1.5 h. The MeOH was evaporated in vacuo and 
the remaining solution was diluted with H2O (100 mL). The solution was washed 
with EtOAc (50 mL), acidified with KHSO4 (1 M), and extracted with DCM (3 x 100 
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mL). The combined organic phase was washed with brine (50 mL) and the solvent 
was evaporated in vacuo. The residue was precipitated from EtOAc/hexane. The 
solid was filtered and dried in a vacuum oven overnight. The precipitate was 
recrystallised from MeOH/H2O to give 7.13 1.07 g as a white solid (70% over two 
steps).  
Rf (MeOH/EtOAc 1:1) = 0.59  
1H NMR (250 MHz, CDCl3, two rotamers): δ ppm 7.91 (s, 1H, CH-pur), 7.90 (s, 1H, 
CH-pur), 7.25-7.12 (m, 12H, CH=Mmt), 6.71 (d, J = 9.15 Hz, 2H, CHCOCH3-Mmt), 
5.28 and 5.09 (s, 2H, CH2COO), 4.18 and 4.03 (s, 2H, CH2CO), 3.70 (s, 3H, OCH3-
Mmt), 3.60 (m, 4H, CH2N), 2.47 (s, 3H, CH3C), 2.27 (s, 4H, CH2-Dde), 0.93 (s, 6H, 
(CH3)2-Dde).  
RP-HPLC (method 1): 4.99 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 273 [Mmt]+ (100), 730.5 [M+H]+ (16). 
Mp: 170-180 oC (decomposed). 
 



















7.7 (4.15 mmol, 2.00 g) was added to dry DMF (15 mL) at 0 oC under N2 followed 
by 7.3 (4.15 mmol, 1.23 g), PyBroP (4.15 mmol, 1.94 g, Merck Biosciences), and 
DIPEA (8.31 mmol, 1.45 mL) and the reaction was microwave irradiated for 20 min 
at 60 oC. The solvent was removed in vacuo and the residue was dissolved in DCM 
(150 mL) and the organic phase was washed with KHSO4 (50 mL, 1 M), 10% 
NaHCO3 (50 mL), and brine (50 mL). The organic phase was dried over MgSO4 and 
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concentrated in vacuo, which gave a crude brown solid, which was added to MeOH 
(16.5 mL) followed by drop wise addition of Cs2CO3 (aq, 16.5 mL, 2 M) in the 
reaction was stirred for 1.5 h. MeOH was evaporated in vacuo and the remaining 
solution was diluted with water (100 mL). The solution was washed with DCM (40 
mL x 3), acidified with KHSO4 (1 M) to pH=2. The precipitate was collected by 
filtration, washed with H2O (40 mL x 3). The precipitate was reprecipitated from 
MeOH/H2O and the precipitate was filtered and dried in a vacuum oven overnight to 
yield 7.14 as a white solid 2.66 g (86% over two steps).  
Rf (MeOH/EtOAc 1:1) = 0.63.  
1H NMR (250 MHz, DMSO, two rotamers): δ ppm 10.33 (s, 1H, NH-pur), 7.38 and 
7.35 (s, 1H, NH-Mmt), 7.26 and 7.24 (s, 1H, CH-pur), 7.09-6.91 (m, 12H, CH-Mmt), 
6.63 (d, J = 9.08 Hz, 2H, CHCOCH3-Mmt), 4.25 and 4.02 (s, 2H, CH2COO), 3.78 
and 3.76 (s, 2H, CH2CO), 3.51 (pseudo-dd, J = 6.33, 2.82 Hz, 4H, CH2N), 3.20 (s, 
3H, OCH3-Mmt), 2.34 (s, 3H, CH3C), 2.11 and 2.07 (s, 4H, CH2-Dde), 0.75 (app d, J 
= 1.84 Hz, 6H, (CH3)2-Dde).  
RP-HPLC (method 1): 4.43 min (ELSD, 96.3% purity).  
LRMS (ES+): m/z (%) 744.2 [M+H]+ (100). 
Mp: 171-179 oC (decomposed). 
 
















7.8 (5.43 mmol, 1.00 g) was added to dry DMF (30 mL) under N2 followed by HOBt 
(4.89 mmol, 0.75 g) and the reaction was stirred for 10 min. Thereafter the reaction 
was added to 7.12 (9.78 mmol, 7.99 g, 1.34 mmol/g) pre-swollen in DCM and stirred 
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for 15 min. Then 7.3 (4.89 mmol, 1.45 g) was added and the reaction was microwave 
irradiated for 30 min at 60 oC. DCC/DCU-resin was removed by filtration. The 
solvent was removed in vacuo and the residue was dissolved in DCM (150 mL) and 
the organic phase was washed with KHSO4 (50 mL, 1 M), 10% NaHCO3 (50 mL), 
and brine (50 mL). The organic phase was dried over MgSO4 and concentrated in 
vacuo, which gave a brown solid, which was added to MeOH (20 mL) and Cs2CO3 
(aq, 20 mL, 2 M) was added drop wise and the reaction was stirred for 1.5 h. The 
MeOH was evaporated in vacuo and the remaining solution was acidified with HCl 
(2 M). The solvent was evaporated in vacuo, and the residue was treated with hot 2-
propanol and the hot suspension was filtered and the filtrate was collected and the 
solvent was removed in vacuo. The residue was sonicated with H2O (10 mL), 
filtered, and dried in a vacuum oven overnight to give 7.15 as a white solid 1.58 g 
(65% over two steps).  
Rf (MeOH/EtOAc 1:1) = 0.58.  
1H NMR (250 MHz, DMSO, two rotamers): δ ppm 13.19 and 13.14 (s, 1H, NH-Dde), 
11.31 and 11.29 (s, 1H, COOH), 7.36 and 7.33 (d, J = 1.17 Hz, 1H, CH), 4.72 and 
4.54 (two d, J = 21.81 Hz, J = 8.30 Hz, 2H, CH2COO), 4.30 and 4.03 (s, 2H, 
CH2CO), 3.71 (m, 2H, CH2N), 3.59-3.48 (m, 2H, CH2N), 2.54 and 2.49 (s, 3H, 
CH3C-Dde), 2.30 and 2.28 (s, 4H, CH2-Dde), 1.76 (d, J = 1.00 Hz, 3H, CH3), 0.96 
and 0.95 (s, 6H, (CH3)2-Dde).  
RP-HPLC (method 1): 3.30 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 471.4 [M+Na]+ (100). 
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7.10 (4.53 mmol, 2.00 g) was added to dry DMF (30 mL) under N2 followed by 
HOBt (4.08 mmol, 0.62 g) and the reaction was stirred for 10 min. Subsequently, the 
reaction was added to 7.12 (8.16 mmol, 6.66 g, 1.36 mmol/g) and stirred for 15 min. 
Then 7.3 (4.08mmol, 1.21g) was added and the reaction was microwave irradiated 
for 30 min at 60 oC. DCC/DCU-resin was removed by filtration. The solvent was 
removed in vacuo and the residue was dissolved in DCM (150 mL) and the organic 
phase was washed with KHSO4 (50 mL, 1 M), 10% NaHCO3 (50 mL), and brine (50 
mL). The organic phase was dried over MgSO4 and concentrated in vacuo to give a 
yellow oily solid, which was added to MeOH (20 mL) and Cs2CO3 (aq, 20 mL, 2 M) 
was added drop wise and the reaction was stirred for 1.5 h. The MeOH was 
evaporated in vacuo and the remaining solution was diluted with H2O (100 mL). The 
solution was washed with EtOAc (50 mL), acidified with KHSO4 (1 M), and 
extracted with DCM (100 mL x 3). The combined organic phase was washed with 
brine (50 mL) and the solvent was evaporated in vacuo. The residue was precipitated 
from EtOAc/hexane. The solid was filtered and dried a in a vacuum oven overnight. 
The precipitate was recrystalised from MeOH/H2O to yield 7.16 as a white solid 
2.80g (86%).  
Rf (MeOH/EtOAc 1:1) = 0.62.  
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1H NMR (250 MHz, DMSO, two rotamers): δ ppm 9.92 (s, 1H, NH), 7.42 (d, J = 
7.99 Hz, 1H, CH-Cyt) 7.35-6.92 (m, 12H, CH-Mmt), 6.73 (d, J = 7.09 Hz, 2H, CH-
Mmt), 5.07 (d, J = 7.91 Hz, 1H, CH-Cyt), 4.67 and 4.36 (s, 2H, CH2COO), 4.13 and 
3.98 (s, 2H, CH2CO), 3.67 (m, 7H, OCH3-Mmt and 2 x CH2N), 2.40 (s, 3H, CH3C), 
2.19 (s, 4H, CH2-Dde), 0.88 (s, 6H, (CH3)2-Dde).  
RP-HPLC (method 1): 4.55 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 273 [Mmt]+ (100), 706.2 [M+H]+ (10). 
Mp: 172-179 oC (decomposed). 
 
7.4.13 Functionalised resins for PNA-peptide conjugate 
synthesis14 







Fmoc-Rink linker (4.32 mmol, 2.34 g, GLS Biochem) was added to DMF (40 mL) at 
room temperature followed by HOBt (4.32 mmol, 0.660 g) and stirred for 10 min. 
Hereafter DIC (5.18 mmol, 0.80 mL, Sigma-Aldrich) was added and the reaction was 
stirred for another 10 min. The resulting solution was added to amino-PEGA resin 
(0.237 mmol, 0.056 mmol/g, 4.00 g, Polymer Laboratories) pre-swollen in DCM (40 
mL x 3) and the reaction was microwave irradiated for 30 min at 60 oC. The reaction 
was analysed by qualitative ninhydrin test (negative). The resin was filtered and 
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7.4.13.2 Synthesis of low loading PS-resin 
Fmoc-Rink linker (0.211 mmol, 0.114 g) was added to DMF (21 mL) at room 
temperature followed by PyBOP (0.192 mmol, 0.100 g, GLS Biochem) and NEM 
(0.384 mmol, 54 µL) and the resulting solution was added to PS-resin (3.20 mmol, 
3.26 g, 1.0 mmol/g, 1% DVB, 100-200 mesh, GLS Biochem) pre-swollen DCM (40 
mL x 3) and the reaction was microwave irradiated at 60 oC for 10 min. The resin 
was filtered and washed thoroughly with DMF (x 3), DCM (x 3), and MeOH (x 3). 
The new loading was determined by quantitative Fmoc test. Dry resin (5-10 mg) was 
accurately weighed off and shaken in 20% piperidine in DMF for 10 min. The resin 
was filtered off and the filtrate diluted to with 20% piperidine in DMF (10 mL) and 
the absorbance was measured at 305 nm (ε=7800 L/mol·cm) to give a loading of 
0.063 mmol/g.     
 













Fmoc-Lys-OH (7.41 mmol, 3.00 g, Iris Biotech GmBH) was added to ethanol (50 
mL) at room temperature followed by Dde-OH (2.73 mmol, 2.70 g) and TFA (0.74 
mmol, 0.06 mL) and the reaction was refluxed for 60 h. The solvent was removed by 
evaporation in vacuo and the orange residue was dissolved in EtOAc (150 mL). The 
organic phase was washed with KHSO4 (1 M, 100 mL x 2), dried over Mg2SO4 and 
concentrated in vacuo. The crude oil was tituated with hexane to remove any 
unreacted Dde-OH. The product was crystallised from EtOAc/hexane to yield 7.18 as 
white crystals 2.62 g (66%).  
Rf (EtOAc) = 0.45.  
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1H NMR (250 MHz, CDCl3): δ ppm 13.25 (s, 1H, COOH), 7.75-7.06 (m, 8H, CH-
Fmoc), 5.70 (pseudo-d, J = 8.60 Hz, 1H, CH-Fmoc), 4.66-3.79 (m, 4H, NH, CH, 
CH2-Fmoc), 3.32 (s, 2H, CH2-NH), 2.48 and 2.47 (s, 3H, CH3-Dde), 2.28 (s, 4H, 
CH2-Dde), 2.01-1.33 (m, 6H, CH2-Lys), 0.94 and 0.93 (s, 6H, (CH3)2-Dde).  
RP-HPLC (method 1): 4.47 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 554.5 [M+Na]+ (100). 
 














PEGA-Rink-amine resin (0.103 mmol 2.06 g, 0.050 mmol/g) was prepared by pre-
swelling in DCM and Fmoc deprotection was carried out by treatment with 20% 
piperidine in DMF (30 mL x 2) for 10 min and washing with DMF (x 3), DCM (x 3), 
and MeOH (x 3). Qualitative ninhydrin test was positive. 
 
7.18 (2.16mmol, 1.15 g) was added to DMF (21 mL) at room temperature followed 
by HOBt (2.16mmol, 0.292 g) and stirred for 10 min. Hereafter, DIC (2.59 mmol, 
0.811 mL, Fluka) was added, the reaction was stirred for another 10 min and added 
to the resin and the reaction was microwave irradiated for 30 min at 60 oC. The 
reaction was monitored by a qualitative ninhydrin test (negative). The resin was 
filtered and washed thoroughly with DMF (x 3), DCM (x 3), and MeOH (x 3) to give 
7.19 2.45 g (0.042 mmol/g, 100%). An analytical sample was cleaved with TFA/TIS 
95:5 to give Fmoc-Lys(Dde)-NH2.  
RP-HPLC (method 2): 7.76 min (ELSD, 100% purity).  
LRMS (ES+): m/z (%) 532.3 [M+H]+ (100).  
Nina Svensen                                                                                                   Chapter 7 
  150
   









































































7.4.14.1 PNA-monomer coupling 
PNA-monomer (5.5 equiv.) or 5(6)-carboxyfluorescein (5.5 equiv., Fluka) and 
PyBOP (5.0 equiv.) were added to DMF (final concentrations of 0.11 M and 0.1 M 
respectively) followed by NEM (10 equiv., final concentration of 0.2 M) and the 
solution was mixed for 20 sec. The reaction mixture was added to resin (1 equiv., 
pre-swollen in DMF) and the reaction was shaken for 3 h (the filtrate was collected 
to recover the monomer). The resin was washed with DMF (x 3), DCM (x 3), and 
MeOH (x 3).  
 
7.4.14.2 Recovery of PNA monomers after coupling 
The unreacted monomers were recovered from the reaction mixture after use. The 
reaction mixture was collected after use and the resin rinsed with DMF and the 
filtrates were combined. Ade-, Cyt-, and Gua-monomers: DMF was removed by 
evaporation in vacuo and the monomer is precipitated by MeOH/H2O twice yielding 
the respective monomer as a white solid. Thy-monomer: DMF was removed by 
evaporation in vacuo and the crude was precipitated in DCM/petroleum ether 
followed by EtOAc/hexane and the yellow precipitate was washed with minimum 
amounts of H2O yielding the Thy-monomer as a white solid.     
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7.4.14.3 Amino acid and peptoid couplings 
Fmoc-amino acid (5.5 equiv., GLS Biochem) or butyric acid (5.5 equiv., Fluka) or 
Llp (5.5 equiv., courtesy of Géraldine Escher, University of Edinburgh, UK) was 
added to DMF to a final concentration of 0.11 M followed PyBOP (5.0 equiv.) and 
HOBt (5.0 equiv.) to a final concentration of 0.1 M, hereafter DIPEA was added to a 
final concentration of 0.2 M (10 equiv.) and the solution was mixed for 20 sec. The 
reaction mixture was added to resin (1 equiv.), pre-swollen in DMF and the reaction 
was shaken for 3 h. The resin was washed with DMF (x 3), DCM (x 3), and MeOH 
(x 3).  
 
7.4.14.4 Dde-deprotection 
A stock solution of 25(wt)% imidazole/NH2OH·HCl 1:0.75 in NMP was made up 
from NH2OH·HCl (9.00mmol, 6.25g, Fluka) and imidazole (6.75mmol, 4.59g, 
Sigma-Aldrich) in 25 mL NMP (this was sonicated till complete dissolution). 
Immediately before use a solution of 20(wt%) imidazole/NH2OH·HCl 1:0.75 in 
NMP/DMF 5:1 was made up from 1 mL DMF and 5 mL of the stock solution and 
added to the resin (pre-swollen in DMF) and the reaction was shaken for 1 h. The 
resin was filtered and washed with DMF (x 3), DCM (x 3), and MeOH (x 3).  
 
Dde-deprotection was also carried out with NH2OH/H2O 1:1 (Sigma-Aldrich) instead 
of the NH2OH·HCl salt under the same reaction conditions as described above. 
 
7.4.14.5 Fmoc-deprotection 
Fmoc deprotection was carried out by treatment of the resin with 20% piperidine 
(Sigma-Aldrich) in DMF for 2 x 10 min followed by washing with DMF (x 3), DCM 
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7.4.14.6 Cleavage from resin 
After synthesis the resins were washed twice with 20% piperidine in DMF (2 mL) 
for 10 min to cleave unwanted fluorescein dimmers. The PNA-peptide conjugates 
and peptides were cleaved from the resin by treatment with TIS (Sigma-
Aldrich)/TFA 5:95 for 2 x 2 h and the products were precipitated by drop wise 
addition to cold ether (x 2) and collected by centrifugation.  
 
Analytical cleavages were carried out on small aliquots of resin as described above 
for 1 h. Samples were analysed by Maldi-TOF or MS and RP-HPLC. 
 
7.4.15 General reaction conditions for microwave PNA-peptide 
conjugate synthesis optimisation 
7.4.15.1 Microwave aided PNA monomer coupling  
PNA-monomer (5.5 equiv., 0.22 M) in NMP or DMF was mixed with PyBOP (5.5 
equiv., 0.20 M) in NMP followed by the addition of NEM (10 equiv.) to a final 
concentration of 0.2 M and the reaction was stirred for 20 s and added to the resin (1 
equiv.), pre-swollen in DMF in a 5 mL glass syringe with a glass filter. The entire 
glass syringe containing the reaction was transferred to a microwave vial, NMP or 
DMF was added around the syringe, and the reaction was microwave irradiated for 
20 min at 60 oC. The resin was washed with DMF (x 3), DCM (x 3), and MeOH (x 
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7.4.15.2 Capping 
After each monomer coupling the unreacted free amino-sites were capped to prevent 
further growth of undesirable sequences. 70% acetic anhydride and 8 (wt)% HOBt in 
DMF was added to the resin pre-swollen in DMF and the reaction was stirred at 
room temperature for 20 min. The resin was washed with DMF (x 3), DCM (x 3), 
and MeOH (x 3). 
  
7.4.15.3 Microwave aided Dde-deprotection 
The Dde-deprotection reaction mixtures described in section 0 were added to the 
resin pre-swollen in DMF in a glass syringe and the reaction was pre-stirred for 20 s. 
The glass syringe was transferred to a microwave vial and NMP was added around 
the syringe and microwave irradiated for 10 min at 60 oC. The resin was filtered and 
washed with DMF (x 3), DCM (x 3), and MeOH (x 3). 
 
7.4.15.4 Microwave aided amino acid couplings and Fmoc-deprotection 
Automated peptide synthesis was performed by solid-phase Fmoc chemistry using an 
automated microwave peptide synthesiser for multiple peptide synthesis (Liberty, 
CEM). Amino acid (5.5 equiv., 0.22 M) or Llp (5.0 equiv., 0.2 M, courtesy of 
Géraldine Escher, University of Edinburgh, UK) in DMF were coupled using HTBU 
(5.0 equiv., 0.2 M, GLS Biochem)/HOBt (5.0 equiv., 0.2 M) in DMF and 20 % 
DIPEA in NMP (final concentration of 0.2 M) under microwave irradiation for 20 
min at 60 oC. The resin was filtered and washed with DMF (x 3) and DCM (x 3). 
Fmoc-deprotection was carried out in the CEM synthesiser as described in section 0.  
 
7.4.16 Synthesis of PNA-peptide conjugates and peptides 
Unless otherwise stated, the PNA-peptide conjugates and peptides were purified by 
precipitation in cold diethyl ether followed by RP-HPLC purification: column: 
XTerra Prep RP18, 19 cm x 150 nm x 5µm; eluting with 100% H2O with 0.1% TFA 
for 5 min 100% H2O with 0.1% TFA to 40% H2O with 0.1% TFA over 10 min, to 
100% CH3CN with 0.1% TFA over 4 min and 100% CH3CN with 0.1% TFA for 2 
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min. Fractions were analysed by ESI-MS or MALDI-TOF and the collected fractions 
were freeze dried overnight.  
 



























RGD-PNA and RGE-PNA conjugates were synthesised using microwave aided PNA 
and amino acid couplings as described above in an automated CEM peptide 
synthesiser. The conjugates were purified by RP-HPLC (method 2) and analysed by 
MALDI-TOF as described above. The following 4-letter codes were applied: 
 
7.24: Arg-Gly-Asp-Ahx-Lys(FAM)-TATCTGTTTCAT-NH2   
RP-HPLC:  12.42 min. (95.2% crude purity). 
MALDI-TOF+/MS: m/z (%) 4193.04 [M]+ (100). 
 
7.25: Arg-Gly-Glu-Ahx-Lys(FAM)-TATCTGTTTCTA-NH2  
RP-HPLC:  12.37 min (93.7% crude purity). 
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7.5 Experimental to Chapter 3 
7.5.1 Synthesis of the 1296 member peptide-PNA library 
The 1296 member peptide-PNA library (Library-1) was synthesised using orthogonal 
Dde/Fmoc-peptide chemistry on Fmoc-Lys(Dde)-Rink-PEGA resin (600 mg, 0.042 
mmol/g) as described in section 0 using the following code:  






Lys TCAT  
 
The split-and-mix synthesis was carried out by splitting the resin into 6 and coupling 
of four PNA monomers (Dde) and the corresponding amino acid (Fmoc) and mixing 
giving 1296 (64) different PNA encoded peptides. Before the first mix, the 6 amino 
acid conjugates were analysed by MALDI-TOF: 
 
Fmoc-Llp-Ahx-Lys(Dde-TTAC)-NH2: RP-HPLC: 2.89 min.  
MALDI-TOF+/MS: m/z (%) 1859.30 [M]+ (100). 
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Fmoc-Pro-Ahx-Lys(Dde-AAAC)-NH2: RP-HPLC:  2.82 min.  
MALDI-TOF+/MS: m/z (%) 1818.21 [M]+ (100). 
 
Fmoc-Leu-Ahx-Lys(Dde-TACA)-NH2: RP-HPLC:  2.84 min.  
MALDI-TOF+/MS: m/z (%) 1824.77 [M]+ (100). 
 
Fmoc-Glu-Ahx-Lys(Dde-ATCT)-NH2: RP-HPLC:  2.83 min.  
MALDI-TOF+/MS: m/z (%) 1831.27 [M]+ (100). 
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Fmoc-Tyr-Ahx-Lys(Dde-ACAA)-NH2: RP-HPLC:  2.91 min.  
MALDI-TOF+/MS: m/z (%) 1883.91 [M]+ (100). 
 
Fmoc-Lys-Ahx-Lys(Dde-TCAT)-NH2: RP-HPLC:  2.84 min.  
MALDI-TOF+/MS: m/z (%) 1829.64 [M]+ (100). 
 
Following split and mix synthesis (amino acid coupling and PNA synthesis) the 
peptide N-termini were capped with acetic anhydride/pyridine while the PNA amino-
terminus was coupled with Fmoc-6-aminohexanoic acid followed by Fmoc cleavage 
and capping with 5(6)-carboxyfluorescein as described in section 0. After synthesis 
the peptide-PNA conjugates were cleaved from the solid support and purified as 
described in section 0 to yield Library-1 81 mg (51%, over 50 steps, appendix I). 
 
7.5.2 Extraction of peptide-PNA conjugates from cells 
HeLa, HEK293T, ARN8, SH-SY5Y, and E14 cells were grown to 70-90% 
confluence in 6-well plates and incubated with Library-1 (800 µL, 100 µM) in 
appropriate growth media at 37 oC for 2 h in 8 wells. Primary neutrophils and 
primary monocytes were grown to 90% confluence in 24-well plates and incubated 
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with Library-1 (300 µL, 100 µM) in appropriate growth media at 37 oC for 30 min in 
12 and 24 wells respectively. Suspension cells, K562 (2x106 cells/mL) and primary 
lymphocytes (5x106 cells/mL) were collected by centrifugation (1100 rpm for 5 min) 
and incubated with Library-1 (100 µM) in RPMI CM (800 µL) and PBS (3 mL) 
respectively at 37 oC for 4 h. After incubation the cells were washed with PBS x 3, 
treated with 1 x trypsin/EDTA for 15 min, collected by centrifugation (1100 rpm for 
5 min), washed with PBS, and lysed with a minimum amount of H2O. peptide-PNA 
conjugates were purified by filter-centrifugation separating between 3,000 Da and 
10,000 Da molecular weight filters (Nunc TM) and concentrated by speed-vac. The 
amount of cell penetrating PNA was estimated using a NanoVue spectrometer. Cell 
penetrating PNA encoded peptides extracted were HeLa (8.0 µg and 6.3 µg), 
HEK293T (6.9 µg), SH-SY5Y (1.9 µg), ARN8 (6.6 µg), K562 (1.5 µg), E14 (6.4 
µg), primary monocytes (7.0 µg and 1.6 µg), primary neutrophils (6.2 µg, 1.8 µg), 
and primary lymphocytes (1.4 µg and 2.2 µg). 
 
7.5.3 Microarray hybridisation of Library-1 extracted from cells 
DNA arrays (OGT) complementary to the Library-1 were hybridised with the PNA-
conjugates purified from cells in 1 x GenHyb buffer (110 µL) buffer overnight from 
50 oC to 32 oC according to microarray wash protocol 2 and imaged with a Tecan LS 
Reloaded microarray scanner. Image analysis was carried out as described in section 
7.2 (appendix II) 
 
7.5.4 Synthesis of selective “hit”-tetramers 
Peptides (X-AA4-AA3-AA2-AA1-NH2) were synthesised in an automated CEM-
peptide synthesiser on Fmoc-Rink-PS-resin using microwave aided amino acid and 
Llp couplings as described in section 0. After amino acid/Llp couplings the N-termini 
were coupled with 6-aminohexanoic acid followed by capping 5(6)-
carboxyfluorescein as described before. After synthesis, the peptide were purified by 
RP-HPLC (method 1) and analysed by ES-MS (positive mode). 
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FAM-Ahx-Pro-Tyr-Glu-Glu-NH2: 23.8 mg (39% yield).  
RP-HPLC: 2.95 min. (84.3% crude purity). 
LRMS (ES+): m/z (%) 747.3 [M-FAM]+ (100), 1007.3 [M+H]+ (13).  
 
FAM-Ahx-Llp-Llp-Pro-Tyr-NH2: 3.97 mg (42% yield) 
RP-HPLC: 2.90 min. (82.6% crude purity). 
LRMS (ES+): m/z (%)703.4 [M-FAM]+ (100), 1061.4 [M+H]+ (7).  
 
FAM-Ahx-Pro-Lys-Pro-Glu-NH2: 25.4 mg (44% yield)  
RP-HPLC: 3.35 min. (80.0% crude purity). 
LRMS (ES+): m/z (%) 470.6 [M+2H]2+ (100), 940.4 [M+H]+ 940.3 (45).  
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FAM-Ahx-Glu-Leu-Llp-Llp-NH2: 12.00 mg (63% yield)  
RP-HPLC: 2.90 min. (78.4% crude purity). 
LRMS (ES+): m/z (%) 521.7 [M+2H]2+ (100), 1042.4.4 [M]+ (24).  
 
FAM-Ahx-Tyr-Pro-Lys-Leu-NH2: 5.92 mg (19% yield)  
RP-HPLC: 3.58 min. (91.5% crude purity). 
LRMS (ES+): m/z (%) 682.3 [M-FAM]+ (100), 1018.3 [M+H]+ (12).  
 
FAM-Ahx-Glu-Pro-Lys-Llp-NH2: 10.7 mg (58% yield)  
RP-HPLC: 2.99 min. (71.0% crude purity). 
LRMS (ES+): m/z (%) 500.1 [M+2H]2+ (100), 999.3 [M+H]+ (27). 
Nina Svensen                                                                                                   Chapter 7 
  161
   
 
FAM-Ahx-Llp-Llp-Pro-Glu-NH2: 10.0 mg (53% yield) 
RP-HPLC: 3.00 min. (86.4% crude purity). 
LRMS (ES+): m/z (%) 514.3 [M+2H]2+ (100), 1027.4 [M+H]+ (29).  
 
FAM-Ahx-Leu-Lys-Llp-Lys-NH2: 11.3 mg (61% yield) 
RP-HPLC: 3.26 min. (78.0% crude purity). 
LRMS (ES+): m/z (%) 502.0 [M+2H]2+ (100).  
 
FAM-Ahx-Leu-Lys-Lys-Pro-NH2: 41.6 mg (72% yield).  
RP-HPLC: 3.18 min. (79.3% crude purity). 
LRMS (ES+): m/z (%) 478.2 [M+2H]2+ (100), 955.3 [M+H]+ (23).  
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FAM-Ahx-Glu-Llp-Glu-Glu-NH2: 7.31 mg (38% yield) 
RP-HPLC: 3.11 min. (91.7% crude purity). 




RP-HPLC: 2.51 min.  
LRMS (ES+): m/z (%) 1113.6 [M+H]+.  
 
7.5.5 Flow cytometry of generic and selective “hit”-tetramers  
Adherent cells, HeLa, HEK293T, ARN8, SH-SY5Y, and E14 were grown to 70-90% 
confluence in 48-well plates and incubated with the “hit”-tetramers (X-AA4-AA3-
AA2-AA1-NH2; 200 µL, 10 µM) in appropriate growth media at 37 
oC for 4 h. 
Suspension cells, K562 (106 cells/mL) were collected by centrifugation (1100 rpm 
for 5 min) and incubated with “hit”-tetramers (X-AA4-AA3-AA2-AA1-NH2; 200 µL, 
10 µM) in RPMI. After incubation, the cells were washed with PBS x 4, treated with 
1 x trypsin/EDTA (20 min) and suspended in tryphan blue (0.04 M, Sigma-Aldrich) 
                                                 
** Synthesised by Geraldine Escher 
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and propidium iodide (1.5 mM, Sigma-Aldrich) in PBS (300 µL). Flow cytometry 
was run analytically using a FACS Aria cytometer (selective “hit”-tetramers: X-AA4-
AA3-AA2-AA1-NH2, FITC and PE-Texas Red filters, 10.000 events) or a FACS 
Calibur cytometer (X-Glu-Llp-Llp-Llp-NH2, FITC and PE/PI filters, 10.000 events). 
 
Anticoagulated whole blood (100 µL) was incubated with “hit”-tetramers (X-AA4-
AA3-AA2-AA1-NH2;100 µL, 20 µM) in PBS at 37 
oC for 4 h. After incubation, the 
red blood cells were selectively lysed by hypertonic cryohemolysis by adding 1.2 x 
PBS (2 mL) at 0 oC for 45 sek, followed by addition of 0.8 x PBS (2 mL) at 0 oC to 
re-establish isotonic concentrations. The leukocytes were collected by centrifugation 
(1100 rpm for 5 min), re-suspended in PBS, and analysed by flow cytometry using a 
FACS Calibur cytometer (FITC filter and 10.000 events). Histograms of cell count 
vs. FITC-fluorescence were created based on scatter plots gated for single, FITC-
only positive, live cells. 
In order to compare the uptake of each “hit”-tetramers (X-AA4-AA3-AA2-AA1-NH2) 
across the cell types, the data set for each cell type were normalised in the same 
manner as the microarray data (i.e. the mean intensity of the entire data set for each 
cell type was arbitrarily set to 100 and 10 mean intensities in each dataset were 
multiplied with respective normalisation factor). 
 
7.5.6 Confocal microscopy of selective “hit”-tetramers 
Adherent cells, HeLa, HEK293, ARN8, SH-SY5Y, E14, primary neutrophils, and 
primary monocytes were grown on glass cover slips (primary cells) or glass cover 
slips coated with 0.01% poly-L-lysine [Sigma-Aldrich, washed with 1 % HCl, 70 % 
EtOH in H2O and 3 x H2O and treated with 10 % poly-lysine in H2O for 5 min and 
dried at room temperature overnight] at 37 oC or 4 oC. Half of the wells were 
incubated with 10 µM “hit”-tetramer (X-AA4-AA3-AA2-AA1-NH2) and incubated at 
37 oC or 4 oC for 2 h in appropriate growth media. All the wells were incubated with 
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a lysosomal tracker dye (300 µL, 75 nM Lysotracker Red, Invitrogen) at 37oC or 4 
oC for 2 h in appropriate growth media.  Suspension cells, K562 (105 cells/ml) and 
primary lymphocytes (6105 cells/ml) were collected by centrifugation (1100 rpm for 
5 min) and incubated with 10 µM “hit”-tetramer (X-AA4-AA3-AA2-AA1-NH2) in 
RPMI (K562) and PBS (lymphocytes) at 37 oC or at 4 oC for 2 h, washed with PBS x 
3 and incubated with LysoTracker Red as described above. Subsequently, the cells 
were spun onto glass cover slips by centrifugation (1100 rpm for 5 min). Cells were 
analysed by confocal microscopy using a Deltavision Tollervey microscope with a 
Photometrics Coolsnap HQ camera, SoftWoRx (Applied Precision) software using 
FITC (Ex = 490/20 nm, Em = 528/38 nm) and TRITC (Ex = 545/30 nm, Em = 
610/75 nm) filters (100 x magnification). 
 
7.5.7 Haemolysis assays 
Erythrocytes were isolated from freshly drawn, anticoagulated, human blood and 
resuspended to 20% in PBS (pH 7.4). In a 96-well microtiter plate, 100 µl of 
erythrocyte suspension was added to 100 µl of the ”hit”-tetramers (final 
concentration 10 µM) in PBS (prepared by 1:2 serial dilutions) or 100 µl of PBS in 
the case of negative controls. One-hundred percent haemolysis wells contained 100 
µl of red cell suspension with 100µl of 0.2% Triton 100. The plate was incubated for 
1 h at 37 °C, and then each well was diluted with 150 µl of PBS. The plate was then 
centrifuged at 1,200 g for 15 min, and 100 µl of the supernatant from each well was 
transferred to a fresh microtiter plate, and A570 was measured. Percentage of 
haemolysis was determined as (A-A0)/(Atotal-A0) X 100, where A is the absorbance 
of the test well, A0 the absorbance of the negative controls, and Atotal the absorbance 
of 100% haemolysis wells, all at 570 nm on a Biotek plate reader. 
 
7.6 Experimental to Chapter 4 
7.6.1 Synthesis of PNA-peptide conjugates and peptides 
Unless otherwise stated the PNA-peptide conjugates and peptides were purified by 
precipitation in cold diethyl ether followed by RP-HPLC purification (column: 
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XTerra Prep RP18, 19 cm x 150 nm x 5µm) eluting with 100% H2O with 0.1% TFA 
for 5 min 100% H2O with 0.1% TFA to 40% H2O with 0.1% TFA over 10 min; to 
100% CH3CN with 0.1% TFA over 4 min and 100% CH3CN with 0.1% TFA for 2 
min. Fractions were analysed by ESI-MS or MALDI-TOF and the collected fractions 










































RGD-, LDV-, and GGG-PNA conjugates were synthesised using microwave aided 
PNA and amino acid couplings as described above in an automated CEM peptide 
synthesiser. The conjugates were purified by RP-HPLC (method 2) and analysed by 
MALDI-TOF as described above. The following 4-letter codes were applied: 
 
7.43: Arg-Gly-Glu-Ahx-Lys(FAM)-TCATTGTTTATC-NH2   
RP-HPLC:  12.42 min. (95.2% crude purity). 
MALDI-TOF: m/z (%) 4164.75 [M+H]+ (100). 
 
7.44: Leu-Glu-Val-Lys(FAM-ATCAAATCTACT)-NH2  
RP-HPLC:  12.37 min. (75.4% crude purity). 
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MALDI-TOF: m/z (%) 4098.25 [M+H]+ (100).  
 
7.45: Gly-Gly-Gly-Ahx-Lys(FAM)-TGTTTGTTTGTT-NH2  
RP-HPLC:  11.80 min. (89.7% crude purity). 




7.6.2 Fabrication of RGD, LDV, and GGG-displaying microarray 
DNA oligonucleotides (200 µM, Sigma-Aldrich) complementary to RGD-PNA, 
LDV-PNA, GGG-PNA, TCTTA (PNA), and marker DNA in 1 x Printing buffer 
(Agilent) were printed by contact printing using 4 solid pins, 1 stamp per ink, 3 
stamps per spot, and 10 ms stamp- and inking time under 70% humidity in 9 
spots/feature (squares) in a 3 x 3 grid x 4 subarrays. After printing the DNA was 
immobilised by keeping the microarray overnight in a box with filter paper soaked 
with NaCl (3 M). Thereafter the array was blocked with perfluorooctyl propylamine 
(2 M) and DIPEA (2 M) in acetonitrile for 30 min. The microarray was briefly 
washed with acetonitrile (3 x 20 mL), H2O (3 x 20 mL), and Tris pH 8 (20 mL, 10 
mM).  
 
7.6.3 Microarray hybridisation of RGD-PNA, LDV-PNA, and 
GGG-PNA conjugates 
Before hybridisation the PNA-peptide conjugate solution was denatured at 40 oC for 
1 min. RGD-PNA, LDV-PNA, GGG-PNA, and TCTTA (1 µM) were hybridised in 1 
x GenHyb buffer from 50-22 oC overnight in a GeneMachines Hyb4 hybridizer and 
the array was washed according to the Codelink microarray wash protocol. 
 
7.6.4 HeLa growth on RGD, LDV, and GGG-displaying 
microarray 
HeLa cells (5 mL, 20,000 cells/mL) detached with partly inactivated trypsin were 
incubated in RPMI CM enriched with CaCl2 (50 µM) and MgCl2 (50 µM) for 72 h. 
The microarray was washed with PBS and attached cells were fixed and stained with 
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phalloidin and DAPI as described in section 0. The microarray was imaged with a 
BioTEc LaVision BioAnalyser and a microscope (Leica DM IRB). 
 
7.6.5 Flow cytometry of RGD-PNA, LDV-PNA, and GGG-PNA 
treated HeLa cells 
HeLa cells were grown to 80% confluence in a 48-well plate and a solution of RGD-, 
GGG-, or LDV-PNA (10 µM) in DMEM enriched with CaCl2 (50 µM) and MgCl2 
(50 µM) was added and incubated for 30 min to 2 h. The media was removed and the 
cells gently washed with PBS x 3. Cells were detached by scraping or by standard 
trypsination (15 min), suspended in PBS enriched with CaCl2 (50 µM) and MgCl2 
(50 µM, 300 µL), and analysed on a Calibur flow cytometer (FITC filter with 10,000 
events).  
 
7.6.6 Microarray hybridisation of Library-2 
The DNA microarrays were hybridised with Library-2 (5 µM) in 1 x GenHyb buffer 
(150 µL, Genetix) overnight from 65 oC to 37 oC.  The arrays were washed according 
to microarray wash protocol 1 and imaged with a Tecan LS Reloaded microarray 
scanner producing 4,000 x 12,000 pixel images.   
  
7.6.7 Cell growth on Library-2 displaying microarrays 
D54 and HEK293T-CCR6 cells were grown to 80% confluence in DMEM CM 
enriched with CaCl2 (50 µM) and MgCl2 (50 µM) and detached by trypsination 
(above). Cells were allowed to re-attach for 8 h to allow regeneration of surface 
receptors. The cells were then detached by gently tapping the flask and incubated (5 
mL, 50,000 cells/mL) with the Library-2 displaying microarray (section 0) in DMEM 
enriched with CaCl2 (50 µM) and MgCl2 (50 µM) for 2 h at 37 
oC. The media was 
removed and fresh media was added and the incubation continued for 16 h. The 
microarray was washed briefly in PBS enriched with CaCl2 (50 µM) and MgCl2 
(50 µM) and attached cells were fixed and stained with phalloidin and DAPI as 
described in section 0. The microarrays were imaged using a Nikon Eclipse 50i 
microscope producing 5,000 x 13,000 pixel images. The DAPI-filtered image and the 
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FITC-filtered image acquired prior to cellular incubation (section 0) were aligned in 
the following manner: the two FITC-filtered images acquired pre and post cellular 
incubation were superimposed and aligned using ImageViewer 1.0 software. 
Hereafter, the resulting realigned FITC-filtered image acquired prior to cellular 
incubation and the DAPI image were analysed as described in section 7.2 (appendix 
III). 
 
7.6.8 Synthesis of integrin and GPCR ligands and non-binding 
peptides 
Peptides were synthesised using microwave aided amino acid couplings and 5(6)-
carboxyfluorescein couplings as described in section 0 and purified by RP-HPLC 








































FAM-Ahx-FQpIYIIIK-NH2: 7.35 mg (41%).  
RP-HPLC:  4.195 min. (46.4% crude purity). 
MALDI-TOF+/MS: m/z (%) 1577.5 [M+H]+ (100).  
 
FAM-Ahx-FQKKYSRIK-NH2: 13.5 mg (72%).  
RP-HPLC:  2.818 min. (65.0% crude purity). 
MALDI-TOF+/MS: m/z (%) 1652 [M+H]+ (100).  
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FAM-Ahx-FQIPYIIIK-NH2: 6.53 mg (36%).  
RP-HPLC:  4.190 min. (55.2% crude purity). 
MALDI-TOF+/MS: m/z (%)1576.6 [M+H]+ (100).  
 
FAM-Ahx-FQPKYSFIK-NH2: 14.4 mg (79%).  
RP-HPLC:  3.457 min. (79.5% crude purity). 
MALDI-TOF+/MS: m/z (%) 1600.4 [M+H]+ (100).  
 
FAM-Ahx-RGD-NH2: 6.65 mg (74%).  
RP-HPLC:  3.030 min. (95.4% crude purity). 
MALDI-TOF+/MS: m/z (%) 789.2 [M+H]+ (100).  
 
7.6.9 Fabrication of “hit”-displaying microarrays 
FAM-Ahx-FQpIYIIIK-NH2 (200 nM), FAM-Ahx-FQKKSRIK-NH2 (200 nM), 
FAM-Ahx-FQIPYIIIK-NH2 (200 nM), and FAM-Ahx-FQPKYSFIK-NH2 (200 nM) 
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in sodium phosphate (50 mM, pH 8.5) were contact printed on Codelink slides (GE 
Healthcare) in 45% humidity using 4 solid pins, 1 stamp per ink, 3 stamps per spot, 
and 10 ms stamp- and inking time in 9 spots/feature (squares) in a 3 x 3 grid in 3 
subarrays using a Genetix QArray Mini Microarrayer. The peptides were 
immobilised by incubating the microarrays in a box with filter paper soaked with 
NaCl (3 M) overnight. Unreacted sites were blocked with 2 M perfluorooctyl 
propylamine and DIPEA (2 M) in acetonitrile for 30 min. The microarrays were 
washed with acetonitrile (2 x 20 mL) briefly, H2O (2 x 20 mL) briefly, 0.1% SDS in 
4 x SSC (20 mL) at 50 oC for 30 min, H2O (2 x 20 mL) briefly, and Tris pH 8 (20 
mL, 10 mM) briefly. The array was imaged with a BioTEc LaVision BioAnalyser. 
 
7.6.10 Cell growth on “hit”-displaying microarrays 
Cell growth on the FAM-Ahx-FQpIYIIIK-NH2/FAM-Ahx-FQKKSRIK-NH2 
displaying microarray (section 0) was carried out as described in section 0 with D54 
(3 mL, 100,000 cells/mL) in DMEM enriched with CaCl2 (50 µM) and MgCl2 
(50 µM). In addition, D54 (3 mL, 20,000 cells/mL) were pre-incubated with FAM-
Ahx-RGD-NH2 (100 µM) in DMEM enriched CaCl2 (50 µM) and MgCl2 (50 µM) 
for 20 min before incubation on the microarray. Likewise, HEK293TCCR6 or 
HEK293T cells (3 mL, 100,000 cells/mL) were incubated on FAM-Ahx-FQIPYIIIK-
NH2/FAM-Ahx-FQPKYSFIK-NH2 displaying microarrays (section 0) in DMEM 
enriched with CaCl2 (50 µM) and MgCl2 (50 µM). In addition, HEK293TCCR6 cells 
(3 mL, 100,000 cells/mL) were pre-incubated with PerCP-Anti human CCR6 (5 
µg/mL, R&D systems) in DMEM enriched CaCl2 (50 µM) and MgCl2 (50 µM) for 
20 min before incubation on the microarray. Cells were fixed and stained as 
described above and imaged with a BioTEc LaVision BioAnalyser and a Nikon 
Eclipse 50i microscope.  
 
7.7 Experimental to Chapter 5 
7.7.1 Fabrication of single oligonucleotide microarray  
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The microarray containing a single DNA oligonucleotide was generated by contact 
printing a 3’-amino modified DNA oligonucleotide (Microsynth) on a Codelink slide 
in a 10 x 10 pattern. After printing, the unreacted sites on the slide were blocked with 
ethanolamine and the array was washed according to the Codelink protocol.  
 
All other DNA microarrays were custom made by OGT. 
 
 
7.7.2 PCR over microarrays 
Extension reaction mix (200 µL) without primers was prepared according to a 
Promega standard protocol using a PCR master mix (Promega; 25 U/mL Taq 
Polymerase, 200 µM dNTP, 1.5 mM MgCl2), which was loaded onto the microarray 
using an Agilent hybridisation cover slide. The first extension step was carried out at 
50 oC (primer-2) or 55 oC (Solexa-primer-2) for 16 h (overnight).  Thereafter, the 
reaction mixture was removed using a pipette and fresh PCR reaction mix (200 µL) 
with primer-1 and 2 (0.1 µM) or Solexa-primer-1 and 2 (0.1 µM) were loaded onto 
the microarray and a standard PCR cycle was set up in a GeneMachines Hyb4 
automated hybridiser [40 cycles; denaturation at 94 oC for 30 s for 10 cycles and 88 
oC for 30 s for 30 cycles, annealing at 49 oC for 1 min, extension at 50 oC for 5 min 
(primer-1 and 2); or denaturation at 94 oC for 30 s, annealing at 65 oC for 1 min, 
extension at 70 oC for 1 min (Solexa-primers-1 and 2)]. In addition, an initial 3 min 
denaturation step at 94 oC and a final 15 min extension step at 50 oC (primer-2) or 70 
oC (Solexa-primer-2) were carried out. Immediately after the PCR had finished the 
reaction mix was collected using a pipette and the microarray washed with H2O (3 x 
50 µL). The aqueous fractions were pooled together and concentrated by speed vac 
followed by purification by preparative DNA gel electrophoresis (dsDNA-3875: 1.75 
Nina Svensen                                                                                                   Chapter 7 
  172
   
µg, 40% isolated yield; dsDNA-Library-2: 1.65 µg, 40% isolated yield; equation 
7.2)††. 
































  (Equation 7.2) 
 
7.7.3 PCR in solution  
The purified products (250-875 ng) from each of the PCR “read-off” microarrays 
were used as templates in another round of PCR with Primer 1 and 2 (1 µM) or 
Solexa-primer-1 and 2 (1 µM) in a 1 x PCR Master Mix (200 µL) in a Techne TC-
312 PCR cycler with the same cycle as on microarray. After PCR the samples were 
concentrated by speed vac followed by purification by preparative DNA gel 
electrophoresis (dsDNA-3875-2: 1.11 µg, 27% isolated yield; dsDNA-Library-2-2: 
16.8 µg, 30% isolated yield). 
 
The PCR products were amplified in another round of PCR carried out with DNA 
(250-875 ng), primer-1, and primer-2-FAM (2.5 µM), or primer-3, and primer-4-
FAM [2.5 µM, Sigma-Aldrich; 40 cycles; denaturation at 94 oC for 30 s for 10 cycles 
and 88 oC for 30 s for 30 cycles, annealing at 49 oC for 1 min, extension at 50 oC for 
5 min (primer-1 and primer-2-FAM); or denaturation at 94 oC for 30 s, annealing at 
58 oC for 1 min, extension at 66 oC for 1 min (primers-3 and primer-4-FAM)]. In 
addition, an initial 3 min denaturation step at 94 oC and a final 15 min extension step 
at 50 oC (primer-1 and primer-2-FAM) or 66 oC (primers-3 and primer-4-FAM) were 
carried out. After PCR, the samples were concentrated by speed vac followed by 
purification by preparative DNA gel electrophoresis (dsDNA-Library-2-FAM: 20.5 
µg, 29% isolated yield; dsDNA-3875-FAM: 28.3 µg, 30% isolated yield). 
 
                                                 
†† Yield calculations were based on an assumed 25.000 DNA oligos per spot on the 
microarray. The actual amount of DNA per feature could not be disclosed by the 
manufacturer.  
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dsDNA_Library-2_FAM and dsDNA3,875_FAM were used as templates in ssDNA 
PCR amplification with Microarray Primer FAM (10 µM) in 1 x PCR Master Mix 
(600 µL) with the same cycle as described before for this primer. After PCR the 
samples were concentrated by speed vac followed by purification by preparative 
DNA gel electrophoresis (7.60 µg ssDNA-3875-FAM; 6.04 µg ssDNA-Library-2-
FAM). 
 
7.7.4 Digestion enzyme assay  
dsDNA-Library-2-2 (200 ng) or dsDNA-3875-2 (200 ng) were digested with 0.25 
units/µL EcoICRI (Promega) in 1 x RE buffer (20 µL, Promega) containing 0.1 
µg/µL Acetylated BSA (Promega) at 37 oC for 4 h followed by analytical DNA gel 
electrophoresis. 
 
7.7.5 Microarray hybridisation of the PCR products 
The purified fluorescent PCR constructs were dissolved in 0.1% SDS in 4 x SSPE 
buffer (110 µL) and denatured at 65 oC for minimum 5 min. This solution was 
hybridised on customized DNA arrays (OGT) in an Agilent hybridisation chamber 
from 65-27 oC over 24 h. The arrays were washed according to microarray wash 
protocol 3 and the microarray was imaged with a Tecan LS Reloaded microarray 
scanner. Image analysis was carried out as described in section 7.2 (appendix IV). 
 
7.7.6 Solexa Illumina Sequencing 
dsDNA-Library-2 (200 nmol) was sequenced by Illumina Solexa DNA sequencing 
of 36-base reads off the Solexa Primer 1 domain at the end of each oligonucleotide 
(The GenePool, The University of Edinburgh). The resulting reads were clustered 
against a list of the 10,000 oligonucleotides in the 10,000 library and a list of the 
identified sequences was generated, including the number of times each 
oligonucleotide was seen. Another list of the sequences not seen by Illumina Solexa 
sequencing was generated (appendix V). 
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7.8 Experimental to Chapter 6 
7.8.1 Library-2 extraction from cells 
D54 and HEK293TCCR6 grown to 80-90% confluence in a T-25 flasks were 
incubated with Library-229 (4 mL, 10 µM) in DMEM enriched with CaCl2 (50 µM) 
and MgCl2 (50 µM) for 30 min at 37
 oC. The media was removed and the cells were 
washed with PBS (x 4) enriched with CaCl2 (50 µM) and MgCl2 (50 µM)
 and treated 
with 1 x pronase/EDTA (Merck Chemicals) in PBS for 20 min at 37 oC. The cells 
were pelleted by centrifugation (1100 rpm for 5 min) and the supernatant was 
recovered. PNA-peptide conjugates were purified by filter-centrifugation (3,000 Da 
and 10,000 Da molecular weight, Nunc TM) and the amount of PNA was quantified 
by measuring the emission of 5(6)-carboxyfluorescein at 520 nm. This afforded 
surface bound PNA encoded peptides extracted from D54 (4.4 pmol), and 
HEK293TCCR6 (2.4 pmol). 
 
7.8.2 Production of ssDNA-Library-2 
PCR was carried out with dsDNA-Library-2 (~750 ng, section 0) in 1 x PCR Master 
Mix (600 µL, Promega) with primer-3 (10 µM, Sigma-Aldrich) via: 40 cycles; 
denaturation at 94 oC for 30 s; annealing at 62 oC for 2 min; and extension at 68 oC 
for 2 min in a Techne TC-312 PCR cycler. In addition, an initial 3 min denaturation 
step at 94 oC and a final 15 min extension step at 68 oC were carried out. After PCR, 
the samples were concentrated by speed vac followed by purification by preparative 
DNA gel electrophoresis.  
 
7.8.3 Amplification of PNA 
7.8.3.1 Single oligonucleotide 
Oligonucleotide-1 (0.30 nmol, Sigma, Table 6.1) was hybridised with peptide-PNA 
(Gly-Gly-Gly-TGTTTGTTTGTT, 0.3 nmol) and oligonucleotide-2 and 3 (0.60 nmol, 
Sigma, Table 6.1) in 4 x SSPE buffer (30 µL, Invitrogen) from 65 oC to 37 oC over 
24 h. Half of the warm solutions were kept as a positive control for PNA/DNA 
hybridisation and the remaining were diluted 10 times with 37 oC 1.1 x S1 Nuclease 
Reaction buffer (Promega) and the sample was treated with DNA S1 Nuclease (100 
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U/1 µg, Promega) for 15 min at 37 oC. Similarly, oligonucleotide-1 (0.15 nmol) was 
hybridised with oligonucleotide-2 and 3 (0.30 nmol) as a positive control for primer 
hybridisation. The hybridisation mixtures were analysed by DNA gel electrophoresis.  
 
7.8.3.2 10,000 oligonucleotides 
ssDNA-Library-2 (0.20 nmol, section 0) was hybridised with PNA-Library-229 (0.10 
nmol) and oligonucleotide-2 and 3 (0.40 nmol, Table 6.1) as described above. 
Similarly, ssDNA-Library-2 (5 equiv.) was hybridised with oligonucleotide-2 and 3 
(6 equiv., Table 6.1) as well as PNA-D54 (4.4 pmol, 1 equiv.) or PNA-HEK293T-
CCR6 (2.44 pmol, 1 equiv.). The warm solutions were diluted 10 times with 37 oC 
1.1 x S1 Nuclease Reaction buffer (Promega) and the sample was treated with 100 
U/1 µg DNA S1 Nuclease (Promega) for 15 min at 37 oC. The dsDNA/PNA-Library-
2 complexes were purified by Sephadex G-25 gel column filtration (GE Healthcare) 
according to manufacturer’s protocol and the eluates concentrated by speed vac.   
 
The purified dsDNA/PNA complexes were amplified by PCR in 1 x PCR Master 
Mix (50 µL) with primer-3 (2 µM) and primer-4-FAM (2 µM) in a Techne TC-312 
PCR cycler with the same cycle as described before. The PCR products were 
concentrated by speed vac purified by preparative DNA gel electrophoresis. The 
product was amplified by PCR again in new PCR mix (600 µL) according to the 
same PCR cycle and purification procedure. The dsDNA-FAM were used as 
templates in ssDNA PCR amplification in 1 x PCR Master Mix (600 µL) with 
primer-4-FAM (10 µM) carried out with the same cycle as described above. After 
PCR, the samples were concentrated by speed vac followed by purification by 
preparative DNA gel electrophoresis (ssDNA-Library-2-FAM: 6.75 µg, ssDNA-
D54-FAM: 4.73 µg, ssDNA-HEK293TCCR6-FAM: 3.21 µg). 
 
7.8.4 Microarray hybridisation of ssDNA-Library-2 
Library-2 complementary DNA microarrays (OGT) were hybridised with the 
purified ssDNA-FAM in 0.1% SDS in 4 x SSPE buffer (110 µL) overnight from 65 
oC to 27 oC and the arrays were washed according to microarray wash protocol 3 and 
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imaged with a Tecan LS Reloaded microarray scanner. Image analysis was carried 
out as described in section 7.2 (appendix VI). 
 
7.8.5 Peptide synthesis of integrin and GRCP ligands and non-
binding peptides 
Peptides were synthesised using microwave aided amino acid couplings and 5(6)-
5(6)-carboxyfluorescein couplings as described in section 0 and purified by RP-
HPLC method 3 and ES-MS (positive mode). 
FAM-Ahx-FQSIYPpIK-NH2: 12.8 mg (73%).  
RP-HPLC: 3.943 min. (81.1% crude purity). 
MALDI-TOF+/MS: m/z (%) 1633.4 [M]+ (100).  
FAM-Ahx-FQKEYKFIK-NH2: 13.0 mg (68%).  
RP-HPLC:  3.197 min. (72.8% crude purity). 
MALDI-TOF+/MS: m/z (%) 1672.7 [M+H]+ (100).  
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FAM-Ahx-FQPaYPFIK-NH2: 11.2 mg (63%).  
RP-HPLC:  3.868 min. (48.8% crude purity). 


























Rho-Ahx-RGD-NH2: 10.2 mg (100%).  
RP-HPLC:  3.269 min. (71.5% crude purity). 
MALDI-TOF+/MS: m/z (%) 899.3 [M+1H]+ (100).  
 
7.8.6 Flow cytometry of integrin and GRCP ligands and non-
binding peptides 
D54, HEK293T, and HEK293TCCR6 cells were grown to 80-90% confluence in 24-
well plates. HEK293T and HEK293TCCR6 cells were incubated with PerCP-anti 
human CCR6 (10 µg/mL), FITC-anti human CCR6 (10 µg/mL, R&D systems), 
FAM-Ahx-FQSIYPpIK-NH2 (10 µM), FAM-Ahx-FQPaYPFIK-NH2 (10 µM), 
PerCP-anti human CCR6 (10 µg/mL) and FAM-Ahx-FQSIYPpIK-NH2 (10-100 µM) 
or FAM-Ahx-FQPaYPFIK-NH2 (10 µM). D54 incubation with: FAM-Ahx-RGD-
NH2 (10 µM), Rho-Ahx-RGD-NH2 (10 µM), FAM-Ahx-FQIPYIIIK-NH2 (10 µM), 
FAM-Ahx-FQKDYKFIK-NH2, (10 µM) Rho-Ahx-RGD-NH2 (10 µM) and FAM-
Ahx-FQIPYIIIK-NH2  (10-100 µM) or FAM-Ahx-FQKDYKFIK-NH2 (10 µM) in 
DMEM enriched with CaCl2 (50 µM) and MgCl2 (50 µM) for 30 min at 37
 oC. The 
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media was removed and the cells were washed with PBS x 3, detached by scraping 
or by treatment with 1 x pronase/EDTA for 15 min at 37 oC, and suspended in PBS 
enriched with CaCl2 (50 µM) and MgCl2 (50 µM). The samples were analysed by 
flow cytometry using a BD FACSAria cytometer (D54 cells, FITC and PE-Texas 
Red filters and 10,000 events) or a BD Calibur cytometer (HEK293T and 
HEK293TCCR6 cells, FITC and PE/PI filters and 10,000 events). 
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